Synthetic method and application of hairyvein agrimony phenol compound
By developing efficient AGB derivative synthesis methods, the problem of heavy separation process and low yield of Cyperus B from plants was solved, and efficient anti-cancer drugs were provided, which significantly improved the therapeutic effect on lung cancer.
Patent Information
- Application Number
- CN202380023160.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-22
- Filing Date
- 2023-02-21
- Publication Date
- 2024-11-15
AI Technical Summary
In the prior art, the process of isolate ceramophenol B (AGB) from plants is heavy and time-consuming, and has low yield, which limits its application in the development of anti-cancer drugs and lacks efficient synthetic methods.
AGB derivatives with anti-cancer properties and their efficient synthesis methods were developed. The total yield of AGB and its derivatives was improved through specific reactants and conditions, and a drug formulation that can be used to treat cancer was prepared.
It has achieved efficient synthesis and application of AGB and its derivatives, provided drugs with anti-cancer effects, which can effectively inhibit cancer cell growth and induce cancer cell apoptosis, and significantly improved the potential for treating lung cancer.
Smart Images

Figure BDA0005005394460000021 
Figure BDA0005005394460000031 
Figure BDA0005005394460000032
Abstract
Description
Field of the Invention
[0001] The present invention generally belongs to the field of agrimonol B and its derivatives, as well as synthesis methods and uses thereof. Background of the Invention
[0003] Cancer, also known as malignant tumor, is a common and frequent disease that threatens human health. Lung cancer is the main cause of death in cancer patients. There are many treatments for lung cancer, among which surgery is the first choice. However, the vast majority of lung cancer patients are diagnosed with advanced stage at the time of their first visit and have a high recurrence rate after surgery. Adjuvant chemotherapy after surgery is an effective strategy to prevent recurrence and metastasis. With the recent development of molecular biology, more and more targeted proteins have been discovered, which provide newly developed drugs based on the identified targets for the treatment of advanced lung cancer.
[0004] Bioactive components isolated from plants are an important source for the discovery and development of anticancer drugs in this regard. In the past few decades, research on natural products has provided a large number of potential lead compounds with unique folding and mechanisms of action. Agrimonia ol B (AGB) is a propylacylphloroglucinol compound that was originally isolated from Agrimonia pilosa. Although AGB has been obtained from plants for decades, there has been almost no research on the activity and application of AGB. In addition, the isolation of AGB from plants is a cumbersome and time-consuming task, and the amount of AGB in plants is extremely low, which limits its further development and application. Previous reports on the synthesis of AGB have problems such as low yield, complex synthesis and low atomic efficiency (Li et al., Acta Chimica Sinica, 36 (1): 43-48 (1978); Pei et al., Acta Pharmaceutica Sinica, (1989) 431-437; and CN108264454, Huang et al.).
[0005] There remains a need to develop compounds having anticancer properties and methods for the synthesis of these compounds with improved overall yields.
[0006] Therefore, it is an object of the present invention to provide AGB derivatives having anticancer properties.
[0007] Another object of the present invention is to provide a method for synthesizing AGB and AGB derivatives with improved overall yield.
[0008] Another object of the present invention is to provide methods of using AGB and AGB derivatives as anticancer agents. Summary of the invention
[0009] AGB and AGB derivatives (also referred to herein as "compounds") have been developed that have anticancer properties. AGB or an AGB derivative may have the structure of Formula I:
[0010]
[0011] Wherein: (a) L1 and L2 can independently be a bond (single bond, double bond or triple bond), a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, a carbonyl or an alkoxyl group; (b) L3 can be a bond (single bond, double bond or triple bond), a substituted or unsubstituted alkyl, or a carbonyl group; (c) A1 and A2 can independently be hydrogen, a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted aryl, a carbonyl or an alkoxyl group, and at least one of A1 and A2 can be a substituted or unsubstituted aryl group; (d) A3 can be hydrogen, a substituted or unsubstituted alkyl, a substituted or unsubstituted aryl, a carbonyl or an alkoxyl group; (e) R1-R3 can independently be hydrogen, a hydroxyl group, , substituted or unsubstituted alkyl, carbonyl, alkoxy, thiol, or amino; and (f) the substituents may independently be substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, carbonyl, alkoxy, halogen, hydroxy, phenoxy, thiol, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amide, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphoalkyl, phosphoryl, or phosphonyl.
[0012] In some forms, the compound may have the structure of Formula III:
[0013]
[0014] Wherein: (a) L1 and L2 can independently be a bond (single bond, double bond or triple bond), substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, carbonyl, or alkoxy; (b) L3-L5 can independently be a bond (single bond, double bond or triple bond), substituted or unsubstituted alkyl, or carbonyl; (c) A3-A5 can independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, carbonyl, or alkoxy; (d) R1-R3 and R9-R 16 and (e) the substituents may be as defined above for Formula I.
[0015] In some forms, -L1-A1 is the same as -L2-A2, and the compound may have a structure of Formula IV:
[0016]
[0017] wherein: (a) L3 and L7 can independently be a bond (single bond, double bond or triple bond), a substituted or unsubstituted alkyl, or a carbonyl group; (b) L6 can be a bond (single bond, double bond or triple bond), a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, a carbonyl group, or an alkoxy group; (c) A3 and A7 can independently be hydrogen, a substituted or unsubstituted alkyl, a substituted or unsubstituted aryl, a carbonyl group, or an alkoxy group; (d) R1-R3 and R 18 -R 21 and (e) the substituents may be as defined above for Formula I.
[0018] In some forms, R1-R3, R8-R 16 , and / or R 18 -R 21 In some forms, R1-R3 may be hydroxyl. In some forms, R8-R 16 and / or R 18 -R 21 They may independently be hydroxyl, substituted or unsubstituted alkyl, or -OR4, and R4 may be substituted or unsubstituted alkyl.
[0019] In some forms, -L3-A3, -L4-A4, -L5-A5, and / or -L7-A7 can independently be substituted or unsubstituted alkyl, or R 17 It may be a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, or m can be an integer from 0 to 5, R 26 is a carboxylic acid, an ester, an amino group, or an amide. In some forms, R 17 It may be a substituted or unsubstituted C1-C5 alkyl, a substituted or unsubstituted C1-C4 alkyl, a substituted or unsubstituted C1-C3 alkyl, a substituted or unsubstituted C1-C2 alkyl, or a substituted or unsubstituted methyl. 17 It may be a C6 cycloalkyl group. In some forms, R 17 may be unsubstituted phenyl. In some forms, R 26 It may be an ester.
[0020] In some forms, -L1-A1 is different from -L2-A2, wherein the compound has the following structure:
[0021]
[0022] wherein: (a) L1 and L2 are independently a single bond, a substituted or unsubstituted alkylene group, a substituted or unsubstituted alkenylene group, -C(O)-, or an alkoxy group; (b) A1 is a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted aryl group, a carbonyl group, or an alkoxy group; (c) R1-R3 and / or R 13 -R 16 are independently hydrogen, hydroxy, substituted or unsubstituted alkyl, -OR4, -SR5, or -NR6R7, R4-R7 are independently hydrogen or substituted or unsubstituted alkyl; (d) -L3-A3 is R 17 is substituted or unsubstituted alkyl, substituted or unsubstituted aryl; and (e)-L5-A5 is hydrogen, substituted or unsubstituted alkyl, or R 17 is a substituted or unsubstituted alkyl group.
[0023] In some forms, -L1-A1 is different from -L2-A2, wherein the compound has the following structure:
[0024]
[0025] Wherein: (a) L1 and L2 are independently substituted or unsubstituted alkylene or -C(O)-; (b) A1 is substituted or unsubstituted aryl, or C1-C6 alkoxy; (c) R1-R3 are hydroxyl; (d) R 13 -R 16 are independently hydroxy, hydrogen, substituted or unsubstituted alkyl, or -OR4, R4 is C1-C6 alkyl; (e) -L3-A3 is R 17 is substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted aryl; and (f) -L5-A5 is hydrogen, substituted or unsubstituted C1-C6 alkyl, or R 17 is a substituted or unsubstituted C1-C6 alkyl group.
[0026] In some forms, A1 is an alkoxy-substituted phenyl. In some forms, A1 is an unsubstituted phenyl. In some forms, -L3-A3 is R 17 It is an unsubstituted phenyl group.
[0027] In some forms, -L1-A1 is different from -L2-A2, wherein the compound has the following structure:
[0028]
[0029] Wherein: (a) L1 and L2 are independently substituted or unsubstituted alkylene or -C(O)-; (b) A1 is C1-C6 alkoxy; (c) R1-R3 are hydroxyl groups; (d) R 13 -R 16 is hydroxyl, substituted or unsubstituted C1-C6 alkyl, or -OR4, R4 is substituted or unsubstituted C1-C6 alkyl; (e) -L3-A3 is R 17 is a substituted or unsubstituted C1-C6 alkyl group; and (f)-L5-A5 is R 17 is a substituted or unsubstituted C1-C6 alkyl group.
[0030] In some forms, the compound is not In some forms, the compound may be:
[0031]
[0032]
[0033] Disclosed are pharmaceutical formulations comprising one or more compounds disclosed herein, a pharmaceutically acceptable carrier and / or excipient. In some forms, one or more compounds may have an effective amount for treating cancer, reducing cancer, or treating or improving one or more symptoms associated with cancer in a subject. In some forms, an effective amount of one or more compounds may effectively induce mitochondrial dysfunction and / or inhibit the transport of ER to the Golgi apparatus in a subject's cancer cells. In some forms, an effective amount of one or more compounds may effectively induce apoptosis of cancer cells in a subject. In some forms, an effective amount of one or more compounds may effectively inhibit tumor growth in a subject by at least 40%, at least 50%, or at least 55%, compared to the same tumor in a control subject.
[0034] In some forms, the total concentration of one or more compounds in the pharmaceutical formulation may be at least 0.01 wt%, at least 0.05 wt%, at least 0.1 wt%, 0.01 wt% to 50 wt%, 0.05 wt% to 50 wt%, 0.1 wt% to 50 wt%, 0.01 wt% to 40 wt%, 0.05 wt% to 40 wt%, 0.1 wt% to 40 wt%, 0.01 wt% to 30 wt%, 0.05 wt% to 30 wt%, 0.1 wt% to 30 wt%, 0.01 wt% to 20 wt%, 0.05 wt% to 20 wt%, 0.1 wt% to 20 wt%, 0.01 wt% to 10 wt%, 0.05 wt% to 10 wt%, or 0.1 wt% to 10 wt%. In some forms, the pharmaceutical formulation may be in unit dosage form, wherein the dose of the compound may be from about 0.002 mg to about 1 mg, from about 0.006 mg to about 0.6 mg, from about 0.01 mg to about 0.4 mg, from about 0.02 mg to about 0.3 mg, or from about 0.01 mg to about 0.2 mg. In some forms, the pharmaceutical formulation may include a second active agent, optionally more than one second active agent, optionally the second active agent may be an anticancer agent.
[0035] A method for synthesizing AGB and its derivatives with high overall yield (i.e., overall yield ≥ 7%) has been developed. The method may include: (i) heating a reaction mixture at a suitable temperature for a period of time sufficient to form a product comprising the compound, wherein the reaction mixture comprises a solvent, a first reactant having a structure of formula V,
[0036]
[0037] The second reactant having the structure of formula VI
[0038]
[0039] and a third reactant having the structure of formula VII
[0040]
[0041] wherein (a) L1 and L2 may independently be a bond (single bond, double bond or triple bond), substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, carbonyl or alkoxy; (b) L3 may be a bond (single bond, double bond or triple bond), substituted or unsubstituted alkyl, or carbonyl; (c) A1 and A2 may independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, carbonyl or alkoxy, and at least one of A1 and A2 may be substituted or unsubstituted aryl; (d) A3 may be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, carbonyl or alkoxy; (e) R1-R3 may independently be hydrogen, hydroxyl, substituted or unsubstituted alkyl, carbonyl, alkoxy, thiol or amino; (f) R 23 -R 25 and (g) the substituents may be as defined above for Formula I. The second reactant may be the same as or different from the third reactant.
[0042] In some forms, -L3-A3 may be R 17 Can be unsubstituted C1-C 10 Alkyl, or m can be an integer from 0 to 5, R 26 It can be a carboxylic acid, an ester, an amino group, or an amide.
[0043] In some forms, A1 may be A2 can be Wherein: (a) L4 and L5 can independently be a bond (single bond, double bond or triple bond), a substituted or unsubstituted alkyl group, or a carbonyl group; (b) A4 and A5 can independently be hydrogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, a carbonyl group, or an alkoxy group; (c) R9-R 16 and (d) the substituents may be as defined above for Formula I.
[0044] In some forms, the second reactant may be the same as the third reactant and have the following structure:
[0045]
[0046] wherein: (a) L6 can be a bond (single bond, double bond or triple bond), substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, carbonyl or alkoxy; (b) L7 can be a bond (single bond, double bond or triple bond), substituted or unsubstituted alkyl, or carbonyl; (c) A7 can be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, carbonyl or alkoxy; (d) R 18 -R 21may independently be hydrogen, hydroxy, substituted or unsubstituted alkyl, carbonyl, alkoxy, thiol, or amino; (e) R 23 -R 25 and (f) substituents may be as defined above for Formula I.
[0047] In some forms, the method may further comprise: (ia) converting a pre-reactant having a structure of Formula VIII' into a reactant having a structure of Formula VIII:
[0048]
[0049] Wherein: (a) L7 can be a bond (single bond, double bond or triple bond), a substituted or unsubstituted alkyl group, or a carbonyl group; (b) A7 can be hydrogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, a carbonyl group, or an alkoxy group; (c) R 18 -R 21 and (d) the substituents may be as defined above for Formula I.
[0050] In some forms, R 19 can be substituted or unsubstituted alkyl, such as unsubstituted methyl. In some forms, R 18 Can be -OR 22 , each R 22 can be hydrogen or substituted or unsubstituted alkyl. In some forms, R 20 and R 21 In some forms, R 19 It may be a substituted or unsubstituted alkyl group, such as an unsubstituted methyl group; R 18 Can be -OR 22 , each R 22 It can be hydrogen or substituted or unsubstituted alkyl; R 20 and R 21 In some forms, -L7-A7 may be R 17 Can be unsubstituted C1-C 10 alkyl, unsubstituted C1-C8 alkyl, unsubstituted C1-C6 alkyl, unsubstituted C1-C4 alkyl, unsubstituted C1-C3 alkyl, or m can be an integer from 0 to 5, R 26 Can be carboxylic acid, ester, amino, or amide. In some forms, -L7-A7 can be R 17 Can be unsubstituted C1-C 10The invention also includes an unsubstituted C1-C8 alkyl group, an unsubstituted C1-C6 alkyl group, an unsubstituted C1-C4 alkyl group, or an unsubstituted C1-C3 alkyl group.
[0051] The method may further comprise: (ib) converting a suitable starting material into a pre-reactant having a structure of Formula VIII'.
[0052] In some forms of step (ib), the method may include: (i-b1) converting a first starting material having a structure of formula X into a first intermediate having a structure of formula IX, and (i-b2) converting the first intermediate having a structure of formula IX into a pre-reactant having a structure of formula VIII':
[0053]
[0054] Where: (a) R 20 and R 21 may independently be hydrogen, hydroxy, substituted or unsubstituted alkyl, carbonyl, alkoxy, thiol, or amino; (b) R 22 may be hydrogen or substituted or unsubstituted alkyl; and (c) the substituents may be as defined above for Formula I. In some forms, R 20 and R 21 It may be a hydroxyl group.
[0055] In some forms, the conversion of the first starting material of formula X into the first intermediate of formula IX (i.e., step (i-b1)) may include a methylation step and / or an acylation step. In some forms, the conversion of the first starting material of formula X into the first intermediate of formula IX may include a methylation step and an acylation step. In some forms, the methylation step may be performed before the acylation step.
[0056] In some forms, in the methylation step of step (i-b1), the starting material may be converted into a methylated compound having the formula XI':
[0057]
[0058] Where (a) R 20 and R 21 may independently be hydrogen, hydroxy, substituted or unsubstituted alkyl, carbonyl, alkoxy, thiol, or amino; (b) R 22 (c) the substituents may be as defined above for Formula I.
[0059] In some forms, in the acylation step of step (i-b1), the methylated compound of formula XI' can be converted into an acylated compound having the structure of formula XI:
[0060]
[0061] Where (a) R 20 and R 21 may independently be hydrogen, hydroxy, substituted or unsubstituted alkyl, carbonyl, alkoxy, thiol, or amino; (b) R 22 (c) the substituents may be as defined above for Formula I.
[0062] In some forms, the conversion of the starting material of formula X to the intermediate of formula IX further comprises a reduction step, wherein the acylated compound having the structure of formula XI can be converted to the intermediate having the structure of formula IX. In some forms, the conversion of the acylated compound of formula XI to the intermediate of formula IX is carried out via a Vilsmeier-Haack reaction.
[0063] In some forms, converting the first intermediate of Formula IX into a pre-reactant of Formula VIII' (i.e., step (i-b2)) may include an acylation step and a decarboxylation step performed sequentially. An exemplary step for converting the first intermediate of Formula IX into a pre-reactant of Formula VIII' is as follows:
[0064] In an alternative form of step (ib) (converting a suitable starting material into a pre-reactant having a structure of formula VIII'), the method may include: (i-b1') converting phloroglucinol (as a starting material) into a second intermediate having a structure of formula XVII, and (i-b2') converting the second intermediate having a structure of formula XVII into a pre-reactant having a structure of formula VIII':
[0065]
[0066] Wherein: (a) L7 can be a bond (single bond, double bond or triple bond), a substituted or unsubstituted alkyl group, or a carbonyl group; (b) A7 can be hydrogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, a carbonyl group, or an alkoxy group; (c) R 19 (d) P1 and P2 may be independently protecting groups such as methoxymethyl ether, tetrahydropyranyl ether, butyl ether, allyl ether, acetone, benzylidene acetal, acetate, pivalate, tert-butyldimethylsilyl ether, tert-butyldibenzylsilyl ether, anisole, benzoic acid ester, benzoate ester, benzoate salt; and (e) the substituents may be as defined above for Formula I. In some forms, R 19 It may be a substituted or unsubstituted alkyl group, such as an unsubstituted C1-C 10alkyl, unsubstituted C1-C8 alkyl, unsubstituted C1-C6 alkyl, unsubstituted C1-C4 alkyl, unsubstituted C1-C3 alkyl, or unsubstituted C1-C2 alkyl, such as unsubstituted methyl.
[0067] In some forms, the second intermediate of formula XVII converted from phloroglucinol (i.e., step (i-b1')) may include an acylation step. In some forms, the second intermediate of formula XVII converted from phloroglucinol may include an oxidation step, a reduction step, and an acylation step that are performed in sequence. In some forms, the second intermediate of formula XVII converted from phloroglucinol may include an oxidation step, a reduction step, an acylation step, and a protection step that are performed in sequence. The exemplary steps of converting the second intermediate of formula XVII from phloroglucinol are as follows.
[0068] In some forms, the conversion of the second intermediate of Formula XVII into the pre-reactant of Formula VIII' (i.e., step (i-b2')) may include an acylation step and an optional deprotection step. In some forms, in the acylation step of step (i-b2'), the second intermediate of Formula XVII may be converted into an acylated compound having a structure of Formula XVIII:
[0069]
[0070] Wherein: (a) L7 can be a bond (single bond, double bond or triple bond), a substituted or unsubstituted alkyl group, or a carbonyl group; (b) A7 can be hydrogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, a carbonyl group, or an alkoxy group; (c) R 19 can be hydrogen, hydroxy, substituted or unsubstituted alkyl, carbonyl, alkoxy, thiol, or amino; (d) R 22 (e) P1 and P2 may independently be protecting groups as defined above for Formula XVII; and (f) the substituents may be as defined above for Formula I.
[0071] In some forms, the first reactant may be
[0072]
[0073] The second reactant may be the same as the third reactant and has the structure of Formula XIII:
[0074]
[0075] wherein: (a) A3 and A7 may independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, carbonyl, or alkoxy; (b) L6 may be a bond (single bond, double bond, or triple bond), substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, carbonyl, or alkoxy; (c) R 22may be hydrogen or substituted or unsubstituted alkyl; (d) R 23 -R 25 and (e) substituents may be as defined above for Formula I.
[0076] In some forms, the solvent in the reaction mixture can be dichloromethane, dimethyl sulfate, dimethyl sulfoxide, dimethylformamide, butyryl chloride, dichloroethane, nitrobenzene, dioxane, 2-methylbutyryl chloride, ethyl acetate, ethyl lactate, acetone, 1-butanol, 1-propanol, 2-propanol, ethanol, isopropyl acetate, methanol, methyl ethyl ketone, tert-butanol, tetrahydrofuran, 2-methyltetrahydrofuran, acrylonitrile, or toluene, or a combination thereof, or a mixture thereof with water. In some forms, the reaction mixture can be heated at a temperature of up to 130°C, about 100°C to about 130°C, about 100°C to about 125°C, about 100°C to about 120°C, such as about 110°C, for a period of about 30 min to about 4 h, about 30 min to about 3.5 h, about 30 min to about 3 h, about 30 min to about 2.5 h, about 1 h to about 4 h, about 1 h to about 3 h, or about 1 h to about 2 h at 1 atm, optionally under reflux. In some forms, the method may further include: mixing the first reactant, the second reactant, the third reactant, and the solvent to form a reaction mixture before step (i), and / or purifying the prodrug-containing product after step (i).
[0077] In some forms, AGB or AGB derivatives formed using the disclosed methods may have an overall yield of at least 7%, at least 10%, at least 15%, at least 20%, at least 25%, or at least 30%.
[0078] Disclosed are methods for treating cancer, reducing cancer, or treating or ameliorating one or more symptoms associated with cancer in a subject using synthetic AGB and AGB derivatives. In general, the method comprises: (i) administering to a subject a pharmaceutical formulation comprising one or more disclosed compounds, wherein step (i) is performed one or more times. In some forms, the subject may be a mammal. In some forms, the pharmaceutical formulation may be administered by oral administration, parenteral administration, inhalation, mucosal administration, topical, or a combination thereof. In some forms, the cancer treated using the disclosed method is non-small cell lung cancer. In some forms, the method may further comprise: administering to the subject a second active agent, optionally more than one second active agent, before, during, and / or after step (i), optionally the second active agent may be an anticancer agent.
[0079] In some forms, the method may include only a single administration of a pharmaceutical formulation, wherein the pharmaceutical formulation contains an effective amount of a compound that inhibits tumor growth in a subject by at least 40%, at least 50%, or at least 55% compared to the same tumor in a control subject. In some forms, the method may include more than one step of administering a pharmaceutical formulation to a subject, wherein after all administration steps, the subject has been administered an effective amount of a compound that inhibits tumor growth in the subject by at least 40%, at least 50%, or at least 55% compared to the same tumor in a control subject. In some forms, the effective amount of the compound administered to the subject may be about 0.1 mg / kg to about 50 mg / kg, about 0.3 mg / kg to about 30 mg / kg, about 0.5 mg / kg to about 20 mg / kg, about 1 mg / kg to about 15 mg / kg, or about 0.5 mg / kg to about 10 mg / kg, such as about 3 mg / kg.
[0080] Also disclosed are methods of using the synthetic AGB and AGB derivatives for treating cancer cells and / or cancer stem cells in a subject in need thereof. In general, the method comprises: (i) administering to the subject a pharmaceutical formulation comprising one or more disclosed compounds, wherein step (i) is performed one or more times.
[0081] In some forms, the compound is tested under the same conditions and has an IC 50 The values are lower than the IC values of the same compounds against non-cancer cells. 50 In some forms, the test cancer cells may be MDA-MB-231, MCF-7, HepG2, Hela, AGS, HTC116, SW480, SUNE-1, H460, HCC827, H1650, or A549, or a combination thereof. In some forms, the non-cancer cell may be CCD-19Lu.
[0082] In some forms, the method may include only a single administration of a pharmaceutical formulation, wherein the pharmaceutical formulation contains an effective amount of a compound that induces mitochondrial dysfunction and / or inhibits ER to Golgi transport in cancer cells in the subject as compared to the subject prior to administration of the pharmaceutical formulation. In some forms, the method may include more than one step of administering the pharmaceutical formulation to the subject, wherein after all administration steps, an effective amount of a compound that induces mitochondrial dysfunction and / or inhibits ER to Golgi transport in cancer cells in the subject as compared to the subject prior to administration of the pharmaceutical formulation has been administered to the subject.
[0083] In some forms, the method may include only a single administration of a pharmaceutical formulation, wherein the pharmaceutical formulation contains an effective amount of a compound to induce apoptosis of cancer cells in the subject compared to the subject prior to administration of the pharmaceutical formulation. In some forms, the method may include more than one step of administering a pharmaceutical formulation to a subject, wherein after all administration steps, an effective amount of a compound to induce apoptosis of cancer cells in the subject compared to the subject prior to administration of the pharmaceutical formulation has been administered to the subject. BRIEF DESCRIPTION OF THE DRAWINGS
[0084] Figure 1A is a bar graph showing the IC50 values of AGB against the indicated cell lines. Cells were treated with various concentrations of AGB for 48 h and used for MTT assay. 50 Values are half maximal inhibitory concentrations, determined by fitting the curves using the equation from GraphPad Prism 8. Figure 1B is a bar graph showing the inhibition of colony formation of NCI-H460 cells by AGB. Cells were treated with the indicated concentrations of AGB for 8 h. The medium containing AGB was then aspirated and the cells were re-seeded in a new 12-well cell culture plate. After 14 days, the cells were fixed by ethanol and then stained with crystal violet. The number of colonies was counted and normalized to the vehicle control group. Colonies containing more than 50 cells were considered. **, p<0.01; ***, p<0.001. Figure 1C Cell migration was shown using a wound healing assay. NCI-H460 cell monolayers were scraped with a sterile 200 μl pipette tip and then treated with DMSO (vehicle) or AGB at the indicated concentrations for 16h and 32h. Images were acquired at 100x in bright field. Figure 1D is a bar graph showing that AGB inhibits the self-renewal and growth of CSCs. The number of tumor spheres formed was counted and normalized to the primary culture control group. Three independent experiments were performed and the data are shown as mean ± SD. * , p<0.05, ## , p<0.01. Scale bar: 200 μm. Figure 1E is a graph showing the cell viability of CSCs determined by MTT analysis. The absorbance of each well was normalized to the control well, and the data were displayed as the percentage of cell viability. The response curve of cell viability was drawn by GraphPad Prism, and the curve was fitted by the Boltzmann equation. Figures 1F-1G Shown are patient-derived organoids from metastatic lung cancer tumors after 72 h of treatment with different concentrations of AGB ( Figure 1F ) and 72h after treatment using CellTiter Glo TM The cell viability was measured ( Figure 1G ) images. Figures 1H-1Jis a graph showing the relative tumor volume curves for each treatment group: A549 xenograft model ( Figure 1H ), NCI-H460 xenograft model ( Fig. 1I ), and the NCI-H460 cancer stem cell-like xenograft model using NOD / SCID mice ( Figure 1J ) (n=5). Tumor volume was normalized to the tumor volume on the first day. Data are expressed as mean±SEM; *, p<0.05. Figure 1K HE-stained images of vital organs (kidney and liver in this experiment) and tumor samples with or without AGB treatment are shown.
[0085] Figures 2A-2C is a graph showing the results of ProTargetMiner analysis of various expressed proteins induced by AGB. Figure 2A An orthogonal partial least squares discriminant analysis (OPLS-DA) model is shown for comparison of the AGB proteomic signal with all other anticancer drugs in the library. Three classes of proteins are highlighted as having the highest specific regulation induced by AGB: mitochondrial ribosomal proteins (MRPs), NADH dehydrogenases, and vesicular transporters. Figure 2B The most specific regulated proteins highlighted by OPLS-DA analysis were clustered by k-means of STRING. The top 30 of those down-regulated and up-regulated proteins were submitted for analysis. Three main clusters of interactions were obtained, grouped into three different colors: proteins in cluster A belong to mitochondrial ribosomal proteins; cluster B mainly contains vesicular transporters that regulate ER to Golgi trafficking; cluster C represents proteins for biological functions of mitochondrial respiratory chain complex I components. Figure 2C GO analysis of biological processes affected upon treatment with AGB is shown.
[0086] Figure 3A is a graph showing changes in fluorescence intensity after AGB treatment for the indicated times, as determined by flow cytometry. Figure 3B Shown are images of the ultrastructure of mitochondria treated with AGB and mitochondrial cristae (displaying fragmentation).
[0087] Figure 4 is a graph showing AGB-induced apoptosis in NCI-H460 cells by Annexin-V / PI double staining analysis. After treatment with AGB for 24 h and 36 h, the cells were stained with Annexin V-FITC and propidium iodide and analyzed by flow cytometry.
[0088] Figure 5AVolcano plot of TPP data (ΔTm, p-value) obtained from NCI-H460 cells treated with 4 μM AGB for 1 h. Criteria were set as ΔTm>2°C and p<0.05. CS, TALDO1, and HSPD1 proteins are highlighted in the figure. Figure 5B is a graph showing the results of tryptophan fluorescence quenching experiments for direct interactions between AGB and three target proteins. Top: Tryptophan fluorescence titration of recombinant proteins with AGB. After titration of different concentrations of AGB, the tryptophan fluorescence of the target proteins excited at 260nm showed a decrease in intensity. For CS, when the AGB concentration increased to about 32μM, its fluorescence reduction reached saturation. Bottom: The normalized tryptophan intensity at 320nm emission was plotted as a function of the total added AGB concentration. The dissociation constants (K) between AGB and the three proteins were then calculated by fitting the plot with the Stern-Volmer equation. d ). Figure 5C The bar graph shows that AGB reduces the refolding activity of MDH in a dose-dependent manner. * , p<0.05; ** , p<0.01. Figure 5D The graph shows the fluorescence intensity of EGFP and Mito-RFP after treatment with different concentrations of AGB. The fluorescence intensity is expressed as a percentage relative to the control group. Figure 5E The bar graph shows the relative CS activity after treatment with different concentrations of AGB. AGB reduced CS catalytic activity in a dose-dependent manner. * , p<0.05; ** , p<0.01. Fig. 5F Bar graph showing that AGB reduces the amount of pentose phosphate channel intermediates in cells. Figure 5G Bar graph showing that AGB reduces the intracellular level of NADPH. ** , p<0.01. (K) Docking results of AGB with HSP60, CS, and TALDO1.
[0089] Figures 6A-6M Spectra of some AGB derivatives are shown. DETAILED DESCRIPTION
[0090] I. Definitions
[0091] It should be understood that unless otherwise specified, the disclosed compounds, compositions, and methods are not limited to specific synthetic methods, specific analytical techniques, or specific reagents, and are therefore variable. It should also be understood that the terminology used herein is for the purpose of describing particular forms and embodiments only and is not intended to be limiting.
[0092] As used herein, "substituted" refers to all permissible substituents of the compounds or functional groups described herein. In the broadest sense, permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds. Illustrative substituents include, but are not limited to, halogens, hydroxyl groups, or any other organic group containing any number of carbon atoms, preferably 11-14 carbon atoms, and optionally include one or more heteroatoms such as oxygen, sulfur, or nitrogen groups, etc., in the form of straight chain, branched, or cyclic structures. Representative substituents include substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted phenyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, halogen, hydroxy, alkoxy, phenoxy, aryloxy, silyl, thiol, alkylthio, substituted alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, substituted or unsubstituted carbonyl, carboxyl, amino, amide, oxo, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphinyl, phosphoryl, phosphonyl, amino acid. Such substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted phenyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, halogen, hydroxy, alkoxy, phenoxy, aryloxy, silyl, thiol, alkylthio, substituted alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, substituted or unsubstituted carbonyl, carboxyl, amino, amide, oxo, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphoalkyl, phosphoryl, phosphonyl, and amino acid may be further substituted.
[0093] The heteroatoms such as nitrogen may have hydrogen substituents and / or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms. It is understood that "substitution" or "substituted" includes the implicit proviso that such substitution is consistent with the permissible valences of the substituted atom and the substituents, and that the substitution results in a stable compound, i.e., a compound that does not spontaneously undergo transformations such as rearrangement, cyclization, elimination, etc.
[0094] As used herein, "alkyl" refers to a saturated aliphatic group, including straight chain alkyl groups, branched chain alkyl groups, and cycloalkyl (alicyclic). In some forms, a straight chain or branched chain alkyl group has 30 or fewer (e.g., C1-C2 for a straight chain) in its backbone. 30 , for the branched chain it is C3-C 30), 20 or less, 15 or less or 10 or less carbon atoms.Alkyl includes methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, amyl, hexyl, heptyl, octyl, decyl, tetradecyl, hexadecyl, eicosyl, tetracosyl etc.Similarly, cycloalkyl is a non-aromatic carbonyl ring comprising at least 3 carbon atoms, such as a non-aromatic monocyclic or non-aromatic polycyclic containing 3-30 carbon atoms, 3-20 carbon atoms or 3-10 carbon atoms in its ring structure, and has 5, 6 or 7 carbons in the ring structure.Cycloalkyl containing polycyclic system can have two or more non-aromatic rings (that is, "condensed cycloalkyl ring") in which two or more carbons are common to two adjacent rings.The example of cycloalkyl group includes but is not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl etc.
[0095] The term "alkyl" as used throughout the specification, examples and claims is intended to include "unsubstituted alkyl" and "substituted alkyl", the latter referring to an alkyl moiety having one or more substituents replacing hydrogen on one or more carbons on the hydrocarbon backbone. Such substituents may be any of the substituents described above, for example, halogen (such as fluorine, chlorine, bromine, or iodine), hydroxy, carbonyl (such as carboxyl, alkoxycarbonyl, formyl, or acyl), thiocarbonyl (such as thioacid, thioacetate, or thioformate), aryl, alkoxy, aralkyl, phosphonium, phosphoalkyl, phosphonyl, phosphoryl, phosphate, phosphonic acid, phosphinyl, amino, amide, amidine, imine, cyano, nitro, azido, oxo, sulfhydryl, thiol, alkylthio, silyl, sulfinyl, sulfate, sulfonic acid, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, aromatic or heteroaromatic moieties. -NRR', wherein R and R' are independently hydrogen, alkyl, or aryl, wherein the nitrogen atom is optionally quaternized; -SR, wherein R is phosphonyl, sulfinyl, silyl, hydrogen, alkyl, or aryl; -CN; -NO2; -COOH; carboxylate; -COR, -COOR, or -CON(R)2, wherein R is hydrogen, alkyl, or aryl; imino, silyl, ether, haloalkyl (such as -CF3, -CH2-CF3, -CCl3); -CN; -NCOCOCH2CH2; -NCOCOCHCH; and -NCS; and combinations thereof. The term "alkyl" also includes "heteroalkyl".
[0096] Those skilled in the art will appreciate that, in appropriate cases, the substituted moieties on the hydrocarbon chain can themselves be substituted. For example, the substituents of the substituted alkyl can include halogen, hydroxyl, nitro, thiol, amino, aralkyl, azido, imino, amide, phosphonium, phosphoalkyl, phosphoryl (including phosphonic acid and phosphinic acid), oxo, sulfonyl (including sulfate, sulfonamido, sulfamoyl and sulfonic acid), and silyl groups, as well as ethers, alkylthio, carbonyl (including ketone, aldehyde, carboxylate, and ester), haloalkyl, -CN, etc. Cycloalkyl can be substituted in the same manner.
[0097] Unless otherwise specified, "lower alkyl" as used herein means an alkyl group as defined above but having 1-10 carbons, more preferably 1-6 carbon atoms in its backbone structure. Similarly, "lower alkenyl" and "lower alkynyl" have similar chain lengths.
[0098] As used herein, "heteroalkyl" refers to a linear or branched or cyclic carbon-containing alkyl group containing at least one heteroatom, or a combination thereof. Suitable heteroatoms include, but are not limited to, O, N, Si, P, and S, wherein nitrogen, phosphorus, and sulfur atoms are optionally oxidized, and the nitrogen heteroatom is optionally quaternized. For example, the term "heterocycloalkyl group" is a cycloalkyl group as defined above in which at least one ring carbon atom is substituted with a heteroatom such as, but not limited to, nitrogen, oxygen, sulfur, or phosphorus.
[0099] The term "alkenyl" as used herein is a hydrocarbon group having 2-24 carbon atoms and a structural formula containing at least one carbon-carbon double bond. Alkenyl groups include straight chain alkenyl groups, branched alkenyl groups, and cycloalkenyl groups. Cycloalkenyl groups are non-aromatic carbonyl rings containing at least 3 carbon atoms and at least one carbon-carbon double bond in their ring structure, such as non-aromatic monocyclic or non-aromatic polycyclic rings containing 3-30 carbon atoms and at least one carbon-carbon double bond, 3-20 atoms and at least one carbon-carbon double bond, or 3-10 carbon atoms and at least one carbon-carbon double bond, and have 5, 6, or 7 carbons and at least one carbon-carbon double bond in the ring structure. Cycloalkenyl groups containing polycyclic ring systems can have two or more non-aromatic rings (i.e., "fused cycloalkyl rings") in which two or more carbons are common to two adjacent rings, and contain at least one carbon-carbon double bond. Asymmetric structures such as (AB)C=C(C'D) are intended to contain both E and Z isomers. This can be inferred from the structural formulas in which asymmetric olefins are present herein, or it can be explicitly shown by the bond symbol C. The term "alkenyl" as used throughout the specification, examples and claims is intended to include "unsubstituted alkenyl" and "substituted alkenyl", the latter referring to alkenyl moieties having one or more replacements of hydrogen on one or more carbons on the hydrocarbon backbone. The term "alkenyl" also includes "heteroalkenyl".
[0100] The term "substituted alkenyl" refers to an alkenyl moiety having one or more substituents replacing one or more hydrogen atoms on one or more carbons of the hydrocarbon backbone. Such substituents may be any of the substituents described above, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as carboxyl, alkoxycarbonyl, formyl, or acyl), silyl, ether, ester, thiocarbonyl (such as thioacid, thioacetate, or thioformate), alkoxy, phosphonium, phosphoalkyl, phosphoryl, phosphate, phosphonate, phosphinate, amino (e.g., quaternized amino), amide, amidine, imine, cyano, nitro, azido, oxo, sulfhydryl, alkylthio, sulfate, sulfonic acid, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkylaryl, haloalkyl, -CN, aryl, heteroaryl, polyaryl, polyheteroaryl, and combinations thereof.
[0101] As used herein, "heteroalkenyl" refers to a linear or branched or cyclic carbon-containing alkenyl group containing at least one heteroatom, or a combination thereof. Suitable heteroatoms include, but are not limited to, O, N, Si, P, and S, wherein nitrogen, phosphorus, and sulfur atoms are optionally oxidized, and the nitrogen heteroatom is optionally quaternized. For example, the term "heterocycloalkenyl group" is a cycloalkenyl group as defined above in which at least one ring carbon atom is substituted with a heteroatom such as, but not limited to, nitrogen, oxygen, sulfur, or phosphorus.
[0102] The term "alkynyl" as used herein is a hydrocarbon group having 2-24 carbon atoms and a structural formula containing at least one carbon-carbon triple bond. Alkynyl groups include straight chain alkynyl groups, branched chain alkynyl groups, and cycloalkynyl groups. Cycloalkynyl is a non-aromatic carbonyl ring containing at least 3 carbon atoms and at least one carbon-carbon triple bond in its ring structure, such as a non-aromatic monocyclic or non-aromatic polycyclic ring containing 3-30 carbon atoms and at least one carbon-carbon triple bond, 3-20 atoms and at least one carbon-carbon triple bond, or 3-10 carbon atoms and at least one carbon-carbon triple bond, and has 5, 6, or 7 carbons and at least one carbon-carbon triple bond in the ring structure. The cycloalkynyl containing polycyclic system can have two or more non-aromatic rings (i.e., "condensed cycloalkyl ring") in which two or more carbons are common to two adjacent rings, and comprises at least one carbon-carbon triple bond. Asymmetric structures such as (AB)C=C(C"D) and the like are intended to encompass both E and Z isomers. This may be inferred from the presence of asymmetric alkyne formulae herein, or it may be explicitly indicated by the bond symbol C. The term "alkynyl" as used throughout the specification, examples and claims is intended to include both "unsubstituted alkynyls" and "substituted alkynyls," the latter referring to alkynyl moieties having one or more substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. The term "alkynyl" also includes "heteroalkynyls."
[0103] The term "substituted alkynyl" refers to an alkynyl moiety having one or more substituents replacing one or more hydrogen atoms on one or more carbons of the hydrocarbon backbone. Such substituents may be any of the substituents described above, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as carboxyl, alkoxycarbonyl, formyl, or acyl), silyl, ether, ester, thiocarbonyl (such as thioacid, thioacetate, or thioformate), alkoxy, phosphonium, phosphoalkyl, phosphoryl, phosphate, phosphonate, phosphinate, amino (e.g., quaternized amino), amide, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonic acid, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkylaryl, haloalkyl, -CN, aryl, heteroaryl, polyaryl, polyheteroaryl, and combinations thereof.
[0104] As used herein, "heteroalkynyl" refers to a linear or branched or cyclic carbon-containing alkynyl group containing at least one heteroatom, or a combination thereof. Suitable heteroatoms include, but are not limited to, O, N, Si, P, and S, wherein nitrogen, phosphorus, and sulfur atoms are optionally oxidized, and the nitrogen heteroatom is optionally quaternized. For example, the term "heterocycloalkynyl group" is a cycloalkynyl group in which at least one ring carbon atom is substituted with a heteroatom such as, but not limited to, nitrogen, oxygen, sulfur, or phosphorus.
[0105] The term "aryl" as used herein refers to any C5-C 26 Carbon-based aromatic, heteroaromatic, fused aromatic, or fused heteroaromatic groups. For example, "aryl" as used herein may include 5-, 6-, 7-, 8-, 9-, 10-, 14-, 18-, and 24-membered monocyclic aromatic groups, including but not limited to benzene, naphthalene, anthracene, phenanthrene, "Aryl" also encompasses polycyclic systems having two or more rings in which two or more carbons are common to two adjacent rings (i.e., "fused aromatic rings"), wherein at least one ring is aromatic, for example, the other one or more rings may be cycloalkyl, cycloalkenyl, cycloalkynyl, aryl and / or heterocyclic. Aryl groups may be substituted with one or more groups including, but not limited to, alkyl, alkynyl, alkenyl, aryl, halide, nitro, amino, ester, ketone, aldehyde, hydroxyl, carboxylic acid, or alkoxy.
[0106] The term "substituted aryl" refers to aryl groups in which one or more hydrogen atoms on one or more aromatic rings are replaced with one or more substituents. Such substituents can be any of the substituents described above, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxy, alkoxy, carbonyl (such as ketone, aldehyde, carboxyl, alkoxycarbonyl, formyl, or acyl, etc.), silyl, ether, ester, thiocarbonyl (such as thioacyl, thioacetyl, or thioformyl), alkoxy, phosphonium, phosphanyl, phosphoryl, phosphate, phosphonate, phosphinate, amino (e.g., quaternized amino), amide, amidine, imine, cyano, nitro, azido, sulfhydryl, imino, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkylaryl, haloalkyl (such as CF3, -CH2-CF3, -CCl3), -CN, aryl, heteroaryl, and combinations thereof.
[0107] "Heterocycle" and "heterocyclyl" are used interchangeably and refer to cyclic radicals containing 3-30 ring atoms, 3-20 ring atoms, 3-10 ring atoms, or 5-6 ring atoms connected through non-aromatic monocyclic or polycyclic ring carbon atoms or ring nitrogen atoms, wherein each ring contains carbon and 1-4 heteroatoms, each of which is selected from the group consisting of non-peroxide oxygen, sulfur, and N(Y), wherein Y is absent or is H, O, C1-C 10 alkyl, phenyl or benzyl, and optionally containing 1-3 double bonds and optionally substituted by one or more substituents. The definition of heterocyclic radical is different from heteroaryl. Heterocycle can be heterocycloalkyl, heterocycloalkenyl, heterocycloalkynyl, etc., such as piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, dihydrofuran [2,3-b] tetrahydrofuran, morpholinyl, piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, piperonyl, pyranyl, 2H-pyrrolyl, 4H-quinolizinyl, quinuclidinyl, tetrahydrofuranyl, 6H-1,2,5-thiadiazinyl. The heterocyclic group can be optionally substituted by one or more substituents defined above for alkyl and aryl.
[0108] The term "heteroaryl" refers to a C5-C 30-Member aromatic, fused aromatic, biaromatic ring system, or a combination thereof, wherein one or more carbon atoms on one or more aromatic ring structures have been replaced by heteroatoms. Suitable heteroatoms include, but are not limited to, oxygen, sulfur, and nitrogen. Broadly speaking, "heteroaryl" as used herein includes 5-, 6-, 7-, 8-, 9-, 10-, 14-, 18-, and 24-membered monocyclic aromatic groups, which may include 1-4 heteroatoms, such as pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, tetrazole, pyrazole, pyridine, pyrazine, pyridazine, pyrimidine, etc. Heteroaryl groups may also be referred to as "aryl heterocycles" or "heteroaromatic groups". "Heteroaryl" also encompasses a polycyclic system (i.e., "fused rings") having two or more rings in which two or more carbons are common to two adjacent rings, wherein at least one ring is heteroaromatic, for example, one or more additional rings may be cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocycle, or a combination thereof. Examples of heteroaryl rings include, but are not limited to, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzoxazinyl, benzothiazolyl, benzotriazolyl, benzotetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, furanyl, furazanyl, imidazolidinyl, imidazolidinyl, imidazolyl ... oxazolinyl, imidazolyl, 1H-indazolyl, dihydroindolinyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isatoyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, methylenedioxyphenyl, naphthyridinyl, octahydroisoquinolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazole alkyl, oxazolyl, oxindolyl, pyrimidinyl, phenanthridinyl, o-phenanthrenyl, phenazinyl, phenothiazinyl, phenoxathinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, tetrahydroisoquinolyl, tetrahydroquinolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, and xanthenyl. One or more rings may be substituted, as defined below for "substituted heteroaryl".
[0109] The term "substituted heteroaryl" refers to heteroaryl groups in which one or more hydrogen atoms on one or more heteroaromatic rings are replaced with one or more substituents. Such substituents can be any of the substituents described above, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxy, alkoxy, carbonyl (such as ketone, aldehyde, carboxyl, alkoxycarbonyl, formyl, or acyl, etc.), silyl, ether, ester, thiocarbonyl (such as thioacyl, thioacetyl, or thioformyl), alkoxy, phosphonium, phosphanyl, phosphoryl, phosphate, phosphonate, phosphinate, amino (e.g., quaternized amino), amide, amidine, imine, cyano, nitro, azido, sulfhydryl, imino, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkylaryl, haloalkyl (such as CF3, -CH2-CF3, -CCl3), -CN, aryl, heteroaryl, and combinations thereof.
[0110] The term "polyaryl" refers to a chemical moiety comprising two or more aryl, heteroaryl, and combinations thereof. Aryl, heteroaryl, and combinations thereof are fused, or connected via a single bond, ether, ester, carbonyl, amide, sulfonyl, sulfonamide, alkyl, azo, and combinations thereof. For example, "polyaryl" can be a polycyclic system (i.e., "fused aromatic ring") having two or more rings common to two adjacent rings where two or more carbons are present, wherein two or more rings are aromatic. When two or more heteroaryl groups are involved, a chemical moiety can be referred to as "polyheteroaryl".
[0111] The term "substituted polyaryl" refers to a polyaryl in which one or more aryl or heteroaryl groups are substituted by one or more substituents. Such substituents may be any of the substituents described above, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as carboxyl, alkoxycarbonyl, formyl, or acyl), silyl, ether, ester, thiocarbonyl (such as thioacid, thioacetate, or thioformate), alkoxy, phosphonium, phosphoalkyl, phosphoryl, phosphate, phosphonate, phosphinate, amino (such as quaternized amino), amide, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonic acid, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkylaryl, haloalkyl, -CN, aryl, heteroaryl, and combinations thereof. When two or more heteroaryls are involved, the chemical moiety may be referred to as a "substituted polyheteroaryl".
[0112] The term "ring" or "cyclic group" refers to a substituted or unsubstituted monocycle or a substituted or unsubstituted polycycle (such as those formed by a monocycle or condensed ring system), such as a substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, or substituted or unsubstituted heterocyclyl having 3 to 30 carbon atoms where geometric constraints permit. Substituted cycloalkyl, cycloalkenyl, cycloalkynyl, and heterocyclyl are substituted as defined above for alkyl, alkenyl, alkynyl, and heterocyclyl, respectively.
[0113] The term "aralkyl" as used herein is an aryl or heteroaryl group having an alkyl, alkynyl, or alkenyl group as defined above attached to an aryl group, such as an aryl, heteroaryl, polyaryl, or polyheteroaryl. An example of an aralkyl group is a benzyl group.
[0114] The terms "alkoxy" or "alkyloxy", "aryloxy" or "aryloxy" generally describe a radical of the formula -OR v A compound represented by v Including but not limited to substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic radical, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted assorted alkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, phosphonium, phosphine, phosphonyl, sulfinyl, silyl, mercaptan, amide and amino. Exemplary alkoxy groups include methoxy, ethoxy, propoxy, tert-butoxy etc. "low alkoxy" group is an alkoxy group containing 1-6 carbon atoms. "ether" is two functional groups covalently linked by oxygen, as defined below. Thus, the substituent of the alkyl group that makes the alkyl group ether is an alkoxy group or an alkoxy-like group, such as represented by one of the following: -O-alkyl, -O-alkenyl, -O-alkynyl, -O-aralkyl, -O-aryl, -O-heteroaryl, -O-polyaryl, -O-polyheteroaryl, -O-heterocyclyl, etc.
[0115] The term "substituted alkoxy" refers to an alkoxy moiety having one or more substituents replacing one or more hydrogen atoms on one or more carbons of the alkoxy backbone. Such substituents may be any of the substituents described above, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as carboxyl, alkoxycarbonyl, formyl, or acyl), silyl, ether, ester, thiocarbonyl (such as thioacid, thioacetate, or thioformate), alkoxy, phosphonium, phosphoalkyl, phosphoryl, phosphate, phosphonate, phosphinate, amino (e.g., quaternized amino), amide, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, oxo, sulfate, sulfonic acid, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkylaryl, haloalkyl, -CN, aryl, heteroaryl, and combinations thereof.
[0116] As used herein, the term "ether" is a 2 OA 1 Indicates that A 2 and A 1 The above-described substituted or unsubstituted alkyl group, substituted or unsubstituted alkenyl group, substituted or unsubstituted alkynyl group, substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl group, substituted or unsubstituted heteroaryl group, substituted or unsubstituted aralkyl group, substituted or unsubstituted polyaryl group, substituted or unsubstituted polyheteroaryl group, phosphonium group, phosphane group, phosphonyl group, sulfinyl group, silyl group, thiol group, substituted or unsubstituted carbonyl group, alkoxy group, amide group, or amino group may be independently selected.
[0117] The term "polyether" as used herein is represented by the formula:
[0118]
[0119] Among them A 3 , A 2 , and A 1 It may independently be a substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, phosphonium, phosphanyl, substituted or unsubstituted carbonyl, alkoxy, amide, or amino group described above; g may be a positive integer of 1-30.
[0120] The term "phenoxy" is art-recognized and refers to a radical of the formula -OR v A compound wherein R v Those skilled in the art will recognize that phenoxy is a type of aryloxy.
[0121] The term "substituted phenoxy" refers to a phenoxy group as defined above having one or more substituents replacing one or more hydrogen atoms on one or more carbons of a benzene ring. Such substituents include, but are not limited to, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as carboxyl, alkoxycarbonyl, formyl, or acyl), silyl, ether, ester, thiocarbonyl (such as thioacid, thioacetic acid, or thioformic acid), alkoxy, phosphonium, phosphoalkyl, phosphoalkyl, phosphoryl, phosphate, phosphonic acid, phosphinic acid, amino (such as quaternized amino, etc.), amide, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonic acid, sulfamoyl, sulfonamido, sulfonyl, heterocyclic, alkylaryl, haloalkyl, -CN, aryl, heteroaryl, and combinations thereof.
[0122] The terms "aryloxy" and "aryloxy" are used interchangeably herein and are represented by -O-aryl or -O-heteroaryl, wherein aryl and heteroaryl are as defined herein.
[0123] The terms "substituted aryloxy" and "substituted aryloxy" are used interchangeably herein and refer to an -O-aryl or -O-heteroaryl group as defined herein having one or more substituents replacing one or more hydrogen atoms on one or more ring atoms of the aryl and heteroaryl groups. Such substituents can be any of the substituents described above, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as carboxyl, alkoxycarbonyl, formyl, or acyl), silyl, ether, ester, thiocarbonyl (such as thioacyl, thioacetyl, or thioformyl), alkoxy, phosphonium, phosphanyl, phosphanyl, phosphoryl, phosphate, phosphonate, phosphinate, amino (such as quaternized amino), amide, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkylaryl, haloalkyl, -CN, aryl, heteroaryl, polyaryl, polyheteroaryl, and combinations thereof.
[0124] As used herein, the term "amino" includes the following groups:
[0125]
[0126] wherein E is absent or E is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclyl, wherein R is independent of E, x , R xi , and R xiiEach independently represents a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted carbonyl group, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aralkyl group (e.g., a substituted or unsubstituted alkylaryl group, a substituted or unsubstituted arylalkyl group), a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted polyaryl group, a substituted or unsubstituted polyheteroaryl group, a substituted or unsubstituted heterocyclic group, a hydroxyl group, an alkoxy group, a phosphonium group, a phosphine group, a phosphino group, a sulfinyl group, a silyl group, a thiol group, an amide group, an amino group, or -(CH2) m -R"'; R"' represents a hydroxyl group, a substituted or unsubstituted carbonyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted cycloalkenyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted polyaryl group, a substituted or unsubstituted polyheteroaryl group, an alkoxy group, a phosphonium group, a phosphine group, an amide group, or an amino group; and m is 0 or an integer ranging from 1 to 8. The term "quaternized amino group" also includes groups wherein nitrogen, R x , R xi , and R xii The N + Completion is a heterocyclyl or heteroaryl group having 3 to 14 atoms in the ring structure.
[0127] The terms "amide" or "amido" are used interchangeably to refer to both "unsubstituted amide" and "substituted amide" and are represented by the following general formula:
[0128]
[0129] wherein E is absent, or E is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, or substituted or unsubstituted heterocyclyl, wherein, independently of E, R and R' each independently represent hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl , substituted or unsubstituted carbonyl, substituted or unsubstituted heterocyclic, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclic, hydroxy, alkoxy, phosphonium, phosphine, phosphino, sulfinyl, silyl, thiol, amide, amino, or -(CH2) m-R"', or R and R' together with the N atom to which they are attached complete a heterocyclic ring having 3-14 atoms in the ring structure; R"' represents a hydroxyl group, a substituted or unsubstituted carbonyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted cycloalkenyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted polyaryl group, a substituted or unsubstituted polyheteroaryl group, an alkoxy group, a phosphonium group, a phosphine group, an amide group, or an amino group; and m is 0 or an integer ranging from 1-8. In some forms, when E is oxygen, a carbamate group is formed.
[0130] As used herein, "carbonyl" is art-recognized and includes moieties such as those represented by the following general formula:
[0131]
[0132] wherein X is a bond or represents oxygen or sulfur, and R represents hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbonyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclyl, hydroxy, alkoxy, phosphonium, phosphoalkyl, amide, amino, or -(CH2) m -R", or a pharmaceutically acceptable salt; E" is absent, or E" is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclyl; R' represents hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbonyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclyl, hydroxy, alkoxy, phosphonium, phosphoalkyl, amide, amino, or -(CH2) m-R"; R" represents a hydroxyl group, a substituted or unsubstituted carbonyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted cycloalkenyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted polyaryl group, a substituted or unsubstituted polyheteroaryl group, an alkoxy group, a phosphonium group, a phosphine group, an amide group, or an amino group; and m is 0 or an integer ranging from 1 to 8. When X is oxygen and R is as defined above, the moiety is also referred to as a carboxyl group. When X is oxygen and R is hydrogen, the formula represents a "carboxylic acid". When X is oxygen and R' is hydrogen, the formula represents a "formyl group". When X is oxygen and R or R' is not hydrogen, the formula represents an "ester". Generally, when the oxygen atom of the above formula is replaced by a sulfur atom, the formula represents a "thiocarbonyl" group. When X is sulfur and R or R' is not hydrogen, the formula represents a "thioacid group". When X is sulfur and R is hydrogen, the formula represents a "thiocarboxylic acid". When X is sulfur and R' is hydrogen, the formula represents a "thioformyl". When X is a bond and R is not hydrogen, the above formula represents a "ketone". When X is a bond and R is hydrogen, the above formula represents an "aldehyde".
[0133] The term "substituted carbonyl" refers to a carbonyl group wherein R, R' or R' is or are:
[0134]
[0135] One or more hydrogen atoms in the connected group are independently replaced by a carbonyl as defined above. Such substituents can be any substituent described above, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as carboxyl, alkoxycarbonyl, formyl, or acyl), silyl, ether, ester, thiocarbonyl (such as thioacid, thioacetate, or thioformate), alkoxy, phosphonium, phosphoalkyl, phosphoryl, phosphate, phosphonate, phosphinate, amino (such as quaternized amino), amide, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonic acid, sulfamoyl, sulfonamido, sulfonyl, heterocyclic, alkylaryl, haloalkyl, -CN, aryl, heteroaryl, and combinations thereof.
[0136] The term "carboxyl" is as defined above for a carbonyl group, more specifically a group of the formula -R iv COOH definition, where R iv is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, or substituted or unsubstituted heteroaryl.
[0137] The term "substituted carboxyl" refers to a group in which Riv One or more hydrogen atoms in the substituted carboxyl group as defined above. Such substituents may be any of the substituents described above, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as carboxyl, alkoxycarbonyl, formyl, or acyl), silyl, ether, ester, thiocarbonyl (such as thioacid, thioacetate, or thioformate), alkoxy, phosphonium, phosphoalkyl, phosphoryl, phosphate, phosphonate, phosphinate, amino (such as quaternized amino), amide, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonic acid, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkylaryl, haloalkyl, -CN, aryl, heteroaryl, polyaryl, polyheteroaryl, and combinations thereof.
[0138] The term "phosphanyl group" is represented by the formula:
[0139]
[0140] wherein E is absent or E is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aralkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclyl, wherein, independently of E, R vi and R vii Each independently represents hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbonyl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, etc.), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclic group, hydroxyl, alkoxy, phosphonium, phosphinyl, phosphino, sulfinyl, silyl, thiol, amide, amino, or -(CH2) m -R"', or R vi and R vii Together with the P atoms to which they are attached, they complete a heterocycle having 3 to 14 atoms in the ring structure; R'' represents a hydroxyl group, a substituted or unsubstituted carbonyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted cycloalkenyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted polyaryl group, a substituted or unsubstituted polyheteroaryl group, an alkoxy group, a phosphonium group, a phosphoalkyl group, an amide group, or an amino group; and m is 0 or an integer ranging from 1 to 8.
[0141] The term "phosphonium" is represented by the following formula:
[0142]
[0143] wherein E is absent or E is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aralkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclyl, wherein, independently of E, R vi , R vii , and R viii Each independently represents hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbonyl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, etc.), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclic group, hydroxyl, alkoxy, phosphonium, phosphinyl, phosphino, sulfinyl, silyl, thiol, amide, amino, or -(CH2) m -R"', or R vi , R vii , and R viii The P + The atoms together complete a heterocycle having 3 to 14 atoms in the ring structure; R'' represents a hydroxyl group, a substituted or unsubstituted carbonyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted cycloalkenyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted polyaryl group, a substituted or unsubstituted polyheteroaryl group, an alkoxy group, a phosphonium group, a phosphine group, an amide group, or an amino group; and m is 0 or an integer ranging from 1 to 8.
[0144] The term "phosphono" is represented by the formula:
[0145]
[0146] wherein E is absent, or E is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, etc.), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclyl, oxygen, alkoxy, aryloxy, or substituted alkoxy, or substituted aryloxy, wherein, independently of E, R vi and R viiindependently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbonyl, substituted or unsubstituted heterocyclic, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, etc.), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclic, hydroxy, alkoxy, phosphonium, phosphine, phosphino, sulfinyl, silyl, thiol, amide, amino, or -(CH2) m -R"', or R vi and R vii Together with the P atoms to which they are attached, they complete a heterocycle having 3 to 14 atoms in the ring structure; R'' represents a hydroxyl group, a substituted or unsubstituted carbonyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted cycloalkenyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted polyaryl group, a substituted or unsubstituted polyheteroaryl group, an alkoxy group, a phosphonium group, a phosphoalkyl group, an amide group, or an amino group; and m is 0 or an integer ranging from 1 to 8.
[0147] The term "substituted phosphono" refers to a group in which E, R vi , and R vii The substituents may be any of the substituents described above, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as carboxyl, alkoxycarbonyl, formyl, or acyl), silyl, ether, ester, thiocarbonyl (such as thioacid, thioacetate, or thioformate), alkoxy, phosphoryl, phosphate, phosphonate, phosphinate, amino (such as quaternized amino), amide, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonic acid, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkylaryl, haloalkyl, -CN, aryl, heteroaryl, polyaryl, polyheteroaryl, and combinations thereof.
[0148] The term "phosphoryl" defines a phosphonyl group wherein E is absent, oxygen, alkoxy, aryloxy, substituted alkoxy, or substituted aryloxy as defined above, and independently of E, R vi and R vii R is independently hydroxy, alkoxy, aryloxy, substituted alkoxy, or substituted aryloxy as defined above. As will be appreciated by those skilled in the art, when E is oxygen, the phosphoryl group cannot be attached to another chemical species such as to form an oxygen-oxygen bond or other unstable bond. vi , and R viiWhen substituted, the substituents include, but are not limited to, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as carboxyl, alkoxycarbonyl, formyl, or acyl), silyl, ether, ester, thiocarbonyl (such as thioacid, thioacetate, or thioformate), alkoxy, phosphoryl, phosphate, phosphonate, phosphinate, amino (e.g., quaternized amino), amide, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkylaryl, haloalkyl, -CN, aryl, heteroaryl, polyaryl, polyheteroaryl, and combinations thereof.
[0149] The term "sulfinyl" is represented by the formula:
[0150]
[0151] wherein E is absent, or E is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, etc.), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, wherein, independently of E, R represents hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbonyl, substituted or unsubstituted heterocyclic, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclic, hydroxy, alkoxy, phosphonium, phosphine, phosphino, phosphono, silyl, thiol, amide, amino, or -(CH2) m -R"', or E and R together with the S atom to which they are attached complete a heterocycle having 3-14 atoms in the ring structure; R"' represents a hydroxyl group, a substituted or unsubstituted carbonyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted cycloalkenyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted polyaryl group, a substituted or unsubstituted polyheteroaryl group, an alkoxy group, a phosphonium group, a phosphoalkyl group, an amide group, or an amino group; and m is 0 or an integer ranging from 1 to 8.
[0152] The term "sulfonyl" is represented by the formula:
[0153]
[0154] wherein E is absent or E is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, etc.), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, wherein, independently of E, R represents hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbonyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclyl, hydroxy, alkoxy, phosphonium, phosphinyl, amide, amino, or -(CH2) m -R"', or E and R together with the S atom to which they are attached complete a heterocyclic ring having 3-14 atoms in the ring structure; R"' represents a hydroxyl group, a substituted or unsubstituted carbonyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted cycloalkenyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted polyaryl group, a substituted or unsubstituted polyheteroaryl group, an alkoxy group, a phosphonium group, a phosphine group, an amide group, or an amino group; and m is 0 or an integer ranging from 1 to 8.
[0155] The term "substituted sulfonyl" refers to a sulfonyl group in which E, R, or both are independently substituted. Such substituents may be any of the substituents described above, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as carboxyl, alkoxycarbonyl, formyl, or acyl), silyl, ether, ester, thiocarbonyl (such as thioacid, thioacetate, or thioformate), alkoxy, phosphonium, phosphoalkyl, phosphoryl, phosphate, phosphonate, phosphinate, amino (such as quaternized amino), amide, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonic acid, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkylaryl, haloalkyl, -CN, aryl, heteroaryl, polyaryl, polyheteroaryl, and combinations thereof.
[0156] The term "sulfonic acid" refers to a sulfonyl group as defined above wherein R is hydroxy and E is absent or E is substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, or substituted or unsubstituted heteroaryl.
[0157] The term "sulfate" refers to a sulfonyl group as defined above wherein E is absent, oxygen, alkoxy, aryloxy, substituted alkoxy, or substituted aryloxy as defined above and R is independently hydroxy, alkoxy, aryloxy, substituted alkoxy, or substituted aryloxy as defined above. As will be appreciated by those skilled in the art, when E is oxygen, the sulfate group cannot be attached to another chemical species such as to form an oxygen-oxygen bond or other unstable bond.
[0158] The term "sulfonic acid" refers to a sulfonyl group as defined above: wherein E is oxygen, alkoxy, aryloxy, substituted alkoxy, or substituted aryloxy as defined above, and R is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted amino, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, -(CH2) m -R"', R"' represents a hydroxyl group, a substituted or unsubstituted carbonyl group, an aryl group, a cycloalkyl ring, a cycloalkenyl ring, a heterocycle, an amide group, an amino group, or a polycycle; and m is 0 or an integer ranging from 1 to 8. As is known to those skilled in the art, when E is oxygen, the sulfonic acid group cannot be connected to another chemical substance such as to form an oxygen-oxygen bond or other unstable bonds.
[0159] The term "sulfamoyl" refers to a sulfonamide or sulfonamide represented by the formula:
[0160]
[0161] wherein E is absent, or E is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted cycloalkyl, etc.), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclyl, wherein, independently of E, R and R' each independently represent hydrogen, substituted or unsubstituted alkyl ... a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted carbonyl group, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aralkyl group (e.g., a substituted or unsubstituted alkylaryl group, a substituted or unsubstituted arylalkyl group, etc.), a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted polyaryl group, a substituted or unsubstituted polyheteroaryl group, a substituted or unsubstituted heterocyclic group, a hydroxyl group, an alkoxy group, a phosphonium group, a phosphine group, an amide group, an amino group, or -(CH2) m-R"', or R and R' together with the N atom to which they are attached complete a heterocyclic ring having 3-14 atoms in the ring structure; R"' represents a hydroxyl group, a substituted or unsubstituted carbonyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted cycloalkenyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted polyaryl group, a substituted or unsubstituted polyheteroaryl group, an alkoxy group, a phosphonium group, a phosphine group, an amide group, or an amino group; and m is 0 or an integer ranging from 1 to 8.
[0162] The term "silyl group" as used herein is represented by the formula -SiRR'R", wherein R, R', and R" can independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, etc.), substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted carbonyl, phosphonium, phosphoalkyl, phosphono, sulfinyl, thiol, amide, amino, alkoxy, or oxo as described above.
[0163] The term "thiol" is used interchangeably and is represented by -SR, wherein R may be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, etc.), substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted carbonyl, phosphonium, phosphoalkyl, amide, amino, alkoxy, oxo, phosphono, sulfinyl, or silyl as described above.
[0164] The term "alkylthio" refers to an alkyl group as defined above having a sulfenyl group attached thereto. "Alkylthio" is represented by -S-alkyl. Representative alkylthio groups include methylthio, ethylthio, and the like. The term "alkylthio" also includes cycloalkyl groups having a sulfenyl group attached thereto.
[0165] The term "substituted alkylthio" refers to an alkylthio group having one or more substituents replacing one or more hydrogen atoms on one or more carbons of the alkylthio backbone. Such substituents include, but are not limited to, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as carboxyl, alkoxycarbonyl, formyl, or acyl), silyl, ether, ester, thiocarbonyl (such as thioacid, thioacetate, or thioformate), alkoxy, phosphonium, phosphoalkyl, phosphoryl, phosphate, phosphonate, phosphinate, amino (e.g., quaternized amino, etc.), amide, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonic acid, sulfamoyl, sulfonamido, sulfonyl, heterocyclic, alkylaryl, haloalkyl, -CN, aryl, heteroaryl, and combinations thereof.
[0166] The term "phenylthio" is art-recognized and refers to -S-C6H5, ie, a phenyl group attached to a sulfur atom.
[0167] The term "substituted phenylthio" refers to a phenylthio group as defined above having one or more substituents replacing hydrogen on one or more carbons of the phenyl ring. Such substituents include, but are not limited to, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as carboxyl, alkoxycarbonyl, formyl, or acyl), silyl, ether, ester, thiocarbonyl (such as thioacid, thioacetate, or thioformate), alkoxy, phosphonium, phosphoalkyl, phosphoryl, phosphate, phosphonate, phosphinate, amino (e.g., quaternized amino), amide, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonic acid, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkylaryl, haloalkyl, -CN, aryl, heteroaryl, and combinations thereof.
[0168] "Arylthio" means an -S-aryl or -S-heteroaryl group in which aryl and heteroaryl are as defined above.
[0169] The term "substituted arylthio" refers to an -S-aryl or -S-heteroaryl having one or more substituents replacing hydrogen atoms on one or more ring atoms of aryl and heteroaryl rings as defined herein. Such substituents include, but are not limited to, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as carboxyl, alkoxycarbonyl, formyl, or acyl), silyl, ether, ester, thiocarbonyl (such as thioacid, thioacetate, or thioformate), alkoxy, phosphonium, phosphoalkyl, phosphoryl, phosphate, phosphonate, phosphinate, amino (e.g., quaternized amino), amide, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonic acid, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkylaryl, haloalkyl, -CN, aryl, heteroaryl, and combinations thereof.
[0170] The disclosed compounds and substituted groups can independently have two or more of the groups listed above. For example, if the compound or substituted group is a straight chain alkyl group, one of the hydrogen atoms of the alkyl group can be substituted by a hydroxyl group, an alkoxy group, etc. Depending on the selected group, the first group can be added to the second group, or alternatively, the first group can be side-joined (i.e., connected) to the second group. For example, when the phrase "alkyl group comprising an ester group" is used, the ester group can be added to the main chain of the alkyl group. Alternatively, the ester can be connected to the main chain of the alkyl group. The idiosyncrasy of the selected group will determine whether the first group is embedded in the second group or connected to the second group.
[0171] The compounds and substituents may independently be substituted with substituents as described above in the definition of "substituted".
[0172] II. Composition
[0173] Synthetic agrimonol B (AGB) and its derivatives have been developed. The synthetic compounds disclosed herein have anticancer properties and should be suitable for treating or ameliorating the symptoms of various types of cancer. For example, these compounds are suitable for treating or ameliorating the symptoms of non-small cell lung cancer. Without being bound by any theory, the dimerized acylphloroglucinol and acyl groups on the ring structure contribute to the anticancer activity of these compounds, making them useful for binding to certain biological targets, thereby inducing apoptosis of cancer cells. For example, it is believed that the mechanism of the anticancer activity of AGB and its derivatives includes mitochondrial dysfunction and / or blocking ER-Golgi transport, thereby inducing apoptosis of cancer cells. As illustrated in the examples, the biological targets of AGB were determined to be citrate synthase (CS), transaldolase 1 (TALDO1), and heat shock protein 60 (HSP60) by an unbiased thermoproteomics analysis method.
[0174] Also disclosed is a pharmaceutical composition containing the compound.
[0175] A. Agrimonia phenol B and its derivatives
[0176] AGB and its derivatives (also referred to herein as "compounds") may have the structure of Formula I:
[0177]
[0178] Wherein: (a) L1 and L2 can independently be a bond (single bond, double bond or triple bond), a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, a carbonyl or an alkoxyl group; (b) L3 can be a bond (single bond, double bond or triple bond), a substituted or unsubstituted alkyl, or a carbonyl group; (c) A1 and A2 can independently be hydrogen, a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted aryl, a carbonyl or an alkoxyl group, and at least one of A1 and A2 is a substituted or unsubstituted aryl group; (d) A3 can be hydrogen, a substituted or unsubstituted alkyl, a substituted or unsubstituted aryl, a carbonyl or an alkoxyl group; (e) R1-R3 can independently be hydrogen, a hydroxyl group, , substituted or unsubstituted alkyl, carbonyl, alkoxy, thiol, or amino; and (f) the substituents may independently be substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, carbonyl, alkoxy, halogen, hydroxy, phenoxy, thiol, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amide, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphoalkyl, phosphoryl, or phosphonyl.
[0179] In some forms, the AGB and derivatives thereof described herein, such as those having the structure of Formula I, contain at least two aryl groups, ie, contain 2, 3, or more aryl groups, such as contain 3 or 4 aryl groups, for example, contain 3 aryl groups.
[0180] In some forms, the compound may have the structure of Formula III:
[0181]
[0182] Wherein: (a) L1 and L2 can independently be a bond (single bond, double bond or triple bond), substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, carbonyl, or alkoxy; (b) L3-L5 can independently be a bond (single bond, double bond or triple bond), substituted or unsubstituted alkyl, or carbonyl; (c) A3-A5 can independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, carbonyl, or alkoxy; (d) R1-R3 and R9-R 16 and (e) the substituents may be as defined above for Formula I. In some forms, A3-A5 and / or R1-R3 and R9-R 16 is not a substituted or unsubstituted aryl group. In some forms, A3-A5, R1-R3, and R9-R 16 It is not a substituted or unsubstituted aryl group.
[0183] For any of Formula I, Ia, and III, -L1-A1 may be the same as or different from -L2-A2. For any of Formula I, Ia, and III, -L1-A1 may be the same as -L2-A2. In some forms, the compound may have a structure of Formula IV:
[0184]
[0185] wherein: (a) L3 and L7 can independently be a bond (single bond, double bond or triple bond), a substituted or unsubstituted alkyl, or a carbonyl group; (b) L6 can be a bond (single bond, double bond or triple bond), a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, a carbonyl group, or an alkoxy group; (c) A3 and A7 can independently be hydrogen, a substituted or unsubstituted alkyl, a substituted or unsubstituted aryl, a carbonyl group, or an alkoxy group; (d) R1-R3 and R 18 -R 21 and (e) the substituents may be as defined above for Formula I. In some forms, A3 and A7 and / or R1-R3 and R 18 -R 21 is not a substituted or unsubstituted aryl group. In some forms, A3, A7, R1-R3, and R 18 -R 21 It is not a substituted or unsubstituted aryl group.
[0186] In some forms of Formula IV, R 18 -R 21 They may independently be hydrogen, hydroxy, substituted or unsubstituted alkyl, carbonyl, or alkoxy (eg, methoxy, ethoxy, etc.).
[0187] In some forms, -L1-A1 may be different from -L2-A2. In some forms, the compound may have a structure of Formula XIX:
[0188]
[0189] wherein: (a) L1 and L2 are independently a single bond, a substituted or unsubstituted alkylene group, a substituted or unsubstituted alkenylene group, -C(O)-, or an alkoxy group; (b) A1 is a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted aryl group, a carbonyl group, or an alkoxy group; (c) R1-R3 and / or R 13 -R 16are independently hydrogen, hydroxy, substituted or unsubstituted alkyl, -OR4, -SR5, or -NR6R7, R4-R7 are independently hydrogen or substituted or unsubstituted alkyl; (d) -L3-A3 is R 17 is substituted or unsubstituted alkyl, substituted or unsubstituted aryl; and (e)-L5-A5 is hydrogen, substituted or unsubstituted alkyl, or R 17 is a substituted or unsubstituted alkyl group.
[0190] For any of Formulas I, Ia, II, III, IV, and XIX, R1-R3, R8-R 16 , and / or R 18 -R 21 R4 to R7 may independently be hydrogen, hydroxy, substituted or unsubstituted alkyl, -OR4, -SR5, or -NR6R7; R4 to R7 may independently be hydrogen or substituted or unsubstituted alkyl.
[0191] For any of Formulas I, Ia, II, III, IV, and XIX, R1-R3 can be hydroxyl.
[0192] For any of Formulas Ia, II, III, IV, and XIX, R8-R 16 and / or R 18 -R 21 Can be independently hydrogen, hydroxyl, substituted or unsubstituted alkyl, or -OR4, R4 can be substituted or unsubstituted alkyl. In some forms, R4 can be substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C5 alkyl, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C3 alkyl, substituted or unsubstituted C1-C2 alkyl, or substituted or unsubstituted methyl. In some forms, R4 can be unsubstituted C1-C5 alkyl, unsubstituted C1-C4 alkyl, unsubstituted C1-C3 alkyl, unsubstituted C1-C2 alkyl, or unsubstituted methyl. In some forms, R4 can be unsubstituted straight or branched C1-C5 alkyl, unsubstituted straight or branched C1-C4 alkyl, unsubstituted straight or branched C1-C3 alkyl, unsubstituted C1-C2 alkyl, or unsubstituted methyl.
[0193] For any of Formulas I, Ia, II, III, IV, and XIX, -L3-A3 may independently be substituted or unsubstituted alkyl. In some forms, -L3-A3 may independently be substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C5 alkyl, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C3 alkyl, substituted or unsubstituted C1-C2 alkyl, or substituted or unsubstituted methyl. For any of Formulas I, Ia, II, III, IV, and XIX, -L3-A3, -L4-A4, -L5-A5, and / or -L7-A7 may independently be R 17 It may be a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, or m can be an integer from 0 to 5, R 26 can be a carboxylic acid, an ester, an amino group, or an amide. In some forms, R 17 It may be a substituted or unsubstituted C1-C8 alkyl, a substituted or unsubstituted C1-C7 alkyl, a substituted or unsubstituted C1-C6 alkyl, a substituted or unsubstituted C1-C5 alkyl, a substituted or unsubstituted C1-C4 alkyl, a substituted or unsubstituted C1-C3 alkyl, a substituted or unsubstituted C1-C2 alkyl, or a substituted or unsubstituted methyl. In some forms, R 17 It may be an unsubstituted C1-C6 alkyl. 17 may be an unsubstituted C6 cycloalkyl. 17 can be unsubstituted C1-C5 alkyl, unsubstituted C1-C4 alkyl, unsubstituted C1-C3 alkyl, unsubstituted C1-C2 alkyl, or unsubstituted methyl. 17 It may be an unsubstituted straight or branched C1-C5 alkyl group, an unsubstituted straight or branched C1-C4 alkyl group, an unsubstituted straight or branched C1-C3 alkyl group, an unsubstituted C1-C2 alkyl group, or an unsubstituted methyl group. 17 It may be a substituted or unsubstituted phenyl group. In some forms, R 17 Can be unsubstituted phenyl. In some forms, -L3-A3 can be R 17 Can be unsubstituted C1-C 10 Alkyl, or m can be an integer from 0 to 5, R 26 It can be a carboxylic acid, an ester, an amino group, or an amide. In some embodiments, -L3-A3 can be R 17 Can be unsubstituted C1-C 10 alkyl, unsubstituted C1-C8 alkyl, unsubstituted C1-C6 alkyl, or unsubstituted C1-C5 alkyl. 26 It may be an ester.
[0194] In some forms, -L1-A1 is different from -L2-A2, wherein the compound has the following structure:
[0195]
[0196] Wherein: (a) L1 and L2 are independently substituted or unsubstituted alkylene or -C(O)-; (b) A1 is substituted or unsubstituted aryl, or C1-C6 alkoxy; (c) R1-R3 are hydroxyl; (d) R 13 -R 16 are independently hydroxy, hydrogen, substituted or unsubstituted alkyl, or -OR4, R4 is substituted or unsubstituted C1-C6 alkyl; (e) -L3-A3 is R 17 is substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted aryl; and (f) -L5-A5 is hydrogen, substituted or unsubstituted C1-C6 alkyl, or R 17 is a substituted or unsubstituted C1-C6 alkyl group.
[0197] In some forms, A1 is phenyl substituted with an alkoxy group. In some forms, A1 is unsubstituted phenyl. In some forms, -L3-A3 is R 17 It is an unsubstituted phenyl group.
[0198] In some forms, -L1-A1 is different from -L2-A2, wherein the compound has the following structure:
[0199]
[0200] Formula XIX
[0201] Wherein: (a) L1 and L2 are independently substituted or unsubstituted alkylene or -C(O)-; (b) A1 is C1-C6 alkoxy; (c) R1-R3 are hydroxyl groups; (d) R 13 -R 16 is hydroxyl, substituted or unsubstituted C1-C6 alkyl, or -OR4, R4 is substituted or unsubstituted C1-C6 alkyl; (e) -L3-A3 is R 17 is a substituted or unsubstituted C1-C6 alkyl group; and (f)-L5-A5 is R 17 is a substituted or unsubstituted C1-C6 alkyl group.
[0202] For any of Formulas I, Ia, II, III, IV, and XIX, the substituents may independently be substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl (e.g., benzyl), carbonyl (e.g., carboxyl), alkoxy (e.g., methoxy, ethoxy, aryloxy, benzoether, etc.), halide, hydroxyl, or haloalkyl, or a combination thereof.
[0203] For any of Formulas I, Ia, II, III, IV, and XIX, the substituents may independently be unsubstituted alkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted heterocyclyl, unsubstituted aryl, unsubstituted heteroaryl, unsubstituted polyaryl, unsubstituted polyheteroaryl, unsubstituted aralkyl (e.g., benzyl), alkoxy (e.g., methoxy, ethoxy, aryloxy, benzoether, etc.), carbonyl (e.g., carboxyl), halide, hydroxyl, or haloalkyl, or a combination thereof.
[0204] For any of Formulas I, Ia, II, III, IV, and XIX, the substituents may be unsubstituted alkyl (e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, etc.), alkoxy (e.g., methoxy, ethoxy, etc.), hydroxy, or a combination thereof.
[0205] For any of Formulas I, Ia, II, III, IV, and XIX, the alkyl group may be a straight chain alkyl group, a branched chain alkyl group, or a cyclic alkyl group (monocyclic or polycyclic). The terms "cyclic alkyl group" and "cycloalkyl group" are used interchangeably herein. Exemplary alkyl groups include straight chain C1-C 30 Alkyl, branched C4-C 30 Alkyl, cyclic C3-C 30 Alkyl, straight chain C1-C 20 Alkyl, branched C4-C 20 Alkyl, cyclic C3-C 20 Alkyl, straight chain C1-C 10 Alkyl, branched C4-C 10 Alkyl, cyclic C3-C 10 Alkyl, linear C1-C6 alkyl, branched C4-C6 alkyl, cyclic C3-C6 alkyl, linear C1-C4 alkyl, cyclic C3-C4 alkyl, such as linear C1-C 10C1-C9, C1-C8, C1-C7, C1-C6, C1-C5, C1-C4, C1-C3, or C1-C2 alkyl groups, branched C3-C9, C3-C9, C3-C8, C3-C7, C3-C6, C3-C5, or C3-C4 alkyl groups, or cyclic C3-C9, C3-C9, C3-C8, C3-C7, C3-C6, C3-C5, or C3-C4 alkyl groups. The cyclic alkyl group may be a monocyclic or polycyclic alkyl group, such as C4-C 30 、C4-C 25 、C4-C 20 、C4-C 18 、C4-C 16 、C4-C 15 、C4-C 14 、C4-C 13 、C4-C 12 、C4-C 10 , C4-C9, C4-C8, C4-C7, C4-C6, or C4-C5 monocyclic or polycyclic alkyl groups, etc.
[0206] For any of Formulas I, Ia, II, III, IV, and XIX, the alkenyl group can be a straight chain alkenyl group, a branched chain alkenyl group, or a cyclic alkenyl group (monocyclic or polycyclic), etc. The terms "cyclic alkenyl group" and "cycloalkenyl group" are used interchangeably herein. Exemplary alkenyl groups include straight chain C1-C 30 Alkenyl, branched C4-C 30 Alkenyl, cyclic C3-C 30 Alkenyl, straight chain C1-C 20 Alkenyl, branched C4-C 20 Alkenyl, cyclic C3-C 20 Alkenyl, straight chain C1-C 10 Alkenyl, branched C4-C 10 Alkenyl, cyclic C3-C 10 alkenyl, straight-chain C1-C6 alkenyl, branched-chain C4-C6 alkenyl, cyclic C3-C6 alkenyl, straight-chain C1-C4 alkenyl, cyclic C3-C4 alkenyl, such as straight-chain C1-C 10 C1-C9, C1-C8, C1-C7, C1-C6, C1-C5, C1-C4, C1-C3, C1-C2 alkenyl groups, branched C3-C9, C3-C9, C3-C8, C3-C7, C3-C6, C3-C5, C3-C4 alkenyl groups, or cyclic C3-C9, C3-C9, C3-C8, C3-C7, C3-C6, C3-C5, C3-C4 alkenyl groups. The cyclic alkenyl group can be a monocyclic or polycyclic alkenyl group, such as C4-C 30 、C4-C 25 、C4-C 20 、C4-C18 、C4-C 16 、C4-C 15 、C4-C 14 、C4-C 13 、C4-C 12 、C4-C 10 , C4-C9, C4-C8, C4-C7, C4-C6, or C4-C5 monocyclic or polycyclic alkenyl groups, etc.
[0207] For any of Formulas I, Ia, II, III, IV, and XIX, the alkynyl group can be a straight chain alkynyl group, a branched chain alkynyl group, or a cyclic alkynyl group (monocyclic or polycyclic). The terms "cyclic alkynyl group" and "cycloalkynyl group" are used interchangeably herein. Exemplary alkynyl groups include straight chain C1-C 30 Alkynyl, branched C4-C 30 Alkynyl, cyclic C3-C 30 Alkynyl, straight chain C1-C 20 Alkynyl, branched C4-C 20 Alkynyl, cyclic C3-C 20 Alkynyl, straight chain C1-C 10 Alkynyl, branched C4-C 10 Alkynyl, cyclic C3-C 10 Alkynyl, straight chain C1-C6 alkynyl, branched chain C4-C6 alkynyl, cyclic C3-C6 alkynyl, straight chain C1-C4 alkynyl, cyclic C3-C4 alkynyl, such as straight chain C1-C 10 C1-C9, C1-C8, C1-C7, C1-C6, C1-C5, C1-C4, C1-C3, C1-C2 alkynyl groups, branched C3-C9, C3-C9, C3-C8, C3-C7, C3-C6, C3-C5, C3-C4 alkynyl groups, or cyclic C3-C9, C3-C9, C3-C8, C3-C7, C3-C6, C3-C5, C3-C4 alkynyl groups, etc. The cyclic alkynyl group can be a monocyclic or polycyclic alkynyl group, such as C4-C 30 、C4-C 25 、C4-C 20 、C4-C 18 、C4-C 16 、C4-C 15 、C4-C 14 、C4-C 13 、C4-C 12 、C4-C 10 , C4-C9, C4-C8, C4-C7, C4-C6, or C4-C5 monocyclic or polycyclic alkynyl groups, etc.
[0208] It is understood that any of the exemplary alkyl, alkenyl, and alkynyl groups may be heteroalkyl, heteroalkenyl, and heteroalkynyl, respectively. For example, an alkyl group may be a straight chain C2-C 30 Heteroalkyl, branched C4-C 30 Heteroalkyl, cyclic C3-C 30 Heteroalkyl (i.e., monocyclic heteroalkyl or polycyclic heteroalkyl), straight chain C1-C 20 Heteroalkyl, branched C4-C 20 Heteroalkyl, cyclic C3-C 20 Heteroalkyl, straight chain C1-C 10 Heteroalkyl, branched C4-C 10 Heteroalkyl, cyclic C3-C 10 heteroalkyl, linear C1-C6 heteroalkyl, branched C4-C6 heteroalkyl, cyclic C3-C6 heteroalkyl, linear C1-C4 heteroalkyl, cyclic C3-C4 heteroalkyl, such as linear C1-C 10 C1-C9, C1-C8, C1-C7, C1-C6, C1-C5, C1-C4, C1-C3, C1-C2 heteroalkyl groups, branched C3-C9, C3-C9, C3-C8, C3-C7, C3-C6, C3-C5, C3-C4 heteroalkyl groups, or cyclic C3-C9, C3-C9, C3-C8, C3-C7, C3-C6, C3-C5, C3-C4 heteroalkyl groups, etc. The cyclic heteroalkyl group can be monocyclic or polycyclic, such as C4-C 30 、C4-C 25 、C4-C 20 、C4-C 18 、C4-C 16 、C4-C 15 、C4-C 14 、C4-C 13 、C4-C 12 、C4-C 10 , C4-C9, C4-C8, C4-C7, C4-C6, or C4-C5 monocyclic or polycyclic heteroalkyl groups, etc.
[0209] For any of Formulas I, Ia, II, III, IV, and XIX, the alkenyl group may be a straight chain C2-C 30 Heteroalkenyl, branched C4-C 30 Heteroalkenyl, cyclic C3-C 30 Heteroalkenyl (i.e., monocyclic heteroalkenyl or polycyclic heteroalkenyl), straight-chain C1-C 20 Heteroalkenyl, branched C4-C 20 Heteroalkenyl, cyclic C3-C 20 Heteroalkenyl, straight chain C1-C 10 Heteroalkenyl, branched C4-C 10 Heteroalkenyl, cyclic C3-C10 heteroalkenyl, straight-chain C1-C6 heteroalkenyl, branched C4-C6 heteroalkenyl, cyclic C3-C6 heteroalkenyl, straight-chain C1-C4 heteroalkenyl, cyclic C3-C4 heteroalkenyl, such as straight-chain C1-C 10 C1-C9, C1-C8, C1-C7, C1-C6, C1-C5, C1-C4, C1-C3, C1-C2 heteroalkenyl groups, branched C3-C9, C3-C9, C3-C8, C3-C7, C3-C6, C3-C5, C3-C4 heteroalkenyl groups, or cyclic C3-C9, C3-C9, C3-C8, C3-C7, C3-C6, C3-C5, C3-C4 heteroalkenyl groups, etc. The cyclic heteroalkenyl group can be monocyclic or polycyclic, such as C4-C 30 、C4-C 25 、C4-C 20 、C4-C 18 、C4-C 16 、C4-C 15 、C4-C 14 、C4-C 13 、C4-C 12 、C4-C 10 , C4-C9, C4-C8, C4-C7, C4-C6, or C4-C5 monocyclic or polycyclic heteroalkenyl groups.
[0210] For any of Formulas I, Ia, II, III, IV, and XIX, the alkynyl group can be a straight chain C2-C 30 Heteroalkynyl, branched C4-C 30 Heteroalkynyl, cyclic C3-C 30 Heteroalkynyl (i.e., monocyclic heteroalkynyl or polycyclic heteroalkynyl), straight chain C1-C 20 Heteroalkynyl, branched C4-C 20 Heteroalkynyl, cyclic C3-C 20 Heteroalkynyl, straight chain C1-C 10 Heteroalkynyl, branched C4-C 10 Heteroalkynyl, cyclic C3-C 10 heteroalkynyl, straight chain C1-C6 heteroalkynyl, branched chain C4-C6 heteroalkynyl, cyclic C3-C6 heteroalkynyl, straight chain C1-C4 heteroalkynyl, cyclic C3-C4 heteroalkynyl, such as straight chain C1-C 10C1-C9, C1-C8, C1-C7, C1-C6, C1-C5, C1-C4, C1-C3, C1-C2 heteroalkynyl groups, branched C3-C9, C3-C9, C3-C8, C3-C7, C3-C6, C3-C5, C3-C4 heteroalkynyl groups, or cyclic C3-C9, C3-C9, C3-C8, C3-C7, C3-C6, C3-C5, C3-C4 heteroalkynyl groups. The cyclic heteroalkynyl group can be monocyclic or polycyclic, such as C4-C 30 、C4-C 25 、C4-C 20 、C4-C 18 、C4-C 16 、C4-C 15 、C4-C 14 、C4-C 13 、C4-C 12 、C4-C 10 , C4-C9, C4-C8, C4-C7, C4-C6, or C4-C5 monocyclic or polycyclic heteroalkynyl groups.
[0211] For any of Formulas I, Ia, II, III, IV, and XIX, the aryl group may be C5-C 30 Aryl, C5-C 20 Aryl, C5-C 12 Aryl, C5-C 11 Aryl, C5-C9 aryl, C6-C 20 Aryl, C6-C 12 Aryl, C6-C 11 It should be understood that the aryl group may be a heteroaryl group, such as a C5-C 30 Heteroaryl, C5-C 20 Heteroaryl, C5-C 12 Heteroaryl, C5-C 11 Heteroaryl, C5-C9 heteroaryl, C6-C 30 Heteroaryl, C6-C 20 Heteroaryl, C6-C 12 Heteroaryl, C6-C 11 For any one of I, Ia, II, III, and IV, the polyaryl group may be C 10 -C 30 Polyaryl, C 10 -C 20 Polyaryl, C 10 -C 12 Polyaryl, C 10 -C 11 Polyaryl, or C 12 -C 20It should be understood that the aryl group may be a polyheteroaryl group, such as C 10 -C 30 Polyheteroaryl, C 10 -C 20 Polyheteroaryl, C 10 -C 12 Polyheteroaryl, C 10 -C 11 Polyheteroaryl, or C 12 -C 20 Polyheteroaryl, etc.
[0212] In some forms, the compound is not and not In some forms, the compound is not:
[0214] In some forms, the compound is:
[0215]
[0216]
[0217] The compound may be neutral, or may be one or more pharmaceutically acceptable salts, crystalline forms, amorphous forms, hydrates, or solvates, or combinations thereof. References to the compound may refer to the neutral molecule, and / or its additional forms together or separately in the context. Pharmaceutically acceptable salts of the compound include acid addition salts and base salts thereof.
[0218] Suitable acid addition salts are formed from acids that form nontoxic salts. Examples include acetate, aspartate, benzoate, benzenesulfonate, bicarbonate / carbonate, bisulfate / sulfate, borate, camphorsulfonate, citrate, edisylate, ethanesulfonate, formate, fumarate, gluconate, glucuronate, hexafluorophosphate, hyaluronate, hydrochloride / chloride, hydrobromide / bromide, hydroiodide / iodide, isethionate, lactate, malate, maleate, malonate, methanesulfonate, methylsulfate, naphthoate, 2-naphthalenesulfonate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate / hydrogenphosphate / dihydrogenphosphate, sucrose, stearate, succinate, tartrate, toluenesulfonate, and trifluoroacetate.
[0219] Suitable base salts are formed from bases which form non-toxic salts. Examples include aluminum, arginine, benzathine, calcium, choline, diethylamine, diethanolamine, glycine, lysine, magnesium, meglumine, ethanolamine, potassium, sodium, tromethamine, and zinc salts.
[0220] Hemisalts of acids and bases can also be formed, for example, hemisulphate and hemicalcium salts.
[0221] B. Pharmaceutical Formulations
[0222] Disclosed are pharmaceutical formulations containing one or more compounds disclosed herein in a form suitable for administration to mammals. Typically, the compound in the pharmaceutical formulation is present in an effective amount for treating cancer, reducing cancer, or treating or improving one or more symptoms associated with cancer in a subject. In some forms, the compound in the pharmaceutical formulation is present in an effective amount for inducing mitochondrial dysfunction and / or inhibiting the transport of ER to the Golgi apparatus in a subject's cancer cells. In some forms, the compound in the pharmaceutical formulation is present in an effective amount for inducing apoptosis of cancer cells in a subject. In some forms, the compound in the pharmaceutical formulation is present in an effective amount for inhibiting tumor growth in a subject by at least 40%, at least 50%, or at least 55% compared to the same tumor in a control subject.
[0223] The pharmaceutical formulation containing the compound may also include one or more pharmaceutically acceptable carriers and / or one or more pharmaceutically acceptable excipients. For example, the pharmaceutical formulation may be in liquid form, such as a solution or suspension, and contain one or more disclosed compounds and optionally one or more pharmaceutically acceptable excipients suitable for liquid formulations in an aqueous medium. Optionally, the pharmaceutical formulation has a solid form and contains one or more disclosed compounds and one or more excipients suitable for solid formulations.
[0224] 1. Carriers and excipients
[0225] The pharmaceutical formulation may comprise one or more pharmaceutically acceptable carriers and / or one or more pharmaceutically acceptable excipients. Suitable pharmaceutically acceptable carriers and excipients are generally recognized as safe (GRAS) and can be administered to an individual without causing undesirable biological side effects or unwanted interactions.
[0226] Representative carriers and excipients that can be used in pharmaceutical formulations include solvents (including buffers), diluents, pH adjusters, preservatives, antioxidants, suspending agents, wetting agents, viscosity adjusters, isotonicity agents, and stabilizers, and combinations thereof.
[0227] In some forms, the compound can be dissolved or suspended in a suitable carrier to form a liquid pharmaceutical formulation, such as sterile saline, phosphate buffered saline (PBS), balanced salt solution (BSS), viscous gel, or other pharmaceutically acceptable carriers for administration. The pharmaceutical formulation can also be a sterile solution, suspension, or emulsion in a non-toxic, parenterally acceptable diluent or solvent.
[0228] Excipients may be added to liquid or solid pharmaceutical formulations to aid sterility, stability (e.g., shelf life), integration, and to adjust and / or maintain the pH or isotonicity of the compound in the pharmaceutical formulation, such as diluents, pH adjusters, preservatives, antioxidants, suspending agents, wetting agents, viscosity modifiers, tonicity agents, and stabilizers, and combinations thereof.
[0229] 2. Form
[0230] Pharmaceutical formulations containing one or more disclosed compounds can be in liquid or solid form as liquid or solid formulations for oral administration or parenteral administration (eg, intramuscular, intravenous, intraperitoneal, and subcutaneous administration) to a subject.
[0231] A. Oral Formulations
[0232] In some forms, pharmaceutical formulations containing one or more disclosed compounds may be in a form suitable for oral administration to a subject, such as a mammal, etc. (i.e., an oral formulation). Oral administration may involve swallowing, allowing the compound to enter the gastrointestinal tract, or buccal or sublingual administration may be used, allowing the compound to enter the bloodstream directly from the mouth.
[0233] Formulations suitable for oral administration include solid formulations such as tablets and the like, capsules containing granules, liquids, powders, lozenges (including liquid-filled lozenges), chewables, multi- and nanoparticles, gels, solid solutions, liposomes, films, ovules, sprays, and liquid formulations.
[0234] Liquid formulations for oral administration include suspensions, solutions, syrups, and elixirs. Such oral formulations can be used as fillers in soft capsules or hard capsules, and can include one or more suitable carriers and / or excipients, for example, water, ethanol, polyethylene glycol, propylene glycol, chitosan polymers and chitosan derivatives (e.g., N-trimethylene chloride chitosan, chitosan esters, hydrophilic groups such as amino groups, carboxyl groups, sulfate groups, etc. modified chitosan), methylcellulose, suitable oils, one or more emulsifiers, and / or suspending agents. Liquid formulations for oral administration can also be prepared by the re-liquefaction of solids, for example, from drug bag re-liquefaction.
[0235] Optionally, the compound is contained in a rapidly dissolving and / or rapidly disintegrating dosage form.
[0236] For tablet or capsule dosage forms, in addition to a compound described herein, the tablet generally contains a disintegrant, a binder, a diluent, a surfactant, a lubricant, a glidant, an antioxidant, a colorant, a flavoring agent, a preservative, or a taste-masking agent, or a combination thereof.
[0237] Examples of suitable disintegrants for forming tablets or capsule dosage forms containing the compound include, but are not limited to, sodium carboxymethyl starch, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose, crospovidone, polyvinyl pyrrolidone, methyl cellulose, microcrystalline cellulose, lower alkyl substituted hydroxypropyl cellulose, starch, pregelatinized starch, and sodium alginate. In general, the concentration of the disintegrant may be in the range of about 1wt% to about 25wt%, about 5wt% to about 20wt% of the tablet or capsule dosage form containing the compound.
[0238] Binders are generally used to impart viscosity to tablet formulations. Suitable binders for forming tablets or capsule formulations containing the compound include, but are not limited to, microcrystalline cellulose, gelatin, sugars, polyethylene glycol, natural and synthetic gums, polyvinyl pyrrolidone, pregelatinized starch, chitosan polymers and chitosan derivatives (e.g., N-trimethylene chloride chitosan, chitosan esters, chitosan modified by hydrophilic groups such as amino groups, carboxyl groups, sulfate groups, etc.), hydroxypropyl cellulose, and hydroxypropyl methylcellulose.
[0239] Suitable diluents for forming tablet or capsule formulations containing the polymer include, but are not limited to, lactose (such as, for example, the monohydrate, the spray-dried monohydrate, or the anhydrous form), chitosan polymers and chitosan derivatives (e.g., N-trimethylene chloride chitosan, chitosan esters, chitosan modified with hydrophilic groups such as amino groups, carboxyl groups, sulfate groups, etc.), N-sulfonated derivatives of chitosan, quaternized derivatives of chitosan, carbosyalkylated chitosan, microcrystalline chitosan, mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starch, and dibasic calcium phosphate dihydrate.
[0240] The tablet or capsule formulation containing the compound may also include surfactants such as sodium lauryl sulfate and polysorbate 80, and glidants such as silicon dioxide and talc, etc. When present, the concentration of the surfactant may be about 0.2 wt% to 5 wt% of the tablet or capsule formulation.
[0241] The tablet or capsule formulation containing the compound may also include a lubricant, such as magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, and a mixture of magnesium stearate and sodium lauryl sulfate. The concentration of the lubricant may be about 0.25wt% to 10wt%, about 0.5wt% to about 3wt% of the tablet or capsule formulation.
[0242] Other possible excipients included in the tablet or capsule formulation containing the compound include glidants (e.g., talc or colloidal anhydrous silicon dioxide at about 0.1 wt % to about 3 wt % of the tablet or capsule formulation), antioxidants, colorants, flavoring agents, preservatives, and taste masking agents. When present, the concentration of the glidant may be about 0.2 wt % to 1 wt % of the tablet or capsule formulation.
[0243] An exemplary tablet formulation contains up to about 80 wt % of a compound described herein, about 10 wt % to about 90 wt % of a binder, about 0 wt % to about 85 wt % of a diluent, about 2 wt % to about 10 wt % of a disintegrant, and about 0.25 wt % to about 10 wt % of a lubricant.
[0244] Tablets or capsule blends comprising the compound and one or more suitable excipients may be compressed directly or by rollers to form tablets. Alternatively, the tablet or capsule blend or a portion of the blend may be granulated by wet, dry, or melt granulation prior to tableting, or the materials may be extruded. The final tablet or capsule formulation may comprise one or more layers and may be coated or uncoated; it may even be encapsulated in particles, such as polymer particles or liposome particles, etc.
[0245] Solid formulations containing the compound for oral administration can be formulated to be immediate release and / or modified release. Modified release formulations include delayed release, sustained release, pulsed release, controlled release, targeted release, and programmed release formulations.
[0246] b. Parenteral Formulations
[0247] In some forms, pharmaceutical formulations containing one or more disclosed compounds may be in a form suitable for direct administration into the bloodstream, into a muscle, or into an internal organ. Suitable routes for such parenteral use include intravenous, intraarterial, intraperitoneal, intrathecal, epidural intraventricular, intraurethral, intrasternal, intracranial, intramuscular, and subcutaneous delivery. Suitable means for parenteral administration include needle (including microneedle) syringes, needle-free syringes, and infusion techniques.
[0248] For example, a pharmaceutical formulation containing one or more of the compounds is in a form suitable for intramuscular administration, intravenous administration, intraperitoneal administration, or subcutaneous administration, or a combination thereof.
[0249] Parenteral formulations containing the compounds described herein are typically aqueous solutions, which may include excipients such as salts, sugars, and buffers, etc. (e.g., about pH 6.5 to about pH 8.0, about pH 6.5 to about pH 7.4, about pH 6.5 to about pH 7.0, about pH 7.0 to pH 8.0, or about pH 7.0 to about pH 7.4), but for some applications they may be more appropriately formulated as sterile aqueous solutions or in a dry form for use in conjunction with a suitable vehicle, such as sterile pyrogen-free water, etc.
[0250] Liquid formulations containing the compound for parenteral use may be solutions, suspensions, or emulsions.
[0251] The liquid pharmaceutically acceptable carrier forming the parenteral formulation containing the compound may include one or more physiologically compatible buffers, such as phosphate buffer, etc. One skilled in the art can readily determine the saline content and pH of the aqueous carrier suitable for administration (e.g., about pH 6.5 to about pH 8.0, about pH 6.5 to about pH 7.4, about pH 6.5 to about pH 7.0, about pH 7.0 to pH 8.0, or about pH 7.0 to about pH 7.4).
[0252] Liquid formulations containing the compound suitable for parenteral administration may include one or more suspending agents, such as cellulose derivatives, sodium alginate, polyvinyl pyrrolidone, tragacanth gum, or lecithin. Liquid formulations may also include one or more preservatives, such as ethyl or n-propyl p-hydroxybenzoate.
[0253] In some forms, the liquid formulation containing the compound comprises one or more low toxicity, organic (i.e., non-aqueous), Class 3 residual solvents, such as ethanol, acetone, ethyl acetate, tetrahydrofuran, ether, and propanol, and combinations thereof. When present in the liquid formulation, any such solvents included in the liquid formulation should not react adversely with the compound and any other active agent. As required, solvents such as freon, alcohol, glycol, polyglycol, or fatty acid may also be included in the liquid formulation containing the compound to increase the volatility of the solution or suspension.
[0254] Liquid formulations containing the compound suitable for parenteral administration may also contain small amounts of polymers, surfactants, or other pharmaceutically acceptable excipients known to those skilled in the art. In this context, "small amounts" means amounts that are small enough to avoid adverse effects on the uptake of the compound by target cells such as pituitary gonadotropin cells.
[0255] The preparation of parenteral formulations containing the compounds is generally carried out under sterile conditions, for example, by lyophilization, which can be carried out using standard pharmaceutical techniques known to those skilled in the art.
[0256] Formulations containing the compound for parenteral administration can be formulated to provide immediate and / or modified release of the active agent. Modified release formulations include delayed release, sustained release, pulsed release, controlled release, targeted release, and programmed release formulations.
[0257] c. Pulmonary and mucosal formulations
[0258] In some forms, pharmaceutical formulations containing one or more disclosed compounds may be in a form suitable for pulmonary or mucosal administration. The administration may include delivering the composition to the mucosa of the lungs, nose, mouth (sublingual, buccal), vagina, or rectum.
[0259] For example, the compound can be administered intranasally or by oral inhalation, such as in dry powder form (alone, or as a mixture, for example in a dry blend with lactose, or as a mixed component particle, for example mixed with a phospholipid such as phosphatidylcholine, etc.) from a dry powder inhaler, or as an aerosol spray from a pressurized container, pump, spray, atomizer (atomizer) (such as an atomizer using electrohydrodynamics to produce a fine mist), or nebuliser, with or without a suitable propellant, such as water, ethanol-water mixture, 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane, etc. For intranasal or oral inhalation use, the powder may contain a bioadhesive, for example, chitosan or cyclodextrin. The term aerosol as used herein refers to a preparation of any fine mist of particles, which may be a solution or suspension, whether or not it is made using a propellant. Aerosols can be made using standard techniques, such as ultrasound or high pressure processing.
[0260] The pressurized container, pump, spray, atomizer, or nebuliser contains a solution or suspension of one or more compounds comprising, for example, ethanol, aqueous ethanol, or a suitable alternative agent for dispersing, solubilizing, or prolonging the release of the active, a propellant as a solvent, and optionally a surfactant, such as sorbitan trioleate, oleic acid, or oligolactic acid.
[0261] Prior to use in a dry powder or suspension formulation, the drug product is micronized to a size suitable for delivery by inhalation (generally less than 5 microns). This can be achieved by any suitable comminution method, such as spiral jet milling, fluidized bed jet milling, supercritical fluid processing to form nanoparticles, high pressure homogenization, or spray drying.
[0262] Capsules (made of, for example, gelatin or carboxypropyl methylcellulose), blisters, or cartridges for use in an inhaler or insufflator may be formulated to contain a powder mix of a compound described herein, a suitable powder base such as lactose or starch, and a performance modifier such as l-leucine, mannitol, or magnesium stearate, etc. Lactose may be anhydrous or in the form of a monohydrate, the latter being preferred. Other suitable excipients include dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose, and trehalose.
[0263] A solution formulation containing the compound suitable for use in an atomizer that generates a fine mist using electrohydrodynamics can contain 1 μg to 20 mg of one or more compounds per actuation, and the actuation volume can be 1 μl to 100 μl. Typical formulations can include one or more compounds described herein, propylene glycol, sterile water, ethanol, and sodium chloride. Alternative solvents that can replace propylene glycol include glycerol and polyethylene glycol.
[0264] Suitable flavors, such as menthol and levomenthol, or sweeteners, such as saccharin or saccharin sodium, may be added to those formulations intended for inhaled / intranasal administration.
[0265] Formulations for inhaled / intranasal administration can be formulated for immediate release and / or modified release using, for example, PGLA. Modified release formulations include delayed release, sustained release, pulsed release, controlled release, targeted release, and programmed release formulations.
[0266] In the case of dry powder inhalers and aerosols, the dosage unit is determined by a valve that delivers a metered amount. Units according to the compound are usually set to deliver a metered amount or "puff". The total daily dose will be administered in a single dose, or more commonly as divided doses throughout the day.
[0267] In some forms, the compound can be formulated for pulmonary delivery, such as intranasal administration or oral inhalation. The carrier for pulmonary formulations can be divided into those for dry powder formulations and for use as solutions. For administration via the upper respiratory tract, the formulation can be formulated into an aqueous solution, for example, formulated into buffered or unbuffered water or isotonic saline, or formulated into an aqueous suspension for intranasal administration as drops or as a spray. Such aqueous solutions or suspensions can be isotonic relative to nasal secretions and have the same pH, and the pH range is, for example, about pH 4.0 to about pH 7.4, or pH 6.0 to pH 7.0. The buffer should be physiologically compatible, and only by way of example, includes phosphate buffer. Those skilled in the art can easily determine the saline content and pH of a harmless aqueous solution suitable for use in the nose and / or upper respiratory tract.
[0268] In some forms, the aqueous solution is water, a physiologically acceptable aqueous solution containing salt and / or buffer such as phosphate buffered saline (PBS) or any other aqueous solution acceptable for animal or human administration. Such solutions are well known to those skilled in the art, and include but are not limited to distilled water, deionized water, pure or ultrapure water, saline, phosphate buffered saline (PBS). Other suitable aqueous vehicles include but are not limited to Ringer's solution and isotonic sodium chloride. Aqueous suspensions may include suspending agents such as cellulose derivatives, sodium alginate, polyvinyl pyrrolidone and tragacanth gum, and wetting agents such as lecithin. Preservatives suitable for aqueous suspensions include ethyl p-hydroxybenzoate and n-propyl p-hydroxybenzoate.
[0269] In some forms, solvents such as ethanol, acetone, ethyl acetate, tetrahydrofuran, ether, and propanol, which are low toxic organic (i.e., non-aqueous) Class 3 residual solvents, can be used in formulations containing the compound. The solvent is selected based on the ability of the solvent to easily aerosolize the formulation. The solvent should not react adversely with the compound. A suitable solvent that dissolves the compound or forms a suspension of the compound should be used. The solvent should be sufficiently volatile to enable the formation of an aerosol of a solution or suspension. Additional solvents or aerosolizing agents such as freon, etc. can be added as needed to increase the volatility of the solution or suspension.
[0270] In some forms, the pharmaceutical formulation containing the compound may include a small amount of polymers, surfactants, or other excipients known to those skilled in the art. In this context, "small amount" means that there is no excipient that may affect or mediate the cellular uptake of the compound, and the amount of the excipient present does not adversely affect the cellular uptake of the compound.
[0271] The lipid powder can be directly dispersed in ethanol due to its hydrophobic properties. For lipids stored in organic solvents such as chloroform, the solution of the desired amount is placed in a bottle, and chloroform is evaporated under nitrogen stream to form a dry film on the glass bottle surface. When re-liquefying with ethanol, the film swells easily. For lipid molecules to be fully dispersed in organic solutions, the suspension is subjected to ultrasonic treatment. The non-aqueous suspension of lipids can also be prepared in absolute ethanol using a reusable PARI LC Jet+ atomizer (PARI Respiratory Equipment, Monterey, CA).
[0272] d. Topical preparations
[0273] The compound can be applied directly to the external surface of the skin or mucosa (including the lining of the nose, lungs and mouth) so that the compound can cross the external surface of the skin or mucosa and enter the underlying tissue.
[0274] Formulations for topical administration generally contain a dermatologically acceptable carrier which is suitable for application to the skin, is compatible with the active agent and any other ingredients, and does not present any troublesome safety or toxicity problems.
[0275] The carrier can have a variety of forms. For example, emulsion carriers can be used herein, including but not limited to oil-in-water, water-in-oil, water-in-oil-in-water, and silicone-in-water-in-oil emulsions. These emulsions can cover a wide range of viscosities, for example, from about 100 cps to about 200,000 cps. These emulsions can also be delivered in a spray form using a mechanical pump container or a pressurized aerosol container using a conventional propellant. These carriers can also be delivered in the form of mousse or transdermal patches. Other suitable topical carriers include anhydrous liquid solvents, such as oils, alcohols, and silicones (e.g., mineral oil, ethanol isopropanol, dimethicone, cyclomethicone, etc.); water-based single-phase liquid solvents (e.g., water-alcohol solvent systems, such as mixtures of ethanol and / or isopropanol and water); and thickened forms of these anhydrous solvents and water-based single-phase solvents (e.g., where the viscosity of the solvent has been increased by adding suitable gums, resins, waxes, polymers, salts, etc. to form a solid or semi-solid thickened form). Examples of topical carrier systems that can be used in the formulations of the present invention are described in the following four references, the entire contents of which are incorporated herein by reference in their entirety: "Sun Products Formulary" Cosmetics & Toiletries, Vol. 105, pp. 122-139 (December 1990); "Sun Products Formulary," Cosmetics & Toiletries, Vol. 102, pp. 117-136 (March 1987); U.S. Pat. No. 5,605,894 to Blank et al., and U.S. Pat. No. 5,681,852 to Bissett.
[0276] The formulation containing the compound for topical application can be formulated to release immediately and / or modified release. Modified release formulations include delayed release, sustained release, pulsed release, controlled release, targeted release and programmed release formulations. Therefore, the compound can be formulated as a solid, semisolid or thixotropic liquid, used as an implant reservoir providing a modified release of the compound. The example of such formulations includes drug-coated stents and poly (dl-lactic acid-co-glycolic acid) (PGLA) microspheres.
[0277] 3. Other active agents
[0278] In some forms, the pharmaceutical formulation may include one or more other active agents, such as one or more other anticancer agents, etc. Anticancer agents that may be included in pharmaceutical compositions or formulations are known, for example, see the National Cancer Institute database, "A to Z List of Cancer Drugs", available at cancer.gov / about-cancer / treatment / drugs.
[0279] Exemplary anticancer drugs that can be included in the pharmaceutical formulation containing the compounds include, but are not limited to, olaparib, abemaciclib, abiraterone acetate, methotrexate, paclitaxel, adriamycin, acalabrutinib, brentuximab vedotin, ado-trastuzumab emtansine, aflibercept, afatinib, netupitant, palonosetron, imiquimod, aldesleukin, alectinib, alemtuzumab, pemetrexed disodium, disodium, copanlisib, melphalan, brigatinib, chlorambucil, amifostine, aminolevulinic acid, anastrozole, apalutamide, aprepitant, pamidronate disodium, exemestane, nelarabine, arsenic trioxide,trioxide), ofatumumab, atezolizumab, bevacizumab, avelumab, axicabtageneciloleucel, axitinib, azacitidine, carmustine, belinostat, bendamustine, inotuzumab bozogamicin, bevacizumab, bexarotene, bicalutamide, bleomycin, blinatumomab, bortezomib, bosutinib, brentuximabvedotin), brigatinib, busulfan, irinotecan, capecitabine, fluorouracil, carboplatin, carfilzomib, ceritinib, daunorubicin, cetuximab, cisplatin, cladribine, cyclophosphamide, clofarabine, cobimetinib, cabozantinib-S-malate, dactinomycin, crizotinib, ifosfamide, ramucirumab, cytarabine, dabrafenib, dacarbazine, decitabine, daratumumab, dasatinib, defibrotide, degarelix, denileukindiftitox, denosumab, dexamethasone, dexrazoxane, dinutuximab, docetaxel, doxorubicin, durvalumab, rasburicase, epirubicin, elotuzumab, oxaliplatin, eltrombopagolamine, enasidenib, enzalutamide, eribulin, vismodegib, erlotinib, etoposide, everolimus, raloxifene, toremifene, panobinostat, fulvestrant, letrozole, filgrastim, fludarabine, flutamide, pralatrexate, obinutuzumab, gefitinib, gemcitabine, gemtuzumab ozogamicin, glucarpidase, goserelin, propranolol, trastuzumab, topotecan, palbociclib, ibritumomabtiuxetan), ibrutinib, ponatinib, idarubicin, idelalisib, imatinib, talimogenelaherparepvec, ipilimumab, romidepsin, ixabepilone, ixazomib, ruxolitinib, cabazitaxel, palifermin, pembrolizumab, ribociclib, tisagenlecleucel, lanretinib lanreotide, lapatinib, olaratumab, lenalidomide, lenvatinib, leucovorin, leuprolide, lomustine, trifluridine, olaparib, vincristine, procarbazine, mechlorethamine, megestrol, trametinib, temozolomide, methylnaltrexone hydrobromide bromide, midostaurin, mitomycin C, mitoxantrone, plerixafor, vinorelbine, necitumumab, neratinib, sorafenib, nilutamide, nilotinib, niraparib, nivolumab, tamoxifen, romiplostim, sonidegib, omacetaxine, pegaspargase, ondansetron, osimertinib, panitumumab, pazopanib, interferon α-2b,alfa-2b), pertuzumab, pomalidomide, mercaptopurine, regorafenib, rituximab, rolapitant, rucaparib, siltuximab, sunitinib, thioguanine, temsirolimus, thalidomide, thiotepa, trabectedin, valrubicin, vandetanib, vinblastine, vemurafenib, vorinostat, zoledronic acid acid), or a combination thereof, such as cyclophosphamide, methotrexate, 5-fluorouracil (CMF); doxorubicin, cyclophosphamide (AC); nitrogen mustard, vincristine, procarbazine, prednisolone (MOPP); doxorubicin (sdriamycin), bleomycin, vinblastine, dacarbazine (ABVD); cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP); rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone RCHOP; bleomycin, etoposide, cisplatin (BEP); epirubicin, cisplatin, 5-fluorouracil (ECF); epirubicin, cisplatin, capecitabine (ECX); methotrexate, vincristine, doxorubicin, cisplatin (MVAC).
[0280] 4. Dosage / wt% concentration
[0281] In some forms, the pharmaceutical formulation contains an effective amount of a compound to treat cancer, reduce cancer, or treat or ameliorate one or more symptoms associated with cancer in a subject.
[0282] In some forms, the compound is present in the pharmaceutical formulation in an amount effective to induce mitochondrial dysfunction and / or inhibit ER to Golgi transport in a cancer cell in a subject.
[0283] In some forms, the pharmaceutical formulation contains an amount of the compound that is effective to induce mitochondrial dysfunction as shown by: mitochondrial fission, decreased ATP production, and / or decreased membrane potential depolarization compared to cancer cells in the subject before treatment with the compound. Mitochondrial fission can be determined by: changes in mitochondrial morphology to punctate structures as measured by imaging compared to mitochondria in cancer cells before treatment with the compound; at least a 5% decrease in the expression of classification markers such as Muff and / or DRP1; translocation of DRP1 from the cytoplasm to mitochondria; and / or fragmentation of OPA1.
[0284] In some forms, the pharmaceutical formulation contains the following amount of the compound: the amount is effective to inhibit the transport of ER to the Golgi apparatus in the subject's cancer cells, as shown by: Golgi redistribution and / or disruption measured by imaging and / or ER stress compared to the subject's cancer cells before treatment with the compound. ER stress can be determined by: ER morphological disruption measured by imaging; increased expression of ER stress markers such as glucose-regulated protein 78 (GRP78) and C / -EBP homologous protein (CHOP); and / or the presence of phosphorylated eIF2α.
[0285] In some forms, the pharmaceutical formulation contains an amount of the compound effective to induce mitochondrial dysfunction and inhibit ER to Golgi transport in cancer cells of the subject, as indicated by the above parameters, compared to cancer cells in the subject before treatment with the compound.
[0286] In some forms, the compound is present in a pharmaceutical formulation in an effective amount to induce apoptosis of cancer cells in a subject. Whether apoptosis of cancer cells is induced can be determined by: compared with the relevant biomarkers or gene expression profiles in the subject's biological sample before treatment with the compound, there is at least a 5% change in the biomarker or gene expression profile in the subject's biological sample. Exemplary biomarkers showing apoptosis of cancer cells include, but are not limited to: HER2 for breast cancer; PSA for prostate cancer; carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC), neuron-specific enolase (NSE), cytokeratin 19 fragment (CYFRA), and gastrin-releasing peptide precursor (proGRP) for lung cancer. Alternatively or additionally, whether apoptosis of cancer cells is induced can be determined by: chromatin condensation and fragmentation; and / or PARP, caspase-9, and / or caspase-3 cleavage. In some forms, the pharmaceutical formulation contains an amount of the compound that is effective to induce apoptosis in cancer cells as shown by: chromatin condensation and fragmentation; PARP, caspase-9, and / or caspase-3 cleavage; and / or changes in the levels of proteins involved in apoptotic signaling using Western blotting.
[0287] In some forms, the compound is present in the pharmaceutical formulation in an effective amount to inhibit tumor growth in the subject by at least 40%, at least 50%, or at least 55% compared to the same tumor in the control subject. Tumor inhibition can be determined by known methods, such as by measuring the size of isolated solid tumors or using imaging to measure tumor size in vivo, etc. In some forms, the pharmaceutical formulation contains the following amount of the compound: this amount is such that at the end of the monitoring period (such as 21 days, 28 days, 31 days, 2 months, 3 months, 6 months, or 1 year, etc.), the tumor growth in the subject is effectively inhibited by at least 40%, at least 50%, or at least 55% compared to the same tumor in the control subject, optionally without any toxicity, as shown by the stable weight of the subject with the tumor. Stable weight refers to a change in weight of less than about 10% during and at the end of the monitoring period.
[0288] The total concentration of the compound in the pharmaceutical formulation may be at least 0.01 wt%, at least 0.05 wt%, at least 0.1 wt%, 0.01 wt% to 50 wt%, 0.05 wt% to 50 wt%, 0.1 wt% to 50 wt%, 0.01 wt% to 40 wt%, 0.05 wt% to 40 wt%, 0.1 wt% to 40 wt%, 0.01 wt% to 30 wt%, 0.05 wt% to 30 wt%, 0.1 wt% to 30 wt%, 0.01 wt% to 20 wt%, 0.05 wt% to 20 wt%, 0.1 wt% to 20 wt%, 0.01 wt% to 10 wt%, 0.05 wt% to 10 wt%, or 0.1 wt% to 10 wt%. The term "total concentration of the compound in the pharmaceutical formulation" refers to the sum of the weights of all compounds relative to the weight of the formulation.
[0289] In some forms, the total concentration of the compound in a pharmaceutical formulation effective for treating cancer, reducing cancer, or treating or ameliorating one or more symptoms associated with cancer in a subject may be at least 0.01 wt%, at least 0.05 wt%, at least 0.1 wt%, 0.01 wt% to 50 wt%, 0.05 wt% to 50 wt%, 0.1 wt% to 50 wt%, 0.01 wt% to 40 wt%, 0.05 wt% to 40 wt%, 0.1 wt% to 40 wt%, 0.01 wt% to 30 wt%, 0.05 wt% to 30 wt%, 0.1 wt% to 30 wt%, 0.01 wt% to 20 wt%, 0.05 wt% to 20 wt%, 0.1 wt% to 20 wt%, 0.01 wt% to 10 wt%, 0.05 wt% to 10 wt%, or 0.1 wt% to 10 wt%.
[0290] In some forms, the total concentration of the compound in the pharmaceutical formulation effective to induce mitochondrial dysfunction and / or inhibit ER to Golgi transport in a cancer cell in a subject may be at least 0.01 wt%, at least 0.05 wt%, at least 0.1 wt%, 0.01 wt% to 50 wt%, 0.05 wt% to 50 wt%, 0.1 wt% to 50 wt%, 0.01 wt% to 40 wt%, 0.05 wt% to 40 wt%, 0.1 wt% to 40 wt%, 0.01 wt% to 30 wt%, 0.05 wt% to 30 wt%, 0.1 wt% to 30 wt%, 0.01 wt% to 20 wt%, 0.05 wt% to 20 wt%, 0.1 wt% to 20 wt%, 0.01 wt% to 10 wt%, 0.05 wt% to 10 wt%, or 0.1 wt% to 10 wt%.
[0291] In some forms, the total concentration of the compound in the pharmaceutical formulation effective to induce apoptosis in cancer cells in a subject may be at least 0.01 wt%, at least 0.05 wt%, at least 0.1 wt%, 0.01 wt% to 50 wt%, 0.05 wt% to 50 wt%, 0.1 wt% to 50 wt%, 0.01 wt% to 40 wt%, 0.05 wt% to 40 wt%, 0.1 wt% to 40 wt%, 0.01 wt% to 30 wt%, 0.05 wt% to 30 wt%, 0.1 wt% to 30 wt%, 0.01 wt% to 20 wt%, 0.05 wt% to 20 wt%, 0.1 wt% to 20 wt%, 0.01 wt% to 10 wt%, 0.05 wt% to 10 wt%, or 0.1 wt% to 10 wt%.
[0292] In some forms, the total concentration of the compound in the pharmaceutical formulation effective to inhibit tumor growth in a subject by at least 40%, at least 50%, or at least 55% at the end of the monitoring period as compared to the same tumor in a control subject can be at least 0.01 wt%, at least 0.05 wt%, at least 0.1 wt%, 0.01 wt% to 50 wt%, 0.05 wt% to 50 wt%, 0.1 wt% to 50 wt%, 0.01 wt% to 40wt%, 0.05wt% to 40wt%, 0.1wt% to 40wt%, 0.01wt% to 30wt%, 0.05wt% to 30wt%, 0.1wt% to 30wt%, 0.01wt% to 20wt%, 0.05wt% to 20wt%, 0.1wt% to 20wt%, 0.01wt% to 10wt%, 0.05wt% to 10wt%, or 0.1wt% to 10wt%.
[0293] In some forms, the pharmaceutical formulation containing the compound can be provided in unit dosage form. The dosage of the compound in the pharmaceutical formulation in unit dosage form can be from about 0.002 mg to about 1 mg, from about 0.006 mg to about 0.6 mg, from about 0.01 mg to about 0.4 mg, from about 0.02 mg to about 0.3 mg, or from about 0.01 mg to about 0.2 mg.
[0294] III. Methods for Synthesizing AGB and Its Derivatives
[0295] A method for synthesizing AGB and its derivatives with high overall yield (i.e., overall yield ≥ 7%) has been developed. The method for the total synthesis of AGB and its derivatives described herein uses an acylation step and a methylation step to obtain an intermediate, and employs an Eschenmoser methenylation reaction to directly form AGB or its reactant. The overall yield of AGB or its derivatives can be at least 7%, at least 10%, at least 15%, at least 20%, at least 25%, or at least 30% (calculated from the cumulative yield of each step using the starting material). The method described herein can overcome the limitation of insufficient quantity associated with previous methods (Li et al., Acta Chimica Sinica, 36(1):43-48(1978); Pei et al., Acta Pharmaceutica Sinica 24(1989)431-437; and CN108264454, Huang et al.), and provides a feasible route for the total synthesis of AGB and its derivatives. For example, compared to the syntheses described in Li et al., Acta Chimica Sinica, 36(1):43-48(1978) and Pei et al., Acta Pharmaceutica Sinica 24(1989)431-437, the synthesis of AGB and its derivatives described herein has higher yields, involves fewer steps, provides more controllable synthesis conditions, and has higher atom efficiency. For example, compared to CN108264454 of Huang et al., the synthesis of AGB and its derivatives described herein uses simple and readily available starting materials, does not require any catalyst in the latter step, is therefore more environmentally friendly, and provides high overall yields.
[0296] The method generally comprises: (I) heating the reaction mixture at a suitable temperature for a period of time sufficient to form a product. The reaction mixture may comprise a first reactant, a second reactant, a third reactant, and a solvent. The structures of the reactants are described in detail below. The product comprises AGB or an AGB derivative.
[0297] In some forms, the method comprises: (ia) converting the pre-reactant into the second and third reactants, and / or (ib) converting the starting material into the pre-reactant. In some forms, the starting material can first be converted into an intermediate, and then the intermediate can be converted into the pre-reactant. The structures of the starting material, intermediate, pre-reactant and reactant are described in detail below.
[0298] In some forms, the method further comprises mixing the first reactant, the second reactant, the third reactant, and the solvent to form a reaction mixture before step (i); stirring the reaction mixture before and / or during step (i); and / or purifying the product after step (i), optionally by flash column chromatography.
[0299] More specific methods for synthesizing AGB and exemplary AGB derivatives are described in the Examples below.
[0300] A. Heating the reaction mixture at a temperature and for a period of time sufficient to form a product comprising AGB or a derivative thereof
[0301] In general, a reaction mixture containing reactants in a suitable solvent is heated at a suitable temperature for a period of time sufficient to form a product containing AGB or a derivative thereof. Typically, the reaction conditions for carrying out the reaction are mild. For example, the temperature for carrying out the reaction may be at most 130°C, at most 120°C, about 100°C to about 130°C, about 100°C to about 125°C, about 100°C to about 120°C at 1 atm, such as about 110°C at 1 atm, etc.; the period of time for carrying out the reaction may be at most 5h, at most 4h, at most 2h, or at most 1 hour, about 30 minutes to about 5h, about 30 minutes to about 4h, about 30min to about 3.5h, about 30min to about 3h, about 30min to about 2.5h, about 1h to about 5h, about 1h to about 4h, about 1h to 3h, or about 1h to about 2h; and optionally the reaction may be carried out under reflux.
[0302] Reaction mixture can be formed by dissolving reactant in solvent before reaction. Suitable solvent for forming reaction mixture can dissolve each reactant. For example, the solubility of each reactant in solvent is at least 0.01M. Examples of solvents suitable for forming reaction mixture include but are not limited to methylene dichloride, dimethyl sulfate, dimethyl sulfoxide, dimethylformamide, butyryl chloride, ethylene dichloride, nitrobenzene, dioxane, 2-methylbutyryl chloride, ethyl acetate, ethyl lactate, acetone, 1-butanol, 1-propanol, 2-propanol, ethanol, isopropyl acetate, methanol, methyl ethyl ketone, tert-butyl alcohol, tetrahydrofuran, 2-methyltetrahydrofuran, acrylonitrile or toluene or a combination thereof or a mixture of water and the organic solvent described above.
[0303] The reaction mixture comprises a first reactant, a second reactant, and a third reactant. The first reactant may have a structure of Formula V:
[0304]
[0305] The second reactant may have the structure of Formula VI:
[0306]
[0307] The third reactant may have the structure of Formula VII:
[0308]
[0309] wherein: (a) L1 and L2 may independently be a bond (single bond, double bond or triple bond), a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, a carbonyl or an alkoxyl group; (b) L3 may be a bond (single bond, double bond or triple bond), a substituted or unsubstituted alkyl, or a carbonyl group; (c) A1 and A2 may independently be hydrogen, a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted aryl, a carbonyl or an alkoxyl group, and at least one of A1 and A2 may be a substituted or unsubstituted aryl group; (d) A3 may be hydrogen, a substituted or unsubstituted alkyl, a substituted or unsubstituted aryl, a carbonyl or an alkoxyl group; (e) R1-R3 may independently be hydrogen, hydroxyl, a substituted or unsubstituted alkyl, a carbonyl, an alkoxyl group, a thiol or an amino group; (f) R 23 -R 25 and (g) the substituents may be as defined above for Formula I.
[0310] The second reactant may be the same as or different from the third reactant. In some forms, the second reactant may be the same as the third reactant. In some forms, the second reactant may be different from the third reactant.
[0311] In some forms, -L3-A3 may be R 17 Can be unsubstituted C1-C 10 Alkyl, or m can be an integer from 0 to 5, R 26 It can be a carboxylic acid, an ester, an amino group, or an amide.
[0312] In some forms, A1 may be A2 can be Wherein: (a) L4 and L5 can independently be a bond (single bond, double bond or triple bond), a substituted or unsubstituted alkyl group, or a carbonyl group; (b) A4 and A5 can independently be hydrogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, a carbonyl group, or an alkoxy group; (c) R9-R 16and (d) the substituents may be as defined above for Formula I.
[0313] In some forms, the second reactant may be the same as the third reactant. When the second reactant is the same as the third reactant, the reaction mixture comprises two reactants: a first reactant and a second reactant. In these forms, the second reactant may have a structure of Formula VIII:
[0314]
[0315] wherein: (a) L6 can be a bond (single bond, double bond or triple bond), substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, carbonyl or alkoxy; (b) L7 can be a bond (single bond, double bond or triple bond), substituted or unsubstituted alkyl, or carbonyl; (c) A7 can be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, carbonyl or alkoxy; (d) R 18 -R 21 may independently be hydrogen, hydroxy, substituted or unsubstituted alkyl, carbonyl, alkoxy, thiol, or amino; (e) R 23 -R 25 and (f) substituents may be as defined above for Formula I.
[0316] In some forms, the method may further comprise: (ia) converting a pre-reactant having a structure of Formula VIII' into a reactant having a structure of Formula VIII:
[0317]
[0318] Wherein: (a) L7 can be a bond (single bond, double bond or triple bond), a substituted or unsubstituted alkyl group, or a carbonyl group; (b) A7 can be hydrogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, a carbonyl group, or an alkoxy group; (c) R 18 -R 21 and (d) the substituents may be as defined above for Formula I.
[0319] In some forms, R 19 It may be a substituted or unsubstituted alkyl group, such as an unsubstituted methyl group. In some forms, R 18 Can be -OR 22 , each R 22 can be hydrogen or substituted or unsubstituted alkyl. In some forms, R 20 and R 21 In some forms, R 19It may be a substituted or unsubstituted alkyl group, such as an unsubstituted methyl group; R 18 Can be -OR 22 , each R 22 It can be hydrogen or substituted or unsubstituted alkyl; R 20 and R 21 In some forms, -L7-A7 may be R 17 Can be unsubstituted C1-C 10 alkyl, unsubstituted C1-C8 alkyl, unsubstituted C1-C6 alkyl, unsubstituted C1-C4 alkyl, unsubstituted C1-C3 alkyl, or m can be an integer from 0 to 5, R 26 Can be carboxylic acid, ester, amino, or amide. In some forms, -L7-A7 can be R 17 Can be unsubstituted C1-C 10 The invention also includes an unsubstituted C1-C8 alkyl group, an unsubstituted C1-C6 alkyl group, an unsubstituted C1-C4 alkyl group, or an unsubstituted C1-C3 alkyl group.
[0320] For any of Formulas V-VIII and VIII', the alkyl, alkenyl, alkynyl, aryl, and substituents can be any of those described above for Formulas I, Ia, and II-IV.
[0321] In some forms, the reaction mixture comprises a first reactant having the structure of Formula XII:
[0322]
[0323] and a second reactant having the structure of Formula XIII:
[0324]
[0325] wherein: (a) A3 and A7 may independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, carbonyl, or alkoxy; (b) L6 may be a bond (single bond, double bond, or triple bond), substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, carbonyl, or alkoxy; (c) R 22 may be hydrogen or substituted or unsubstituted alkyl; (d) R 23 -R 25 and (e) the substituents may be as defined above for Formula I. In some forms, A3 and A7 may independently be substituted or unsubstituted alkyl, such as unsubstituted alkyl, for example, unsubstituted C1-C 10alkyl, unsubstituted C1-C8 alkyl, unsubstituted C1-C7 alkyl, unsubstituted C1-C6 alkyl, unsubstituted C1-C5 alkyl, unsubstituted C1-C4 alkyl, or unsubstituted C1-C3 alkyl.
[0326] The first reactant having the structure of formula XII can be prepared by reacting phloroglucinol with the corresponding The alkylene oxide may be synthesized by coupling an acyl halide of the structure, wherein A3 may be as defined above for formula XII, and X' is a halogen atom such as Cl, Br, I, or F, for example Cl.
[0327] More specific conditions and reagents for the reaction in step (i) are described in the Examples below.
[0328] B. Converting the starting materials into pre-reactants
[0329] In some forms, the method may include: (ib) converting a suitable starting material into a pre-reactant having a structure of formula VIII'. The conversion from the starting material to the pre-reactant of formula VIII' can be carried out via different synthetic pathways; each synthetic pathway may include a single step, two steps, three steps, four steps, etc. In some forms, the conversion from the starting material to the pre-reactant having a structure of formula VIII can be carried out in a single step. In some forms, the conversion from the starting material to the pre-reactant of formula VIII can be carried out in two steps. In some forms, the conversion from the starting material to the pre-reactant of formula VIII can be carried out in three steps. In some forms, the conversion from the starting material to the pre-reactant of formula VIII can be carried out in four steps. In some forms, the conversion from the starting material to the pre-reactant of formula VIII can be carried out in five steps. In some forms, the conversion from the starting material to the pre-reactant of formula VIII can be carried out in six steps.
[0330] In some forms, the conversion of a starting material into a pre-reactant of formula VIII' may include: (i-b1) converting a first starting material into a first intermediate, and (i-b2) converting the first intermediate into a pre-reactant having a structure of formula VIII' (first synthetic route).
[0331] In some alternative forms, the conversion from the starting material to the pre-reactant of formula VIII' may include: (i-b1') converting phloroglucinol (as the starting material) into a second intermediate, and (i-b2') converting the second intermediate into a pre-reactant having a structure of formula VIII' (second synthetic route).
[0332] 1. The first synthetic route
[0333] In some forms, the methods described herein may include: (i-b1) converting a first starting material having a structure of Formula X into a first intermediate having a structure of Formula IX, and (i-b2) converting the first intermediate having a structure of Formula IX into a pre-reactant having a structure of Formula VIII':
[0334]
[0335] Where: (a) R 20 and R 21 may independently be hydrogen, hydroxy, substituted or unsubstituted alkyl, carbonyl, alkoxy, thiol, or amino; (b) R 22 may be hydrogen or substituted or unsubstituted alkyl; and (c) the substituents may be as defined above for Formula I. In some forms, R 20 and R 21 It may be a hydroxyl group.
[0336] In general, each of steps (i-b1) and (i-b2) can be carried out in a suitable solvent at a suitable temperature for a period of time sufficient to form a product containing the desired compound. In some forms, the reaction conditions for implementing the reaction of steps (i-b1) and (i-b2) are mild, such as a temperature of ≤30°C and a period of time of ≤24h. Solvents suitable for each of steps (i-b1) and (i-b2) can be any solvent described above for step (i), such as dimethyl sulfate, acetone, DMF, butyryl chloride, dichloroethane, nitrobenzene, dioxane, and water, and combinations thereof.
[0337] a. Converting starting materials into intermediates
[0338] In some forms, the conversion of the first starting material of formula X into the first intermediate of formula IX (i.e., step (i-b1)) may include a methylation step and / or an acylation step. In some forms, the conversion of the first starting material of formula X into the first intermediate of formula IX may include a methylation step and an acylation step. In these forms, the methylation step may be performed before the acylation step.
[0339] In some forms, in the methylation step of step (i-b1), the starting material may be converted into a methylated compound having the formula XI':
[0340]
[0341] Where (a) R 20 and R 21 may independently be hydrogen, hydroxy, substituted or unsubstituted alkyl, carbonyl, alkoxy, thiol, or amino; (b) R 22 (c) the substituents may be as defined above for Formula I.
[0342] In some forms, in the acylation step of step (i-b1), the methylated compound of formula XI' can be converted into an acylated compound having the structure of formula XI:
[0343]
[0344] Where (a) R 20 and R 21 may independently be hydrogen, hydroxy, substituted or unsubstituted alkyl, carbonyl, alkoxy, thiol, or amino; (b) R 22 (c) the substituents may be as defined above for Formula I.
[0345] In some forms, the conversion of the first starting material of formula X to the first intermediate of formula IX further comprises a reduction step (i.e., step (i-b3)), wherein the acylated compound having the structure of formula XI can be converted to the first intermediate having the structure of formula IX. In some forms, the conversion of the acylated compound of formula XI to the first intermediate of formula IX is carried out via a Vilsmeier-Haack reaction.
[0346] Each step / reaction for converting the first starting material of formula X into the first intermediate of formula IX can be carried out under the conditions described above. For example, the temperature for carrying out each reaction in step (i-b1) can be at most 35°C, at most 30°C, at most 25°C, in the range of 0°C to 35°C, in the range of 0°C to 30°C, or in the range of 0°C to 25°C, such as 0°C to room temperature (i.e., about 20°C to about 22°C, at 1atm), or room temperature; the period of time for carrying out each reaction in step (i-b1) can be at most 24h, at most 20h, at most 18h, or at most 16h, about 4h to about 24h, about 5h to about 20h, about 6h to about 18h, or about 8h to about 16h, such as about 3h or about 18h; and optionally the reaction can be carried out in the presence of a suitable catalyst such as POCl3, etc.
[0347] More specific conditions and reagents for converting an exemplary first starting material into an exemplary first intermediate are described in the Examples below.
[0348] b. Convert the intermediate into a pre-reactant
[0349] In some forms, converting the first intermediate of Formula IX into a pre-reactant of Formula VIII' (i.e., step (i-b2)) may include an acylation step and a decarboxylation step performed sequentially. An exemplary step for converting the first intermediate of Formula IX into a pre-reactant of Formula VIII' is as follows:
[0350]
[0351] Each step / reaction for converting the first starting material of formula IX into the pre-reactant of formula VIII' can be carried out under the conditions described above. For example, the temperature for carrying out each reaction in step (i-b2) can be at most 90°C, at most 85°C, at most 80°C, in the range of 60°C to 90°C, in the range of 60°C to 85°C, or in the range of 70°C to 90°C at 1 atm, such as about 70°C or about 80°C at 1 atm, etc.; a period of time for carrying out each reaction in step (i-b2) can be at most 24h, at most 20h, at most 18h, or at most 16h, about 4h to about 24h, about 5h to about 20h, about 6h to about 18h, or about 8h to about 16h, such as about 5h or about 16h, etc.; and optionally the reaction can be carried out under reflux and / or in the presence of a suitable catalyst such as a Lewis acid (e.g., AlCl3, ZnCl2, FeCl3, etc.).
[0352] More specific conditions and reagents for converting exemplary first intermediate compounds into exemplary pre-reactants are described in the Examples below.
[0353] 2. Second synthetic route
[0354] In some alternative forms, the methods described herein may include: (i-b1′) converting phloroglucinol (as a starting material) into a second intermediate having a structure of Formula XVII, and (i-b2′) converting the second intermediate having a structure of Formula XVII into a pre-reactant having a structure of Formula VIII′:
[0355]
[0356] Wherein: (a) L7 can be a bond (single bond, double bond or triple bond), a substituted or unsubstituted alkyl group, or a carbonyl group; (b) A7 can be hydrogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, a carbonyl group, or an alkoxy group; (c) R 19 (d) P1 and P2 may be independently protecting groups, such as methoxymethyl ether, tetrahydropyranyl ether, butyl ether, allyl ether, acetone, benzylidene acetal, acetate, pivalate, tert-butyldimethylsilyl ether, tert-butyldibenzylsilyl ether, anisole, benzoic acid ester, benzoate ester, benzoate, etc.; and (e) substituents may be as defined above for Formula I. In some forms, P1 and P2 may be methoxymethyl ether (MOM).
[0357] In some forms, R 19It may be a substituted or unsubstituted alkyl group, such as an unsubstituted C1-C 10 Alkyl, unsubstituted C1-C8 alkyl, unsubstituted C1-C6 alkyl, unsubstituted C1-C4 alkyl, unsubstituted C1-C3 alkyl, or unsubstituted C1-C2 alkyl, etc., such as unsubstituted methyl, etc.
[0358] In general, each of steps (i-b1') and (i-b2') can be carried out in a suitable solvent at a suitable temperature for a period of time sufficient to form a product containing the desired compound. In some forms, the reaction conditions for implementing the reaction of steps (i-b1') and (i-b2') are mild, such as a temperature of ≤90°C and a period of time of ≤15h. Solvents suitable for each of steps (i-b1') and (i-b2') can be any solvent described above for step (i), such as 2-methylbutyryl chloride, dichloroethane, nitrobenzene, DMF, THF, butyryl chloride, acetone, dimethyl sulfate, acetone, methanol, CHCl3, and toluene, and combinations thereof.
[0359] a. Convert phloroglucinol into intermediates
[0360] In some forms, the second intermediate of formula XVII converted from phloroglucinol (i.e., step (i-b1')) may include an acylation step. In some forms, the second intermediate of formula XVII converted from phloroglucinol may include an oxidation step, a reduction step, and an acylation step that are performed in sequence. In some forms, the second intermediate of formula XVII converted from phloroglucinol may include an oxidation step, a reduction step, an acylation step, and a protection step that are performed in sequence. The exemplary steps of converting an exemplary second intermediate from phloroglucinol are as follows.
[0361]
[0362] Each step / reaction for converting phloroglucinol to the second intermediate of formula XVII can be carried out under the conditions described above. For example, the temperature for carrying out each reaction in step (i-b1') may be at most 90°C, at most 85°C, at most 80°C, in the range of 20°C to 90°C, in the range of 40°C to 90°C, in the range of 50°C to 90°C, in the range of 60°C to 90°C, or in the range of 70°C to 90°C, such as about 80°C or room temperature at 1 atm, etc.; the time period for carrying out each reaction in step (i-b1') may be at most 15h, at most 12h, at most 10h, or at most 4h, from about 1h to about 15h, from about 2h to about 15h, from about 3h to about 15h, or from about 1h to about 4h, such as about 1 hour, about 3h, about 4h, or about 15h; and optionally the reaction may be carried out in the presence of a suitable catalyst such as a Lewis acid, etc. (e.g., AlCl3, POCl3, ZnCl2, FeCl3, etc.).
[0363] More specific conditions and reagents for converting phloroglucinol to an exemplary second intermediate are described in the Examples below.
[0364] b. Convert the intermediate into a pre-reactant
[0365] In some forms, the conversion of the second intermediate of Formula XVII into the pre-reactant of Formula VIII' (i.e., step (i-b2')) may include an acylation step and an optional deprotection step. In some forms, in the acylation step of step (i-b2'), the second intermediate of Formula XVII may be converted into an acylated compound having a structure of Formula XVIII:
[0366]
[0367] Wherein: (a) L7 can be a bond (single bond, double bond or triple bond), a substituted or unsubstituted alkyl group, or a carbonyl group; (b) A7 can be hydrogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, a carbonyl group, or an alkoxy group; (c) R 19 can be hydrogen, hydroxy, substituted or unsubstituted alkyl, carbonyl, alkoxy, thiol, or amino; (d) R 22 (e) P1 and P2 may independently be protecting groups as defined above for Formula XVII; and (f) the substituents may be as defined above for Formula I.
[0368] This acylation reaction can be carried out at a temperature of up to 90°C at 1 atm, in a range of 60°C to 90°C, in a range of 60°C to 85°C, or in a range of 60°C to 80°C (such as about 70°C at 1 atm, etc.) for a period of up to 15 h, up to 12 h, from about 5 h to about 15 h, from about 8 h to about 15 h, from about 10 h to about 15 h, or from about 12 h to about 15 h; and optionally the reaction can be carried out under reflux.
[0369] Then, after removing the protecting groups of -OP1 and -OP2, the acylated compound of formula XVIII can be converted into a pre-reactant of formula VIII'. The reaction conditions for removing the protecting groups from the compound are known. For example, the protecting groups of the acylated compound of formula XVIII can be removed under the following conditions: in an acidic solvent, such as 1M HCl in methanol, at 1 atm at most 85°C, in the range of 65°C to 85°C, in the range of 65°C to 80°C, in the range of 65°C to 75°C, or in the range of 65°C to 70°C, such as a temperature of about 65°C, for a period of up to 2h, up to 1 hour, in the range of 10 minutes to 2h, in the range of 10 minutes to 1h, in the range of 15 minutes to 1 hour, or in the range of 20 minutes to 1 hour, such as about 1 hour, etc., and optionally the reaction can be carried out under reflux.
[0370] More specific conditions and reagents for converting exemplary second intermediates into exemplary pre-reactants are described in the Examples below.
[0371] C. Yield
[0372] In general, the AGB or its derivatives in the product formed using the disclosed methods can have a total yield of at least 7%, at least 10%, at least 12%, at least 15%, at least 20%, at least 25%, at least 30%, about 20% to about 75%, about 20% to about 70%, about 20% to about 60%, about 20% to about 50%, about 30% to about 75%, about 30% to about 70%, about 30% to about 60%, or about 30% to about 50%. The total yield of AGB or its derivatives in the product is calculated from the starting material using the cumulative yield of each step. The total number of moles of AGB or its derivatives obtained experimentally can be determined using known methods, such as using NMR with an internal standard of known mass (e.g. 1 H NMR, 19 F NMR, and / or 31 P NMR) spectroscopy, such as using CDCl3-d or MeOD-d4 of known mass as an internal standard.
[0373] In some forms, the products formed using the disclosed methods may have an overall yield of AGB or a derivative of any of Formulas I, Ia, and II-IV of at least 7%, at least 10%, at least 12%, at least 15%, at least 20%, at least 25%, at least 30%, about 20% to about 75%, about 20% to about 70%, about 20% to about 60%, about 20% to about 50%, about 30% to about 75%, about 30% to about 70%, about 30% to about 60%, or about 30% to about 50%.
[0374] In some forms, the products formed from the starting materials of Formula X using the disclosed methods (such as methods including the first synthetic route described above, etc.) can have an overall yield of AGB or a derivative of any of Formulas I, Ia, and II-IV of at least 7%, at least 10%, at least 12%, at least 15%, about 7% to about 75%, about 7% to about 50%, about 7% to about 40%, about 7% to about 30%, about 7% to about 25%, or about 7% to about 20%.
[0375] In some forms, the products formed from phloroglucinol as a starting material using the disclosed methods (such as methods including the second synthetic pathway described above, etc.) may have an overall yield of AGB or a derivative of any of Formulas I, Ia, and II-IV of at least 20%, at least 25%, at least 30%, in the range of about 20% to about 75%, in the range of about 20% to about 70%, in the range of about 20% to about 60%, in the range of about 20% to about 50%, in the range of about 30% to about 75%, in the range of about 30% to about 70%, in the range of about 30% to about 60%, or in the range of about 30% to about 50%.
[0376] Exemplary methods for synthesizing AGB and exemplary AGB derivatives and their corresponding yields are described in the Examples below.
[0377] D. Optional Steps
[0378] The disclosed methods may include one or more optional steps, such as mixing the first reactant, the second reactant, the third reactant, and the solvent to form a reaction mixture before step (i); stirring the reaction mixture before and / or during step (i); and / or purifying the product after step (i), optionally by flash column chromatography.
[0379] 1. Stir the reaction mixture
[0380] Optionally, the reaction mixture is stirred before and / or during step (i), and / or is refluxed during step (i), and the reaction mixture is heated at a temperature for a period of time sufficient to form a product containing AGB or a derivative thereof. For example, the reaction mixture is stirred and / or refluxed at the reaction temperature throughout the reaction time to form a product containing AGB or a derivative thereof. Techniques for stirring and refluxing the reaction mixture during the reaction are known, such as stirring by using a mechanical stirring bar, magnetic stirring beads, etc., and refluxing using a condenser, etc.
[0381] 2. Purification of the product
[0382] Optionally, the disclosed method comprises a step of purifying the product after the reaction in step (i) to remove impurities such as unreacted reactants in the product, thereby obtaining isolated AGB or its derivatives. The product can be purified by known methods, such as flash column chromatography on silica gel or recrystallization in a dichloromethane / hexane mixture.
[0383] IV. Methods of using AGB and its derivatives
[0384] The disclosed compounds have anti-cancer properties and are therefore useful in methods of treating cancer, reducing cancer, or treating or ameliorating one or more symptoms associated with cancer in a subject in need thereof. In some forms, the compounds can be used in methods of treating cancer cells and / or cancer stem cells in a subject in need thereof.
[0385] A. Treat cancer, reduce cancer, or treat or improve one or more symptoms associated with cancer
[0386] Disclosed are methods of using the compounds to treat cancer, reduce cancer, or treat or ameliorate one or more symptoms associated with cancer in a subject.
[0387] Generally, the method comprises: (i) administering to a subject a pharmaceutical formulation comprising one or more disclosed compounds. The administering step can be performed one or more times.
[0388] The subject may be a mammal in need of cancer treatment, such as a human, dog, cat, rat, monkey, rabbit, guinea pig, etc. In some forms, the subject may show symptoms of cancer or be diagnosed with cancer.
[0389] The pharmaceutical formulation can be administered by oral administration, parenteral administration, inhalation, mucosal administration, topical, or a combination thereof. The compound can be administered by a medical professional or by the subject being treated (eg, self-administration).
[0390] 1. Cancer
[0391] Cancers treated using the disclosed methods can be tumors, such as tumors of blood and lymphatic tissue or blood and lymphatic malignancies, tumors affecting the blood, bone marrow, lymph, and lymphatic system, as well as tumors localized in the colon, abdomen, bones, chest, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal glands, parathyroid glands, pituitary gland, testicles, ovaries, thymus, thyroid), eyes, head and neck, nervous system (central and peripheral), lymphatic system, pelvis, skin, soft tissue, spleen, thorax, and genitourinary organs, etc.
[0392] In some forms of the methods, the cancer can be lung cancer, such as non-small cell lung cancer.
[0393] In some forms of the method, the cancer can be colon cancer, breast cancer, ovarian cancer, cervical cancer, lung cancer, kidney cancer, liver cancer, brain cancer, or leukemia, or a combination thereof. In some forms of the method, the cancer can be breast cancer, such as triple negative breast cancer (TNBC), etc.
[0394] In some forms of the methods, the cancer can be AIDS-related malignancies, anal cancer, astrocytoma, biliary tract cancer, bladder cancer, bone cancer, brain stem glioma, brain tumor, breast cancer, renal pelvis and ureter cancer, primary central nervous system lymphoma, central nervous system lymphoma, cerebellar astrocytoma, brain astrocytoma, cervical cancer, childhood (primary) hepatocellular carcinoma, childhood (primary) liver cancer, childhood acute lymphoblastic leukemia, childhood acute myeloid leukemia, childhood brain stem glioma, childhood cerebellar astrocytoma, childhood brain astrocytoma, childhood extracranial germ cell tumor, childhood Hodgkin's disease, childhood Hodgkin's lymphoma, childhood visual pathway and hypothalamic glioma, childhood lymphoblastic leukemia, childhood Medulloblastoma, childhood non-Hodgkin lymphoma, childhood supratentorial primitive neuroectodermal and pineal tumors, childhood primary liver cancer, childhood rhabdomyosarcoma, childhood soft tissue sarcoma, childhood visual pathway and hypothalamic glioma, chronic lymphocytic leukemia, chronic myeloid leukemia, colon cancer, cutaneous T-cell lymphoma, endocrine islet cell carcinoma, endometrial cancer, ependymoma, epithelial cancer, esophageal cancer, Ewing's sarcoma and related tumors, exocrine pancreatic cancer, extracranial germ cell tumors, extragonadal germ cell tumors, extrahepatic biliary cancer, eye cancer, female breast cancer, Gaucher's disease, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumors, gastrointestinal tumors, germ cell tumors, gestational trophoblastic tumors, tricoleumeki a. Head and neck cancer, hepatocellular carcinoma, Hodgkin's disease, Hodgkin's lymphoma, hypergammaglobulinemia, hypopharyngeal cancer, intestinal cancer, intraocular melanoma, islet cell carcinoma, islet cell pancreatic cancer, Kaposi's sarcoma, kidney cancer, laryngeal cancer, lip cancer, liver cancer, lung cancer, lymphoproliferative disorders, macroglobulinemia, male breast cancer, malignant mesothelioma, malignant thymoma, medulloblastoma, melanoma, mesothelioma, occult primary metastatic squamous neck cancer, primary metastatic squamous neck cancer, metastatic squamous neck cancer, multiple myeloma, multiple myeloma / plasma cell neoplasm, myelodysplastic syndrome, myeloid leukemia, myeloproliferative diseases, sinus and nasal cancer, nasopharyngeal cancer, neuroblastoma, non-Hodgkin's lymphoma in pregnancy, non-melanoma skin Skin cancer, non-small cell lung cancer, metastatic squamous cell neck cancer with occult primary, oropharyngeal cancer, malignant fibrous histiocytoma, malignant fibrous osteosarcoma / bone histiocytoma, epithelial ovarian cancer, ovarian germ cell tumor, ovarian low malignant potential tumor, pancreatic cancer, pathoproteinemia, purpura, parathyroid cancer, penile cancer, pheochromocytoma, pituitary tumor, plasma cell neoplasm / multiple myeloma, primary central nervous system lymphoma, primary liver cancer, prostate cancer, rectal cancer, renal cell carcinoma, renal pelvis and ureter cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoidosis, sarcoma, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, squamous cell neck cancer, gastric cancer, pineal and supratentorial primitive neuroectodermal tumors, T-cell lymphoma,Testicular cancer, thymoma, thyroid cancer, transitional cell carcinoma of the renal pelvis and ureter, transitional carcinoma of the renal pelvis and ureter, trophoblastic tumor, cell carcinoma of the renal pelvis and ureter, urethral cancer, uterine cancer, uterine sarcoma, vaginal cancer, optic tract and hypothalamic gliomas, vulvar cancer, Waldenstrom's macroglobulinemia, Wilms' tumor and any other hyperproliferative disease, as well as neoplasms localized in the previously mentioned organs.
[0395] 2. Effective amount / dose
[0396] Generally, following the administering step of the disclosed methods, the pharmaceutical formulation has been administered in an amount effective to treat cancer, reduce cancer, or treat or ameliorate one or more symptoms associated with cancer in the subject.
[0397] In some forms, the compound in the pharmaceutical formulation is administered in an effective amount to inhibit tumor growth in a subject by at least 40%, at least 50%, or at least 55% compared to the same tumor in a control subject. Whether tumor growth is inhibited can be determined by various diagnostic methods known to those skilled in the art, including but not limited to using imaging to observe a reduction in the size or number of tumor masses compared to the same type of tumor in a control subject at the end of a certain period of time after administration of an effective amount of the pharmaceutical formulation. Imaging suitable for measuring the size or number of tumor masses includes but is not limited to transrectal ultrasound, MRI, computed tomography ("CT") scanning, positron emission tomography ("PET") imaging, multi-parameter ultrasound ("US"), or a combination thereof, for example, PET-CT, PET-MRI, MRI-US, etc.
[0398] In some forms, the pharmaceutical formulation is administered in an effective amount to reduce the level of a biomarker associated with cancer in the blood of the subject by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, or at least 30% compared to the level of the biomarker in the blood of the subject before treatment. In some examples, the pharmaceutical formulation is administered in an effective amount to reduce the level of a biomarker associated with lung cancer (e.g., carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC), neuron-specific enolase (NSE), cytokeratin 19 fragment (CYFRA), and pro-gastrin releasing peptide (proGRP)) in the blood of the subject by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, or at least 30% compared to the level of the biomarker in the blood of the subject before treatment.
[0399] Administration of an effective amount of a pharmaceutical formulation may be performed in a single administration step or may be performed using multiple administration steps. For example, if a unit dosage form contains an effective amount of a compound that inhibits tumor growth in a subject by at least 40%, at least 50%, or at least 55% compared to the same tumor in a control subject and / or reduces the level of a biomarker associated with cancer in the subject's blood, then the method requires only a single administration step. Alternatively, if the unit dosage form contains less than the effective amount of a compound required to inhibit tumor growth in a subject by at least 40%, at least 50%, or at least 55% compared to the same tumor in a control subject and / or induce apoptosis of cancer cells, then the method involves at least two steps of administering a pharmaceutical formulation to a subject, and optionally more than two steps of administering a pharmaceutical formulation to a subject, until an effective amount of a pharmaceutical formulation is administered to the subject to inhibit tumor growth in the subject by at least 40%, at least 50%, or at least 55% compared to the same tumor in a control subject and / or reduce the level of a biomarker associated with cancer in the subject's blood. When multiple administration steps are required to administer an effective amount of a pharmaceutical formulation to a patient, each administration step may administer the same dose or a different dose of the pharmaceutical formulation to the patient.
[0400] When needing multiple application steps to apply the pharmaceutical formulation of effective amount to the patient, application step can be carried out regularly or irregularly.For example, application step is carried out with suitable frequency, such as per hour, per 2h, per 5h, per 8h, every day, every 2 days, every 3 days, every 5 days, every 7 days, every 10 days, every 2 weeks or every month etc.For example, application step is carried out per hour, per 2h, per 5h, every 8h, every day, every 2 days, every 3 days, every 5 days, every 7 days, every 10 days, every 2 weeks or every month, for a period of 1 day to 6 months, 1 day to 3 months, 1 to 30 days, 1 to 10 days, 1 to 3 days, 1 to 2 days or 1 day.Alternately, application can be carried out irregularly, for example, application step is used for the first time after 1 day, then for the second time after 2 days, then for the third time after 5 days, then for the fourth time after 7 days, then for the fifth time after 30 days.The time interval between application is determined based on patient needs.
[0401] In some forms, the method comprises only a single administration of a pharmaceutical formulation, wherein the pharmaceutical formulation contains an effective amount of a compound to inhibit tumor growth in the subject by at least 40%, at least 50%, or at least 55% compared to the same tumor in a control subject and / or to reduce the level of a cancer-associated biomarker in the subject's blood compared to the level of the biomarker in the subject's blood before treatment.
[0402] In some forms, the method comprises more than one step of administering the pharmaceutical formulation to the subject, wherein after all administration steps, the subject has been administered an amount of the compound effective to inhibit tumor growth in the subject by at least 40%, at least 50%, or at least 55% as compared to the same tumor in a control subject and / or to reduce the level of a cancer-associated biomarker in the subject's blood as compared to the level of the biomarker in the subject's blood before treatment.
[0403] In some forms, an effective amount of the compound administered to a subject to treat cancer, reduce cancer, or treat or ameliorate one or more symptoms associated with cancer in the subject, such as inhibiting tumor growth in the subject by at least 40%, at least 50%, or at least 55% compared to the same tumor in a control subject and / or reducing the level of a biomarker associated with cancer in the subject's blood compared to the level of the biomarker in the subject's blood before treatment, after a single administration or multiple administrations, can be about 0.1 mg / kg to about 50 mg / kg, about 0.3 mg / kg to about 30 mg / kg, about 0.5 mg / kg to about 20 mg / kg, about 1 mg / kg to about 15 mg / kg, or about 0.5 mg / kg to about 10 mg / kg of the subject, such as about 3 mg / kg of the subject, etc.
[0404] 3. Optional Steps
[0405] a. Administration of other active agents
[0406] One or more active agents other than the compound may be administered to the subject at different intervals throughout the method or during the method. For example, one or more other active agents may be administered to the subject before, during, and / or after step (i). In some forms, one or more other active agents may be included in a pharmaceutical formulation containing the compound and administered to the subject simultaneously with the compound in the pharmaceutical formulation together with one or more pharmaceutically acceptable excipients. In some forms, one or more other active agents may be administered separately from the pharmaceutical formulation containing the compound.
[0407] In some forms, the one or more additional active agents are one or more anti-cancer agents described above. The amount of the one or more additional anti-cancer agents required will vary from individual to individual depending on individual needs.
[0408] B. Treatment of cancer cells and / or cancer stem cells
[0409] In some forms, the compounds can be used in methods of treating cancer cells and / or cancer stem cells in a subject in need thereof.
[0410] The method may follow the method steps described above, for example, administering to a subject a pharmaceutical formulation containing the compound, such as by oral administration, parenteral administration, inhalation, mucosal, topical administration, or a combination thereof. The administering step may be performed one or more times to administer an effective amount of the compound in the pharmaceutical formulation to treat cancer cells and / or cancer stem cells, depending on whether the unit dose contains an effective amount of the compound for treating cancer cells and / or cancer stem cells. When multiple administrations are required to achieve the effective amount of the compound in the subject, the dosage and frequency of each administration may follow the method described above.
[0411] In some forms, the method may include the other steps described above. For example, the user may administer one or more other active agents to the subject before, during, and / or after administering the compound to the subject.
[0412] In some forms of the method, the compound targets the IC of the cancer cell or cancer stem cell 50 The value can be lower than the IC of the same compound measured under the same conditions against non-cancer cells. 50 Value. The cancer cells and / or cancer stem cells treated in the subject may be cancer cells of any of the cancers described above. For example, the cancer cells may be MDA-MB-231, MCF-7, HepG2, Hela, AGS, HTC116, SW480, SUNE-1, H460 (e.g., NCI-H460, stem cell-like NCI-H460, etc.), HCC827, H1650, or A549, or a combination thereof. In some forms, the cancer cells may be NCI-H460, stem cell-like NCI-H460, or A549, or a combination thereof.
[0413] When comparing the IC of compounds against cancer cells or cancer stem cells 50 The IC value of the same compound against non-cancer cells 50 When the value is set, the non-cancerous cell may be from any normal tissue of the subject, such as CCD-19Lu.
[0414] 1. Effective amount / dose
[0415] Generally, following the administering step of the disclosed methods, the pharmaceutical formulation has been administered in an amount effective for treating cancer cells and / or cancer stem cells in the subject.
[0416] In some forms, after the administering step of the disclosed methods, the pharmaceutical formulation has been administered in an amount effective to induce mitochondrial dysfunction and / or inhibit ER to Golgi transport in cancer cells in the subject compared to the subject prior to administration of the pharmaceutical formulation.
[0417] In some forms, after the administering step of the disclosed methods, the pharmaceutical formulation has been administered in an amount effective to induce apoptosis of cancer cells in the subject compared to the subject prior to administration of the pharmaceutical formulation.
[0418] Methods for determining whether mitochondrial dysfunction is induced, whether ER to Golgi transport is inhibited, and whether apoptosis of cancer cells is induced are described above.
[0419] In some forms, the method comprises only a single administration of a pharmaceutical formulation, wherein the pharmaceutical formulation comprises an effective amount of a compound to induce mitochondrial dysfunction, inhibit ER to Golgi transport, and / or induce apoptosis of cancer cells in a subject as compared to the subject prior to administration of the pharmaceutical formulation, as determined using one or more parameters described above.
[0420] In some forms, the method comprises more than one step of administering the pharmaceutical formulation to the subject, wherein after all administration steps, the subject has been administered an effective amount of the compound to induce mitochondrial dysfunction, inhibit ER to Golgi transport, and / or induce apoptosis of cancer cells in the subject as compared to the subject prior to administration of the pharmaceutical formulation, as determined using one or more parameters described above.
[0421] In some forms, after a single administration or multiple administrations, an effective amount of the compound administered to a subject to treat cancer cells and / or stem-like cancer cells in the subject, such as to induce mitochondrial dysfunction, inhibit ER to Golgi transport, and / or induce apoptosis of cancer cells in the subject as compared to the subject before administration of the drug formulation, as determined using one or more parameters described above, can be about 0.1 mg / kg to about 50 mg / kg, about 0.3 mg / kg to about 30 mg / kg, about 0.5 mg / kg to about 20 mg / kg, about 1 mg / kg to about 15 mg / kg, or about 0.5 mg / kg to about 10 mg / kg of the subject, such as about 3 mg / kg of the subject, etc.
[0422] The disclosed compounds and methods can be further understood by the following numbered paragraphs.
[0423] 1. Compounds having the following structure:
[0424]
[0425] in:
[0426] (a) L1 and L2 are independently a bond (single, double or triple bond), a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a carbonyl group or an alkoxy group;
[0427] (b) L3 is a bond (single, double or triple bond), a substituted or unsubstituted alkyl group, or a carbonyl group;
[0428] (c) A1 and A2 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, carbonyl, or alkoxy, and at least one of A1 and A2 is substituted or unsubstituted aryl;
[0429] (d) A3 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, carbonyl, or alkoxy;
[0430] (e) R1-R3 are independently hydrogen, hydroxy, substituted or unsubstituted alkyl, carbonyl, alkoxy, thiol, or amino; and
[0431] (f) the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, carbonyl, alkoxy, halogen, hydroxy, phenoxy, thiol, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amide, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphanyl, phosphoryl, or phosphonyl.
[0432] 2. The compound of paragraph 1, wherein A1 and / or A2 are independently substituted or unsubstituted aryl.
[0433] 3. The compound of paragraph 1 or paragraph 2, wherein the compound has the following structure:
[0434]
[0435] in:
[0436] (a) L1 and L2 are independently a bond (single, double or triple bond), a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a carbonyl group or an alkoxy group;
[0437] (b) L3-L5 are independently a bond (single, double or triple bond), a substituted or unsubstituted alkyl group, or a carbonyl group;
[0438] (c) A3-A5 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, carbonyl, or alkoxy;
[0439] (d) R1-R3 and R9-R 16 are independently hydrogen, hydroxy, substituted or unsubstituted alkyl, carbonyl, alkoxy, thiol, or amino; and
[0440] (e) the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, carbonyl, alkoxy, halogen, hydroxy, phenoxy, thiol, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amide, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphanyl, phosphoryl, or phosphonyl.
[0441] 4. The compound of any one of paragraphs 1-3, wherein -L1-A1 is the same as -L2-A2, wherein the compound has the following structure:
[0442]
[0443] in:
[0444] (a) L3 and L7 are independently a bond (single bond, double bond or triple bond), a substituted or unsubstituted alkyl group, or a carbonyl group;
[0445] (b) L6 is a bond (single bond, double bond or triple bond), substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, carbonyl or alkoxy;
[0446] (c) A3 and A7 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, carbonyl, or alkoxy;
[0447] (d) R1-R3 and R 18 -R 21 are independently hydrogen, hydroxy, substituted or unsubstituted alkyl, carbonyl, alkoxy, thiol, or amino; and
[0448] (e) the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, carbonyl, alkoxy, halogen, hydroxy, phenoxy, thiol, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amide, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphanyl, phosphoryl, or phosphonyl.
[0449] 5. The compound of any one of paragraphs 1 to 4, wherein R1-R3, R8-R 16 , and / or R 18 -R 21R4-R7 are independently hydroxy, substituted or unsubstituted alkyl, -OR4, -SR5, or -NR6R7, and R4-R7 are independently hydrogen or substituted or unsubstituted alkyl.
[0450] 6. The compound of any one of paragraphs 1-5, wherein R1-R3 is hydroxyl.
[0451] 7. The compound of any one of paragraphs 1 to 6, wherein R8-R 16 and / or R 18 -R 21 R4 is independently hydroxy, substituted or unsubstituted alkyl, or -OR4, and R4 is substituted or unsubstituted alkyl.
[0452] 8. The compound of any one of paragraphs 1-7, wherein -L3-A3 is a substituted or unsubstituted C1-C6 alkyl, or R 17 is a substituted or unsubstituted C1-C6 alkyl group, a substituted or unsubstituted aryl group, or m can be an integer from 0 to 5, R 26 It can be a carboxylic acid, an ester, an amino group, or an amide.
[0453] 9. The compound of paragraph 8, wherein R 17 is substituted or unsubstituted C1-C5 alkyl (e.g. unsubstituted C1-C5 alkyl), substituted or unsubstituted C1-C4 alkyl (e.g. unsubstituted C1-C4 alkyl), substituted or unsubstituted C1-C3 alkyl (e.g. unsubstituted C1-C3 alkyl), substituted or unsubstituted C1-C2 alkyl (e.g. unsubstituted C1-C2 alkyl), or substituted or unsubstituted methyl (e.g. unsubstituted methyl).
[0454] 10. The compound of paragraph 8, wherein R 17 It is a C6 cycloalkyl group.
[0455] 11. The compound of paragraph 8, wherein R 17 It is an unsubstituted phenyl group.
[0456] 12. The compound of paragraph 8, wherein R 26 For esters.
[0457] 13. The compound of any one of paragraphs 1-12, wherein -L4-A4, -L5-A5, and / or -L7-A7 are independently R 17 is a substituted or unsubstituted C1-C6 alkyl group.
[0458] 14. The compound of claim 1 or 2, wherein -L1-A1 is different from -L2-A2, wherein the compound has the following structure:
[0459]
[0460] in
[0461] (a) L1 and L2 are independently a single bond, a substituted or unsubstituted alkylene group, a substituted or unsubstituted alkenylene group, -C(O)-, or an alkoxy group;
[0462] (b) A1 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, carbonyl, or alkoxy;
[0463] (c) R1-R3, and / or R 13 -R 16 are independently hydrogen, hydroxy, substituted or unsubstituted alkyl, -OR4, -SR5, or -NR6R7, R4-R7 are independently hydrogen or substituted or unsubstituted alkyl;
[0464] (d)-L3-A3 is R 17 is a substituted or unsubstituted alkyl group, or a substituted or unsubstituted aryl group; and
[0465] (e) -L5-A5 is hydrogen, substituted or unsubstituted alkyl, or R 17 is a substituted or unsubstituted alkyl group.
[0466] 15. The compound of paragraph 1 or 2, wherein -L1-A1 is different from -L2-A2, wherein the compound has the following structure:
[0467]
[0468] in
[0469] (a) L1 and L2 are independently substituted or unsubstituted alkylene or -C(O)-;
[0470] (b) A1 is a substituted or unsubstituted aryl group, or a C1-C6 alkoxy group;
[0471] (c) R1-R3 are hydroxyl groups;
[0472] (d) R 13 -R 16 are independently hydroxy, hydrogen, substituted or unsubstituted alkyl, or -OR4, R4 is substituted or unsubstituted C1-C6 alkyl;
[0473] (e)-L3-A3 is R 17 is a substituted or unsubstituted C1-C6 alkyl group, or a substituted or unsubstituted aryl group; and
[0474] (f) -L5-A5 is hydrogen, substituted or unsubstituted C1-C6 alkyl, or R 17 is a substituted or unsubstituted C1-C6 alkyl group.
[0475] 16. The compound of paragraph 15, wherein A1 is phenyl substituted with an alkoxy group.
[0476] 17. The compound of paragraph 15, wherein A1 is unsubstituted phenyl.
[0477] 18. The compound of any one of paragraphs 15-17, wherein -L3-A3 is R 17 It is an unsubstituted phenyl group.
[0478] 19. The compound of paragraph 1 or 2, wherein -L1-A1 is different from -L2-A2, and wherein the compound has the following structure:
[0479]
[0480] in
[0481] (a) L1 and L2 are independently substituted or unsubstituted alkylene or -C(O)-;
[0482] (b) A1 is C1-C6 alkoxy;
[0483] (c) R1-R3 are hydroxyl groups;
[0484] (d) R 13 -R 16 is hydroxy, substituted or unsubstituted C1-C6 alkyl, or -OR4, R4 is substituted or unsubstituted C1-C6 alkyl;
[0485] (e)-L3-A3 is R 17 is a substituted or unsubstituted C1-C6 alkyl group; and
[0486] (f)-L5-A5 is R 17 is a substituted or unsubstituted C1-C6 alkyl group.
[0487] 20. The compound of any one of paragraphs 1-19, wherein the compound is not and not
[0489] 21. The compound of any one of paragraphs 1-20, wherein the compound is
[0490]
[0491]
[0492] 22. A pharmaceutical formulation comprising:
[0493] One or more compounds of any one of paragraphs 1-21; and
[0494] Pharmaceutically acceptable carriers and / or excipients.
[0495] 23. The pharmaceutical formulation of paragraph 22, wherein the one or more compounds are in an effective amount to treat cancer, reduce cancer, or treat or ameliorate one or more symptoms associated with cancer in a subject.
[0496] 24. The pharmaceutical formulation of paragraph 23, wherein the effective amount of one or more compounds is effective in inducing mitochondrial dysfunction in the subject and / or inhibiting ER to Golgi transport in cancer cells.
[0497] 25. The pharmaceutical formulation of paragraph 23 or 24, wherein the effective amount of the one or more compounds is effective in inducing apoptosis of cancer cells in a subject.
[0498] 26. The pharmaceutical formulation of any of paragraphs 23-25, wherein the effective amount of one or more compounds in the subject inhibits tumor growth in the subject by at least 40%, at least 50%, or at least 55% compared to the same tumor in a control subject.
[0499] 27. The pharmaceutical formulation of any one of paragraphs 22-26, further comprising a second active agent, optionally more than one second active agent, optionally the second active agent is an anti-cancer agent.
[0500] 28. The pharmaceutical formulation of any of paragraphs 22-27, wherein the total concentration of the one or more compounds in the pharmaceutical formulation is at least 0.01 wt%, at least 0.05 wt%, at least 0.1 wt%, 0.01 wt% to 50 wt%, 0.05 wt% to 50 wt%, 0.1 wt% to 50 wt%, 0.01 wt% to 40 wt%, 0.05 wt% to 40 wt%, 0.1 wt% to 40 wt%, 0.01 wt% to 30 wt%, 0.05 wt% to 30 wt%, 0.1 wt% to 30 wt%, 0.01 wt% to 20 wt%, 0.05 wt% to 20 wt%, 0.1 wt% to 20 wt%, 0.01 wt% to 10 wt%, 0.05 wt% to 10 wt%, or 0.1 wt% to 10 wt%.
[0501] 29. The pharmaceutical formulation of any one of paragraphs 22-28, which is in unit dosage form, wherein the dose of the compound is from about 0.002 mg to about 1 mg, from about 0.006 mg to about 0.6 mg, from about 0.01 mg to about 0.4 mg, from about 0.02 mg to about 0.3 mg, or from about 0.01 mg to about 0.2 mg.
[0502] 30. A method for synthesizing a compound according to any one of paragraphs 1 to 21, comprising:
[0503] (i) heating the reaction mixture at a suitable temperature for a period of time sufficient to form a product comprising the compound, wherein the reaction mixture comprises a solvent, a first reactant having a structure of Formula V
[0504]
[0505] The second reactant having the structure of formula VI
[0506]
[0507] and a third reactant having the structure of formula VII
[0508]
[0509] in
[0510] (a) L1 and L2 are independently a bond (single, double or triple bond), a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a carbonyl group or an alkoxy group;
[0511] (b) L3 is a bond (single, double or triple bond), a substituted or unsubstituted alkyl group, or a carbonyl group;
[0512] (c) A1 and A2 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, carbonyl, or alkoxy, and at least one of A1 and A2 is substituted or unsubstituted aryl;
[0513] (d) A3 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, carbonyl, or alkoxy;
[0514] (e) R1-R3 are independently hydrogen, hydroxy, substituted or unsubstituted alkyl, carbonyl, alkoxy, thiol, or amino;
[0515] (f)R 23 -R 25 are independently hydrogen or substituted or unsubstituted alkyl; and
[0516] (g) the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, carbonyl, alkoxy, halogen, hydroxy, phenoxy, thiol, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amide, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphanyl, phosphoryl, or phosphonyl, and
[0517] The second reactant is the same as or different from the third reactant.
[0518] 31. The method of claim 30, wherein:
[0519] A1 is
[0520] and
[0521] A2 is
[0522]
[0523] in:
[0524] (a) L4 and L5 are independently a bond (single, double or triple bond), a substituted or unsubstituted alkyl group, or a carbonyl group;
[0525] (b) A4 and A5 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, carbonyl, or alkoxy;
[0526] (c)R9-R 16 are independently hydrogen, hydroxy, substituted or unsubstituted alkyl, carbonyl, alkoxy, thiol, or amino; and
[0527] (d) the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, carbonyl, alkoxy, halogen, hydroxy, phenoxy, thiol, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amide, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphinyl, phosphoryl, or phosphonyl.
[0528] 32. The method of paragraph 30, wherein the second reactant is the same as the third reactant and has the following structure:
[0529]
[0530] in:
[0531] (a) L6 is a bond (single bond, double bond or triple bond), substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, carbonyl or alkoxy;
[0532] (b) L7 is a bond (single bond, double bond or triple bond), a substituted or unsubstituted alkyl group, or a carbonyl group;
[0533] (c) A7 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, carbonyl, or alkoxy;
[0534] (d) R 18 -R 21 are independently hydrogen, hydroxy, substituted or unsubstituted alkyl, carbonyl, alkoxy, thiol, or amino;
[0535] (e)R 23 -R 25 are independently hydrogen or substituted or unsubstituted alkyl; and
[0536] (f) the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, carbonyl, alkoxy, halogen, hydroxy, phenoxy, thiol, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amide, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphanyl, phosphoryl, or phosphonyl.
[0537] 33. The method of paragraph 32 further comprises: (ia) converting a pre-reactant having a structure of formula VIII' into a reactant having a structure of formula VIII,
[0538]
[0539] in:
[0540] (a) L7 is a bond (single bond, double bond or triple bond), a substituted or unsubstituted alkyl group, or a carbonyl group;
[0541] (b) A7 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, carbonyl, or alkoxy;
[0542] (c)R 18 -R 21 are independently hydrogen, hydroxy, substituted or unsubstituted alkyl, carbonyl, alkoxy, thiol, or amino; and
[0543] (d) the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, carbonyl, alkoxy, halogen, hydroxy, phenoxy, thiol, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amide, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphinyl, phosphoryl, or phosphonyl.
[0544] 34. The method of paragraph 32 or 33, wherein R 19 is methyl; R 18 For-OR 22 , each R 22 is hydrogen or substituted or unsubstituted alkyl.
[0545] 35. The method of paragraph 34, further comprising: (ib) converting the first starting material having the structure of formula X into a pre-reactant having the structure of formula VIII', or (ib) converting phloroglucinol into a pre-reactant having the structure of formula VIII':
[0546]
[0547] Where (a) R 20 and R 21 (a) and (b) the substituents are independently hydrogen, hydroxy, substituted or unsubstituted alkyl, carbonyl, alkoxy, thiol, or amino; and (b) the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, carbonyl, alkoxy, halogen, hydroxy, phenoxy, thiol, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amide, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphinyl, phosphoryl, or phosphonyl.
[0548] 36. The method of paragraph 35, wherein the method comprises: (ib) converting a first starting material having a structure of formula X into a pre-reactant having a structure of formula VIII', wherein step (ib) comprises: (i-b1) converting the first starting material having a structure of formula X into a first intermediate having a structure of formula IX, and (i-b2) converting the first intermediate having a structure of formula IX into a pre-reactant having a structure of formula VIII':
[0549]
[0550] Where (a) R20 and R 21 are independently hydrogen, hydroxy, substituted or unsubstituted alkyl, carbonyl, alkoxy, thiol, or amino; (b) R 22 is hydrogen or substituted or unsubstituted alkyl; and (c) the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, carbonyl, alkoxy, halogen, hydroxy, phenoxy, thiol, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amido, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphinyl, phosphoryl, or phosphonyl.
[0551] 37. The method of paragraph 35, wherein the method comprises: (ib) converting phloroglucinol into a pre-reactant having a structure of Formula VIII', wherein step (ib) comprises: (i-b1') converting phloroglucinol into a second intermediate having a structure of Formula XVII, and (i-b2') converting the second intermediate having a structure of Formula XVII into a pre-reactant having a structure of Formula VIII':
[0552]
[0553] wherein: (a) L7 is a bond (single, double or triple bond), a substituted or unsubstituted alkyl group, or a carbonyl group; (b) A7 is hydrogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, a carbonyl group, or an alkoxy group; (c) R 19 is hydrogen, hydroxyl, substituted or unsubstituted alkyl, carbonyl, alkoxy, thiol, or amino; (d) P1 and P2 are independently protecting groups, such as methoxymethyl ether, tetrahydropyranyl ether, butyl ether, allyl ether, acetone acetal, benzylidene acetal, acetate, pivalate, tert-butyldimethylsilyl ether, tert-butyldibenzylsilyl ether, anisole, benzoic acid ester (benzoic acid ester) and (e) the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, carbonyl, alkoxy, halogen, hydroxy, phenoxy, thiol, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amide, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphanyl, phosphoryl, or phosphonyl.
[0554] 38. The method of any one of paragraphs 30-37, wherein:
[0555] The first reactant is
[0556]
[0557] The second reactant is the same as the third reactant and has the following structure:
[0558]
[0559] in:
[0560] (a) A3 and A7 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, carbonyl, or alkoxy, optionally A3 and A7 are independently substituted or unsubstituted alkyl, such as unsubstituted C1-C 10 Alkyl, unsubstituted C1-C8 alkyl, unsubstituted C1-C7 alkyl, unsubstituted C1-C6 alkyl, unsubstituted C1-C5 alkyl, unsubstituted C1-C4 alkyl, or unsubstituted C1-C3 alkyl;
[0561] (b) L6 is a bond (single bond, double bond or triple bond), substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, carbonyl or alkoxy;
[0562] (c)R 22 is hydrogen or substituted or unsubstituted alkyl;
[0563] (d) R 23 -R 25 are independently hydrogen or substituted or unsubstituted alkyl; and
[0564] (e) the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, carbonyl, alkoxy, halogen, hydroxy, phenoxy, thiol, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amide, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphanyl, phosphoryl, or phosphonyl.
[0565] 39. The method of any of paragraphs 30-38, wherein the solvent is dichloromethane, dimethyl sulfate, dimethyl sulfoxide, dimethylformamide, butyryl chloride, dichloroethane, nitrobenzene, dioxane, 2-methylbutyryl chloride, ethyl acetate, ethyl lactate, acetone, 1-butanol, 1-propanol, 2-propanol, ethanol, isopropyl acetate, methanol, methyl ethyl ketone, tert-butanol, tetrahydrofuran, 2-methyltetrahydrofuran, acrylonitrile, or toluene, or a combination thereof, or a mixture thereof with water.
[0566] 40. The method of any of paragraphs 30-39, wherein the reaction mixture is heated at 1 atm at a temperature of up to 130°C, about 100°C to about 130°C, about 100°C to about 125°C, about 100°C to about 120°C, such as about 110°C, for a period of about 30 minutes to about 4 hours, about 30 minutes to about 3.5 hours, about 30 minutes to about 3 hours, about 30 minutes to about 2.5 hours, about 1 hour to about 4 hours, about 1 hour to about 3 hours, or about 1 hour to about 2 hours, optionally under reflux.
[0567] 41. The method of any of paragraphs 30-40, wherein the compound has an overall yield of at least 7%, at least 10%, at least 15%, at least 20%, at least 25%, or at least 30%.
[0568] 42. The method of any of paragraphs 30-41, further comprising: mixing the first reactant, the second reactant, the third reactant, and a solvent to form a reaction mixture before step (i) and / or purifying the product containing the prodrug after step (i).
[0569] 43. A method for treating cancer, reducing cancer, or treating or ameliorating one or more symptoms associated with cancer in a subject, comprising:
[0570] (i) administering to the subject the pharmaceutical formulation of any one of paragraphs 22-29, wherein step (i) is performed one or more times.
[0571] 44. The method of paragraph 43, wherein the method comprises only a single administration of the pharmaceutical formulation, wherein the pharmaceutical formulation contains an effective amount of the compound to inhibit tumor growth in the subject by at least 40%, at least 50%, or at least 55% compared to the same tumor in a control subject, or
[0572] wherein the method comprises more than one step of administering a pharmaceutical formulation to the subject, wherein after all the administering steps, an effective amount of a compound has been administered to the subject that inhibits tumor growth in the subject by at least 40%, at least 50%, or at least 55% as compared to the same tumor in a control subject.
[0573] 45. The method of paragraph 44, wherein the effective amount of the compound is about 0.1 mg / kg to about 50 mg / kg, about 0.3 mg / kg to about 30 mg / kg, about 0.5 mg / kg to about 20 mg / kg, about 1 mg / kg to about 15 mg / kg, or about 0.5 mg / kg to about 10 mg / kg, such as about 3 mg / kg.
[0574] 46. The method of any of paragraphs 43-45, wherein the subject is a mammal.
[0575] 47. The method of any one of paragraphs 43-46, wherein the pharmaceutical formulation is administered by oral administration, parenteral administration, inhalation, mucosal administration, topically, or a combination thereof.
[0576] 48. The method of any of paragraphs 43-47, wherein the cancer is non-small cell lung cancer.
[0577] 49. The method of any of paragraphs 43-48, further comprising administering a second active agent, optionally more than one second active agent, to the subject before, during, and / or after step (i).
[0578] 50. The method of paragraph 49, wherein the second active agent is an anti-cancer agent.
[0579] 51. A method for treating cancer cells and / or cancer stem cells in a subject in need thereof, comprising: (i) administering to the subject the pharmaceutical formulation of any one of paragraphs 22-29, wherein step (i) is performed one or more times.
[0580] 52. The method of paragraph 51, wherein the compound has an IC against the test cancer cells when tested under the same conditions. 50 The values are lower than the IC values of the same compounds against non-cancer cells. 50 value.
[0581] 53. The method of paragraph 52, wherein the test cancer cell is MDA-MB-231, MCF-7, HepG2, Hela, AGS, HTC116, SW480, SUNE-1, H460, HCC827, H1650, or A549, or a combination thereof.
[0582] 54. The method of paragraph 52 or paragraph 53, wherein the non-cancer cell is CCD-19Lu.
[0583] 55. The method of any one of paragraphs 51-54, wherein the method comprises only a single administration of a pharmaceutical formulation, wherein the pharmaceutical formulation contains an effective amount of a compound to induce mitochondrial dysfunction and / or inhibit ER to Golgi transport in cancer cells in a subject compared to the subject prior to administration of the pharmaceutical formulation, or
[0584] wherein the method comprises more than one step of administering the pharmaceutical formulation to the subject, wherein after all the administering steps, an effective amount of a compound has been administered to the subject that induces mitochondrial dysfunction and / or inhibits ER to Golgi transport in cancer cells in the subject compared to the subject before administration of the pharmaceutical formulation.
[0585] 56. The method of any one of paragraphs 51-55, wherein the method comprises only a single administration of the pharmaceutical formulation, wherein the pharmaceutical formulation contains an effective amount of a compound to induce apoptosis of cancer cells in a subject compared to the subject before administration of the pharmaceutical formulation, or
[0586] wherein the method comprises more than one step of administering the pharmaceutical formulation to the subject, wherein after all administering steps, an effective amount of a compound has been administered to the subject to induce apoptosis of cancer cells in the subject compared to the subject before administration of the pharmaceutical formulation.
[0587] The invention will be further understood with reference to the following non-limiting examples.
[0588] Example
[0589] Example 1. Synthesized agrimonol B and its derivatives show anticancer activity.
[0590] Materials and Methods
[0591] Synthesis of Agrimonial B
[0592] Scheme 1. The first synthetic route of agrimonol B
[0593]
[0594] Reagents and conditions: (a) K2CO3, dimethyl sulfate, acetone, 0℃ to room temperature, 18hr, 87%; (b) DMF, POCl3 catalyst, EtOAc, room temperature, 3hr, 92%; (c) NaBH3CN, THF, room temperature, 3hr, 72%; (d) butyryl chloride, 1,2-dichloroethane / nitrobenzene, AlCl3 catalyst, 80℃, 16hr, 42%; (e) dioxane / H2O (2:5), reflux, 5hr, 85%; (f) Eschenmoser salt, CHCl3, room temperature, 1.5hr, 81%; (g) 2-methylbutyryl chloride, 1,2-dichloroethane / nitrobenzene, AlCl3 catalyst, 80℃, 4hr, 83%; (h) toluene, reflux, 2hr, 53%. The overall yield was 7.3%, significantly higher than the published values (0.6%, Li et al., Acta Chimica Sinica, 1978, 36, 43-48; 0.3%, Zhu et al., Acta Pharmaceutica Sinica, 1989, 24, 431-437).
[0595] Scheme 2. Second synthetic route of agrimonol B
[0596]
[0597] Reagents and conditions: (a) 2-methylbutyryl chloride, 1,2-dichloroethane / nitrobenzene; AlCl3 catalyst, 80℃, 3h, 89%; (b) DMF, POCl3 catalyst, EtOAc, room temperature, 4h, 89%; (c) NaBH3CN, THF, room temperature, pH<4, 4h, 90%; (d) butyryl chloride, 1,2-dichloroethane / nitrobenzene AlCl3 catalyst, 80℃, 3h, 85%; (e) MOMCl, K2CO3, acetone, room temperature, 1h, 88%; (f) dimethyl sulfate, K2CO3, acetone, reflux, overnight, 93%; (g) 1M HCl in methanol, reflux, 1h, 95%; (h) Eschenmoser salt, CHCl3, room temperature, 1.5h, 81%; (i) Toluene, reflux, 2h, 53%. The total yield was 20.2%.
[0598] All reactions were carried out under magnetic agitation, and air-sensitive reactions were carried out in oven-dried glassware using standard Schlenk techniques under an argon atmosphere. All reaction temperatures were recorded using external bath temperatures. All reagents with a purity > 95% were obtained from commercial sources (Sigma Aldrich, J&K, Alfa Aesar, etc.) and used without further purification. Flash column chromatography was carried out with Merck silica gel 60 (0.040-0.063 mm). Analytical thin layer chromatography (TLC) was carried out using Merck silica gel 60 F254 glass substrate plates.
[0599] NMR spectra (1H-NMR and 13C-NMR) were recorded on a Bruker DRX 500 MHz spectrometer in deuterated chloroform (CDCl3-d) or methanol (MeOD-d4) and reported as follows: chemical shift δ in ppm (multiplicity, coupling constant J in Hz, number of protons) for the 1H-NMR spectra, and chemical shift δ in ppm for the 13C-NMR spectra. Multiplicities are abbreviated as follows: s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet, or a combination thereof. The residual solvent peaks of CDCl3 (δH=7.26ppm, δC=77.16ppm) and MeOD-d4 (δH=3.31ppm, δC=49.00ppm) were used as internal references. High resolution mass spectra (HRMS) were recorded on a Bruker's Ultra-High-Resolution maXis II™ ESI-Q-TOF mass spectrometer.
[0600] The first synthetic route
[0601] Methyl 2,6-dihydroxy-4-methoxybenzoate (6)
[0602] Potassium carbonate (14.6 g, 106.4 mmol) and dimethyl sulfate (10.0 mL, 106.4 mmol) were added to a stirred suspension of 2,4,6-trihydroxybenzoic acid 5 (10.0 g, 53.2 mmol) in acetone (300 mL). The reaction mixture was stirred at room temperature overnight, followed by the addition of 100 ml of H2O. The aqueous layer was extracted with ethyl acetate (EtOAc, 3 x 150 mL), and the combined ethyl acetate extracts were washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The title compound 6 (11.9 g, 87% yield) was obtained as a colorless solid using 4:1 hexane / EtOAc by flash column chromatography. 1 H-NMR (500Mhz, chloroform-d): d 6.03 (2H, s, 3&5-ArH), 4.02 (3H, s, 9-CH3), 3.78 (3H, s, 7-CH3). 13C-NMR (126 MHz, chloroform-d): d 171.8 (8-C=O), 166.6 (4-ArC), 166.1 (6-ArC), 165.5 (2-ArC), 94.6 (3&5-ArC), 91.7 (1-ArC), 55.6 (7-CH3), 52.6 (9-CH3). HR-MS (negative mode): [MH] - Calculated: 197.0455; measured: 197.0458.
[0603] Methyl 3-formyl-2,6-dihydroxy-4-methoxybenzoate (7)
[0604] To a solution of 6 (5.94 g, 30 mmol) in EtOAc (60 ml) was added dimethylformamide (DMF, 2.79 ml, 36 mmol) and phosphorus oxychloride (POCl3, 3.37 ml, 36 mmol) at 0 ° C in an ice bath. The ice bath was removed and the solution was stirred for 2 h. Water was added and the reaction mixture was refluxed for 30 min. When the solution cooled, EtOAc was added for extraction. The organic layers were combined and washed with brine and dried over anhydrous Na2SO4. It was then filtered and concentrated in vacuo to give a residue, which was further purified by flash column chromatography on silica gel (hexane-EtOAc, 4:1) to give 7 (6.21 g, 92%) as a light yellow solid. 1 H-NMR (500 MHz, CHLOROFORM-d): d 10.01 (1H, s, 8-CHO), 5.95 (1H, s, 5-ArH), 4.03 (3H, s, 10-CH3), 3.83 (3H, s, 7-CH3). 13 C-NMR (126 MHz, chloroform-d): d 192.0 (8-C=O), 165.4 (9-C=O), 165.3 (4-ArC), 165.3 (2-ArC), 162.9 (6-ArC), 105.5 (3-ArC), 104.3 (1-ArC), 86.0 (5-ArC), 56.3 (7-CH3), 52.4 (10-CH3). HR-MS (negative mode): [MH] - Calculated: 225.0405; measured: 225.0400.
[0605] Methyl 2,6-dihydroxy-4-methoxy-3-methylbenzoate (8)
[0606] To a solution of 7 (4.50 g, 20 mmol) in THF (100 ml) was added sodium cyanoborohydride (3.81 g, 60 mmol) at 0°C in an ice bath, 1 drop of methyl orange was used as a pH indicator, and 1 N hydrochloric acid was added to keep the reaction mixture red (acidic environment). The ice bath was removed and the solution was stirred until the starting material was consumed (about 2-3 h). THF was removed under reduced pressure to give a residue, which was extracted with ethyl acetate and dried over anhydrous Na2SO4, then filtered and concentrated in vacuo to give a residue, which was further purified by flash column chromatography on silica gel (hexane-EtOAc, 2:1) to give compound 8 (3.05 g, 72%) as a white solid. 1 H-NMR (500 Mhz, chloroform-d): d 6.06 (1H, s, 5-ArH), 4.03 (3H, s, 10-CH3), 3.83 (3H, s, 7-CH3), 1.99 (3H, s, 8-CH3). 13 C-NMR (126 MHz, chloroform-d): d 170.1 (9-C=O), 164.4 (2,4 & 6-ArC), 104.9 (3-ArC), 93.6 (1-ArC), 91.5 (5-ArC), 55.8 (7-CH3), 52.6 (10-CH3), 7.5 (8-CH3). HR-MS (negative mode): [MH] - Calculated: 211.0612; measured: 211.0608.
[0607] 3-Butyryl-2,6-dihydroxy-4-methoxy-5-methylbenzoic acid (9)
[0608] A solution of compound 8 (2.12 g, 10 mmol) and anhydrous aluminum chloride (5.33 g, 40 mmol) in 1,2-dichloroethane and nitrobenzene (1:1, 50 ml) under argon atmosphere was stirred in an ice bath for 20 min. Butyryl chloride (1.55 ml, 15 mmol) in 10 ml nitrobenzene was added and the ice bath was removed to allow the reaction mixture to continue stirring at room temperature for 30 min. The reaction mixture was then increased to 80 ° C and kept overnight. After cooling, the reaction mixture was diluted with ethyl acetate. Dilute HCl solution was added to the resulting mixture, resulting in the formation of a white precipitate in the aqueous layer. The organic layer was poured out and the remaining solid residue was washed three times with EtOAc. The combined EtOAc layer was evaporated in vacuo, and the remaining viscous oil was purified by silica gel column chromatography using n-hexane-EtOAc (10:1), first removing nitrobenzene and then changing the eluent to dichloromethane-methanol (5:1) to obtain 9 (1.12 g, 42%). 1H-NMR (500 MHz, methanol-d4): d 3.78 (3H, s, 11-CH3), 2.94-2.96 (2H, t, J = 7.5 Hz, 8-CH2), 2.06 (3H, s, 12-CH3), 1.66-1.72 (2H, q, J = 7.6 Hz, 9-CH2), 0.97-1.00 (3H, t, J = 7.5 Hz, 10-CH3). 13 C-NMR (126 MHz, methanol-d4): d 206.2 (7-C=O), 171.8 (13-C=O), 165.3 (6-ArC), 163.7 (4-ArC), 161.4 (2-ArC), 111.4 (5-ArC), 110.6 (3-ArC), 96.8 (1-ArC), 61.2 (11-CH3), 45.4 (8-CH2), 17.5 (9-CH2), 12.8 (10-CH3), 7.4 (12-CH3). HR-MS (negative mode): [MH] - Calculated: 267.0874; measured: 267.0870.
[0609] 1-(4,6-Dihydroxy-2-methoxy-3-methylphenyl)butan-1-one (4)
[0610] A suspension of 9 (0.80 g, 3 mmol) in dioxane and H2O (2:5, 28 ml) was refluxed under argon atmosphere for 5 h. After cooling to room temperature, dioxane was removed by rotary evaporator, and the solution was extracted three times with EtOAc (10 ml×3). The combined extracts were washed with brine and dried over anhydrous Na2SO4. The solvent was removed in vacuo, and the crude product was purified by flash silica chromatography (hexane: EtOAc=3:1) to give 0.57 g (85%) of the title compound 4. 1 H-NMR (500 MHz, chloroform-d): d 6.19 (1H, s, 5-ArH), 3.74 (3H, s, 11-CH3), 3.03-3.06 (2H, t, J = 7.5 Hz, 8-CH2), 2.10 (3H, s, 12-CH3), 1.69-1.75 (2H, q, J = 7.6 Hz, 9-CH2), 0.96-0.99 (3H, t, J = 7.6 Hz, 10-CH3). 13C-NMR (126 MHz, chloroform-d): d 206.6 (7-C=O), 163.4 (4-ArC), 161.8 (6-ArC), 161.2 (2-ArC), 109.9 (3-ArC), 109.5 (1-ArC), 99.8 (5-ArC), 61.9 (11-CH3), 44.7 (8-CH2), 18.3 (9-CH2), 14.1 (10-CH3), 8.6 (12-CH3). HR-MS (negative mode): [MH] - Calculated: 223.0976; measured: 223.0978.
[0611] 1-(3-Butyryl-2,6-dihydroxy-4-methoxy-5-methylphenyl)-N,N-dimethylmethylammonium iodide (10)
[0612] Eschenmoser salt (555.1 mg, 3 mmol) was added to a solution of 4 (224.1 mg, 1 mmol) in chloroform (5.0 ml) under argon atmosphere. After stirring at room temperature for 30 min, another portion of Eschenmoser salt (92.5 mg, 0.5 mmol) was added and continued to stir for 1 h. Five drops of H2O were then added to the reaction mixture to evaporate it. The obtained crude product was ground in MTBE (methyl tert-butyl ether, containing 10% dichloromethane), filtered to obtain insoluble matter and recovered in MeOH. The resulting solution was evaporated in vacuo to obtain compound 10 (330 mg, 80.7%), which was an orange solid. The product can be used further without any purification. 1 H-NMR (500Mhz, chloroform-d): 4.26 (2H, d, J = 5.8 Hz, 13-CH2), 3.76 (3H, s, 11-CH3), 3.07 (2H, t, J = 7.3 Hz, 8-CH2), 2.86 ( 6H,d,J=5.0Hz,14&15-CH3),2.18(3H,s,12-CH3),1.72(2H,q,J=7.3Hz,9-CH2),0.98(3H,t,J=7.4Hz,10-CH3). 13 C-NMR (126 MHz, chloroform-d): d 207.0 (7-C=O), 163.3 (6-ArC), 163.1 (2-ArC), 163.0 (4-ArC), 110.1 (5-ArC), 109.1 (1-ArC), 102.4 (3-ArC), 61.7 (11-CH3), 50.8 (13-CH2), 44.9 (2C, 15&16-CH3), 42.5 (8-CH2), 18.2 (9-CH2), 14.0 (10-CH3), 9.8 (12-CH3).
[0613] 2-Methyl-1-(2,4,6-trihydroxyphenyl)butan-1-one (2)
[0614] A solution of phloroglucinol 11 (0.63 g, 5 mmol) and anhydrous aluminum chloride (AlCl3, 2.67 g, 20 mmol) in 1,2-dichloroethane and nitrobenzene (1:1, 20 ml) was stirred at room temperature for 15 min under argon atmosphere. 2-Methylbutyryl chloride (0.93 ml, 7.5 mmol) in 5 ml nitrobenzene was added, and the reaction temperature was increased to 80 ° C and maintained for 4 h. After cooling, the reaction mixture was diluted with ethyl acetate and further washed with 1N HCl solution. The organic layer was poured out, and the remaining solid residue was washed three times with EtOAc (20 ml×3). The combined EtOAc extracts were washed with brine and dried over anhydrous Na2SO, evaporated in vacuo, and the remaining residue was purified by silica gel column chromatography using n-hexane-EtOAc (2:1) as eluent to obtain compound 2 (0.87 g, yield 83%). 1 H-NMR (500 MHz, methanol-d4): δ 5.80 (2H, s, 3&5-ArH), 3.91-3.78 (1H, m, 8-CH), 1.81 (1H, dqd, J = 13.8, 7.4, 6.3 Hz, 9-CH2-1'), 1.44-1.30 (1H, dqd, J = 13.8, 7.4, 6.3 Hz, 9-CH2-2'), 1.11 (3H, d, J = 6.7 Hz, 11-CH3), 0.90 (3H, t, J = 7.4 Hz, 10-CH3). 13 C-NMR (126MHz, methanol-d4): δ211.42 (7-C=O), 165.78 (4-ArC), 165.71 (2C, 2&6-ArC), 105.16 (1-ArC), 95.84 (2C, 3&5-ArC), 46.61 (8-CH), 28.04 (9-CH2), 17.08 (11-CH3), 12.31 (10-CH3). HR-MS (negative mode): [MH] - Calculated: 209.0819; measured: 209.0817.
[0615] Agrimonial B
[0616] In this study, Eschenmoser salt was used to form a methylene bridge between the side ring and the intermediate ring of agrimonol B. Compound 10 (Eschenmoser salt of the side ring, 81.8 mg, 0.2 mmol) was added to a solution of compound 2 (intermediate ring, 21 mg, 0.1 mmol) in toluene (5 ml) under argon atmosphere. After reflux in an oil bath for 2 h, the reaction mixture was diluted with 20 ml of dichloromethane and washed with 1 N HCl solution. The resulting aqueous layer was extracted 3 times with dichloromethane (10 ml × 3). The combined dichloromethane extracts were washed with brine and dried with anhydrous Na2SO4, filtered and evaporated. The crude residue was purified by flash silica chromatography (n-hexane-EtOAc=4:1) to obtain the final product agrimonol B (36.2 mg, 53.1%), which was a light yellow powder. 1 H-NMR (500Mhz, chloroform-d): d 15.97-15.62(2H,br,ArOH),10.72(1H,br,ArOH),9.70-9.27(4H,br,ArOH),3.91(1H,m,8 -CH),3.82(4H,s,13'-CH3),3.72(6H,s,11'-CH3),3.09(4H,t,J=7.3Hz,8'-CH2),2.11(6H ,s,12'-CH3),1.80(1H,m,9-CH2),1.74(4H,q,J=7.3Hz,9'-CH2),1.40(1H,m,9-CH2),1.1 5(3H,d,J=6.8Hz,11-CH3), 0.99(6H,t,J=7.4Hz,10'-CH3), 0.91(3H,t,J=7.4Hz,10-CH3). 13C-NMR (126MHz, chloroform-d): δ212.38(7'-C=O), 207.24(7-C=O), 162.13(ArC), 161.81(ArC), 161.32(ArC), 160.41(ArC), 1 59.80(ArC),159.67(ArC),159.57(ArC),158.56(ArC),158.06(ArC),112.73(ArC),112.43(ArC),109.75(ArC),109 .37(ArC),107.94(ArC),106.21(ArC),105.80(ArC),105.45(ArC),61.71(11'-CH3),46.08(8-CH),44.36(8'-CH2),26.99(9-CH2),18.37(9'-CH2),16.84(13'-CH2),16.64(11-CH3),14.08(10'-CH3),12.08(10-CH3),9.32(12'-CH3). HR-MS(negative mode):[MH] - Calculated: 681.2917; measured: 681.2911.
[0617] The second synthetic route
[0618] 2,4,6-Trihydroxybenzaldehyde (12)
[0619] To a solution of 11 (5 g, 39.7 mmol) in EtOAc (60 mL) was added dimethylformamide (DMF, 3.8 mL, 50 mmol) and phosphorus oxychloride (POCl3, 4.5 mL, 50 mmol) at 0°C in an ice bath and stirred for 10 min. The ice bath was removed and the solution was stirred for 4 h at room temperature. 60 mL of H2O was then added and the reaction mixture was refluxed for 30 min. After cooling, 50 mL of ethyl acetate was used to extract 3 times. The organic layers were combined, washed with brine and dried over anhydrous NaSO4. The residue was then filtered and concentrated in vacuo to give a residue, which was purified by flash column chromatography on silica gel (n-hexane: EA = 5: 1) to give compound 12 (5.4 g, 89%) as a white solid. 1 H-NMR (500 MHz, methanol-d4): δ 10.01 (s, 1H), 5.78 (s, 2H). 13 C-NMR (126 MHz, methanol-d4): δ 192.61, 168.78, 165.84, 106.24, 95.12. HR-MS (negative mode): [MH] - Calculated: 153.0193; measured: 153.0191.
[0620] 2-Methylbenzene-1,3,5-triol (13)
[0621] Sodium cyanoborohydride (6.1 g, 97.5 mmol) and methyl orange (4 drops) were added to a solution of 12 (5 g, 32.5 mmol) in THF (30 mL). The reaction mixture solution was adjusted to red (pH <4) using hydrochloric acid (1 M). After stirring at room temperature for 4 h, the mixture was diluted with EtOAc, washed with brine, and separated. The aqueous layer was extracted 3 times with EtOAc (30 mL), and the combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The obtained residue was purified by flash chromatography on silica gel (n-hexane: EA = 3: 1) to give compound 13 (4.1 g, 90%) as a light beige solid. 1 H-NMR (500 MHz, methanol-d4): δ 5.85 (s, 2H), 1.93 (s, 3H). 13 C-NMR (126 MHz, methanol-d4): δ 160.09, 157.64, 156.65, 103.53, 95.48, 95.39, 7.93. HR-MS (negative mode): [MH] - Calculated: 139.0401; measured: 139.0398.
[0622] 1-(2,4,6-Trihydroxy-3-methylphenyl)butan-1-one(14)
[0623] 2-Methylbenzene-1,3,5-triol (13, 2.0 g, 14.3 mmol) in a nitrobenzene-1,2-dichloroethane mixed solution (1:1, 50 mL) was added to a double-necked round-bottom flask, which was stirred in an ice bath while adding aluminum chloride (5.7 g, 43 mmol). After 10-min stirring, butyryl chloride solution (1.8 mL, 17.1 mmol) was added dropwise to the reaction mixture, and then the ice bath was removed and the solution was refluxed for 2 h. After cooling to room temperature, the reaction mixture was then poured into a dilute HCl solution (1 M, 100 mL), and the mixture was extracted 3 times with 15 mL of ethyl acetate. The organic solvents were combined, washed with brine, and then dried over anhydrous Na2SO4. Ethyl acetate was removed under reduced pressure. The oily residue containing acylphloroglucinol was further purified by flash column chromatography on silica gel (n-hexane / EA=1:1) to obtain 14 (2.5 g, 85%) as a light reddish brown solid. 1 H-NMR (500 MHz, methanol-d4): δ 5.90 (s, 1H), 3.12–2.90 (m, 2H), 1.92 (s, 3H), 1.68 (h, J=7.5 Hz, 2H), 0.97 (t, J=7.4 Hz, 3H). 13C-NMR (126 MHz, methanol-d4): δ 206.110, 163.64, 162.44, 160.06, 103.91, 102.28, 93.50, 45.58, 18.34, 13.12, 6.03. HR-MS (negative mode): [MH] - Calculated: 209.0819; measured: 209.0811.
[0624] 1-(2-Hydroxy-4,6-bis(methoxymethoxy)-3-methylphenyl)butan-1-one(15)
[0625] Potassium carbonate (4.1 g, 30 mmol) was added to a solution of 14 (2.1 g, 10 mmol) in dry acetone (10 mL), and the reaction mixture was stirred at room temperature for 5 min, followed by addition of chloromethyl methyl ether (MOMCl, 1.7 mL, 22 mmol). The reaction mixture was stirred at room temperature for 1 h. Acetone was removed from the reaction mixture under reduced pressure, and the residue was placed in ethyl acetate (100 mL) and washed with brine (100 mL). The organic layer was dried over anhydrous Na2SO4, filtered, and ethyl acetate was removed under reduced pressure. The crude product was purified by flash column chromatography on silica gel using n-hexane and EtOAc (10: 1) to obtain compound 15, which was a light yellow powder (2.6 g, 88%). 1 H-NMR (400 MHz, chloroform-d): δ13.89 (s, 1H), 6.39 (s, 1H), 5.24 (s, 2H), 5.22 (s, 2H), 3.51 (s, 3H), 3.48 (s, 3H), 3.04–2.97 (m, 2H), 2.05 (s, 3H), 1.77–1.66 (m, 2H), 0.98 (t, J=7.4 Hz, 3H). 13 C-NMR (101 MHz, chloroform-d): δ 206.45, 163.84, 160.81, 158.42, 108.03, 106.76, 94.84, 94.22, 91.52, 56.79, 56.47, 46.53, 18.39, 14.14, 7.59. HR-MS (negative mode): [MH] - Calculated: 297.1344; measured: 297.1339.
[0626] 1-(2-Methoxy-4,6-bis(methoxymethoxy)-3-methylphenyl)butan-1-one(16)
[0627] Potassium carbonate (2.8 g, 20 mmol) was added to a solution of 15 (2.0 g, 6.7 mmol) in dry acetone (10 mL), and the reaction mixture was stirred at room temperature for 5 min, followed by the addition of dimethyl sulfate (1.0 mL, 10 mmol). The reaction mixture was then heated to reflux for 4 h. After cooling to room temperature, 50 mL of H2O was added to the reaction mixture, followed by extraction with 50 mL of ethyl acetate 3 times. The organic layers were combined, washed with brine, and dried over anhydrous Na2SO4. The crude product obtained after removing ethyl acetate under reduced pressure was further purified by flash column chromatography on silica gel using n-hexane and ethyl acetate (8:1) to obtain compound 16 (1.9 g, 93%), which was a colorless oil. 1 H-NMR (500 MHz, chloroform-d): δ6.68 (s, 1H), 5.17 (s, 2H), 5.10 (s, 2H), 3.69 (s, 3H), 3.47 (s, 3H), 3.44 (s, 3H), 2.74 (t, J = 7.3 Hz, 2H), 2.09 (s, 3H), 1.69 (q, J = 7.3 Hz, 2H), 0.96 (t, J = 7.4 Hz, 3H). 13 C-NMR (126 MHz, chloroform-d): δ 205.05, 157.31, 156.14, 152.54, 121.06, 114.56, 98.11, 95.14, 94.77, 62.53, 56.42, 56.33, 47.16, 17.36, 8.70. HR-MS (positive mode): for [M+H]+, calculated as 313.1646; found as 313.1655.
[0628] 1-(4,6-Dihydroxy-2-methoxy-3-methylphenyl)butan-1-one (4)
[0629] Concentrated HCl (0.5 mL) was added to a solution of 16 (1.57 g, 7 mmol) in methanol (5 mL), and the reaction mixture was refluxed for 2 h. Methanol was removed from the reaction mixture under reduced pressure, and the residue was placed in ethyl acetate (50 mL) and washed with brine (100 mL). The organic layer was dried over anhydrous Na2SO4, filtered, and ethyl acetate was removed under reduced pressure. The crude product was purified by flash column chromatography on silica gel using n-hexane and EtOAc (3: 1) to obtain compound 4 (1.5 g, 95%), which was white needle-shaped crystals. The spectral data were identical to the reported method.
[0630] The synthesis of compound 10 from compound 4, the synthesis of compound 2, and the synthesis of agrimonol B from compound 2 and compound 10 were as described above for synthetic route 1.
[0631] Scheme 3. Synthesis of exemplary AGB derivatives
[0632]
[0633]
[0634] 1-(2,4,6-Trihydroxyphenyl)ethan-1-one(17)
[0635] A solution of phloroglucinol 10 (0.63 g, 5 mmol) and anhydrous aluminum chloride (AlCl3, 2.67 g, 20 mmol) in 1,2-dichloroethane and nitrobenzene (1:1, 10 ml) was stirred at room temperature for 15 min under argon atmosphere. Acetyl chloride (0.41 mL, 6 mmol) in 5 mL nitrobenzene was added, and the reaction temperature was raised to 80 ° C and maintained for 4 h. After cooling, the reaction mixture was diluted with ethyl acetate and further washed with 1M HCl solution. The organic layer was poured out, and the remaining solid residue was washed three times with EtOAc (20 mL×3). The combined EtOAc extracts were washed with brine and dried over anhydrous Na2SO, evaporated in vacuo, and the residue was purified by silica gel column chromatography using n-hexane-EtOAc (2:1) as eluent to obtain compound 17 (0.68 g, yield 81%). 1 H-NMR (500 MHz, methanol-d4): d 5.82 (2H, s), 2.61 (3H, s). 13 C-NMR (126 MHz, methanol-d4): δ 204.6, 166.3, 165.9, 105.6, 95.6, 32.7. HR-MS (negative mode): [MH] - Calculated: 167.0350; measured: 167.0357.
[0636] 1-(2,4,6-Trihydroxyphenyl)butan-1-one(18)
[0637] A solution of phloroglucinol 10 (0.63 g, 5 mmol) and anhydrous aluminum chloride (AlCl3, 2.67 g, 20 mmol) in 1,2-dichloroethane and nitrobenzene (1:1, 10 ml) was stirred at room temperature for 15 min under argon atmosphere. Butyryl chloride (0.64 mL, 6 mmol) in 5 mL nitrobenzene was added, and the reaction temperature was increased to 80 ° C and maintained for 4 h. After cooling, the reaction mixture was diluted with ethyl acetate and further washed with 1M HCl solution. The organic layer was poured out, and the remaining solid residue was washed three times with EtOAc (20 mL×3). The combined EtOAc extracts were washed with brine and dried over anhydrous Na2SO, evaporated in vacuo, and the residue was purified by silica gel column chromatography using n-hexane-EtOAc (2:1) as eluent to obtain compound 18 (0.88 g, yield 90.3%).1 H-NMR (500 MHz, methanol-d4): δ 5.80 (2H, s), 3.01 (t, J = 7.4 Hz, 2H), 1.67 (q, J = 7.4 Hz, 2H), 0.97 (t, J = 7.4 Hz, 3H). 13 C-NMR (126 MHz, methanol-d4): δ 206.0, 164.7, 164.5, 110.1, 104.1, 94.4, 45.5, 18.2, 13.1. HR-MS (negative mode): [MH] - Calculated: 195.0663; measured: 195.0663.
[0638] 1-(2,4,6-Trihydroxyphenyl)octan-1-one(19)
[0639] A solution of phloroglucinol 10 (0.63 g, 5 mmol) and anhydrous aluminum chloride (AlCl3, 2.67 g, 20 mmol) in 1,2-dichloroethane and nitrobenzene (1:1, 10 ml) was stirred at room temperature for 15 min under argon atmosphere. Octanoyl chloride (1.03 mL, 6 mmol) in 3 mL nitrobenzene was added, and the reaction temperature was raised to reflux and maintained for 4 h. After cooling, the reaction mixture was diluted with ethyl acetate and further washed with 1 M HCl solution. The organic layer was poured out, and the remaining solid residue was washed three times with EtOAc (20 mL×3). The combined EtOAc extracts were washed with brine and dried over anhydrous Na2SO, evaporated in vacuo, and the residue was purified by silica gel column chromatography using n-hexane-EtOAc (2:1) as eluent to obtain compound 19 (1.16 g, yield 92%). 1 H-NMR (500 MHz, methanol-d4): δ 5.80 (s, 2H), 3.07-2.94 (m, 2H), 1.65 (t, J=7.3 Hz, 2H), 1.41-1.22 (m, 8H), 0.96-0.84 (m, 3H). 13 C-NMR (126 MHz, methanol-d4): δ 207.52, 165.96, 165.80, 105.35, 95.71, 44.83, 32.95, 30.64, 30.31, 26.25, 23.69, 14.42. HR-MS (negative mode): [MH] - Calculated: 251.1289; measured: 251.1283.
[0640] (S)-2-Methyl-1-(2,4,6-trihydroxy-3-methylphenyl)butan-1-one (20)
[0641] A solution of 12 (0.7 g, 5 mmol) and anhydrous aluminum chloride (AlCl3, 2.67 g, 20 mmol) in 1,2-dichloroethane and nitrobenzene (1:1, 10 ml) was stirred at room temperature for 15 min under argon atmosphere. 2-Methylbutyryl chloride (0.93 mL, 7.5 mmol) in 5 mL nitrobenzene was added, and the reaction temperature was increased to 80 ° C and maintained for 4 h. After cooling, the reaction mixture was diluted with ethyl acetate and further washed with 1M HCl solution. The organic layer was poured out, and the remaining solid residue was washed three times with EtOAc (20 mL×3). The combined EtOAc extracts were washed with brine and dried over anhydrous Na2SO, evaporated in vacuo, and the remaining residue was purified by silica gel column chromatography using n-hexane-EtOAc (1:1) as eluent to obtain compound 20 (0.85 g, yield 76%). 1 H-NMR (500MHz, methanol-d4): δ5.89 (s, 1H), 3.88 (q, J = 6.7Hz, 1H), 1.92 (s, 3H), 1.80 (dt, J = 13. 8,7.0Hz,1H),1.36(dt,J=13.9,7.1Hz,1H),1.11(d,J=6.9Hz,3H),0.89(t,J=7.4Hz,3H). 13 C-NMR (126 MHz, methanol-d4): δ 210.32, 163.87, 162.31, 159.74, 103.84, 102.43, 95.59, 93.68, 45.40, 26.93, 15.96, 11.07, 6.10. HR-MS (negative mode): [MH] - Calculated: 223.0976; measured: 223.0973.
[0642] Agrimonial H
[0643] Compound 16 (98 mg, 0.24 mmol) was added to a solution of compound 17 (21 mg, 0.12 mmol) in toluene (2 mL) under argon atmosphere protection. After reflux in an oil bath for 2 h, the reaction mixture was diluted with 20 mL of dichloromethane and washed with 1 M HCl solution. The aqueous layer was extracted with dichloromethane 3 times (10 mL × 3). The combined dichloromethane extracts were washed with brine and dried over anhydrous Na2SO4, filtered and evaporated. The crude residue was purified by flash silica chromatography using dichloromethane to obtain a product as a reddish brown powder, which is a new compound named agrimonol H (52.2 mg, 68%). 1H-NMR (500MHz, chloroform-d): δ16.08–15.23(m,3H),10.73(s,1H),9.90-8.83(m,4H),3.83(d,J=8.6Hz,4H),3.7 2(s,6H),3.08(q,J=7.9Hz,4H),2.72(s,3H),2.19-2.02(m,7H),0.99(q,J=7.3Hz,9H),0.93-0.73(m,8H). 13 C-NMR (126 MHz, chloroform-d): δ 205.50, 160.42, 158.37, 105.94, 77.36, 61.72, 44.32, 33.16, 32.07, 29.85, 29.51, 22.84, 18.35, 14.27, 14.09, 9.32. HR-MS (negative mode): [MH] - Calculated: 639.2447; measured: 639.2347.
[0644] Agrimoniaol C
[0645] Compound 16 (82 mg, 0.2 mmol) was added to a solution of compound 18 (20 mg, 0.1 mmol) in toluene (2 mL) under argon atmosphere. After reflux in an oil bath for 3 h, the reaction mixture was diluted with 20 mL of dichloromethane and washed with 1 M HCl solution. The aqueous layer was extracted 3 times with dichloromethane (10 mL × 3). The combined dichloromethane extracts were washed with brine and dried over anhydrous Na2SO4, filtered and evaporated. The crude residue was purified by flash silica chromatography using dichloromethane to obtain the product agrimonol C (56.8 mg, 85%), which was a light yellow powder. 1 H-NMR (500 MHz, chloroform-d): 1 H NMR (500MHz, chloroform-d) δ15.48(s,2H),9.43(s,4H),3.80(s,4H),3.71(s,6H),3.06(dt,J=10.8, 7.3Hz, 6H), 2.10 (s, 6H), 1.72 (m, J = 10.9, 7.4, 3.5, 3.1Hz, 6H), 0.98 (td, J = 7.4, 3.9Hz, 9H). 13C-NMR (126 MHz, chloroform-d): δ 207.12, 206.72, 162.72, 161.78, 160.33, 159.63, 112.29, 110.13, 109.64, 108.04, 106.41, 104.14, 96.69, 61.70, 45.74, 44.42, 29.84, 18.36, 18.23, 16.01, 14.10, 14.07, 9.28. HR-MS (negative mode): [MH] - Calculated: 639.2447; measured: 639.2347.
[0646] Agrimonia ol L
[0647] Compound 16 (65.5 mg, 0.16 mmol) was added to a solution of compound 19 (20 mg, 0.08 mmol) in toluene (2 mL) under argon atmosphere protection. After reflux in an oil bath for 4 h, the reaction mixture was diluted with 20 mL of dichloromethane and washed with 1 M HCl solution. The resulting aqueous layer was extracted 3 times with dichloromethane (10 mL × 3). The combined dichloromethane extracts were washed with brine and dried with anhydrous Na2SO4, filtered and evaporated. The crude residue was purified by dichloromethane using flash silica chromatography to obtain a product as a light yellow powder, which is a new compound named agrimonol L (36.2 mg, 53.1%), which is a light yellow powder. 1 H-NMR (500MHz, chloroform-d): δ16.00(br,2H),15.62(s,1H),10.70(s,1H),9.65(d, J=4.4Hz,2H),9.24(s,1H),3.82(s,4H),3.72(s,6H),3.13(t,J=7.4Hz,2H), 3.09(t,J=7.3Hz,4H),2.11(s,6H),1.74(q,J=7.3Hz,4H),1.68-1.61(m,2H) ,1.40-1.28(m,10H),1.25(s,4H),0.99(t,J=7.4Hz,6H),0.93-0.87(m,3H). 13 C-NMR (126 MHz, chloroform-d): δ 208.37, 160.40, 158.03, 110.14, 107.95, 105.73, 61.72, 44.42, 31.90, 29.86, 29.53, 29.39, 24.78, 22.81, 18.37, 14.26, 14.09, 9.32. HR-MS (negative mode): [MH] - Calculated: 723.3386; measured: 723.3374.
[0648] AGF
[0649] Compound 16 (204 mg, 0.5 mmol) was added to a solution of compound 10 (20 mg, 0.16 mmol) in toluene (5 mL) under argon atmosphere protection. After reflux in an oil bath for 2 h, the reaction mixture was diluted with 20 mL of dichloromethane and washed with 1 M HCl solution. The resulting aqueous layer was extracted 3 times with dichloromethane (10 mL × 3). The combined dichloromethane extracts were washed with brine and dried over anhydrous Na2SO4, filtered and evaporated. The crude residue was purified by flash silica chromatography using dichloromethane to obtain product AGF (109 mg, 82%), which was a light yellow powder. 1H-NMR (500 MHz, CHLOROFORM-d): δ15.78 (s, 3H), 10.01 (s, 3H), 9.60 (s, 3H), 3.84 (s, 6H), 3.70 (s, 9H), 3.08 (t, J = 7.3 Hz, 6H), 2.09 (s, 9H), 1.74 (d, J = 7.3 Hz, 6H), 0.98 (t, J = 7.4 Hz, 9H). 13C-NMR (126MHz, chloroform-d): δ207.16, 162.01, 160.24, 159.60, 150.86, 112.54, 110.01, 107.89, 107.16, 61.71, 44.33, 29.84, 18.44, 17.62, 14.06, 9.30. HR-MS (negative mode): [MH] - Calculated: 833.3390; measured: 833.3380.
[0650] Scheme 4. Synthesis of AGB derivatives
[0651]
[0652]
[0653] General procedure for acylation:
[0654] A solution of phloroglucinol 11 (1 equivalent) and anhydrous aluminum chloride (4 equivalents) in 1,2-dichloroethane and nitrobenzene (1:1, v / v, about 1M) was stirred at room temperature under argon atmosphere for 15 min. Acid chloride (1.5 equivalents) in nitrobenzene was added, and the reaction temperature was raised to 80 ° C and maintained for 4 h. After cooling, the reaction mixture was diluted with ethyl acetate and further washed with 1N HCl solution. The organic layer was poured out, and the remaining solid residue was washed three times with EtOAc (20 ml×3). The combined EtOAc extracts were washed with brine and dried over anhydrous Na2SO, evaporated in vacuo, and the remaining residue was purified by silica gel column chromatography using n-hexane-EtOAc as eluent to obtain the compound.
[0655]
[0656] 4-Oxo-4-(2,4,6-trihydroxyphenyl)butyric acid methyl ester (22)
[0657] 1.2 g, yield 75%. 1 H-NMR (600 MHz, methanol-d4): δ 5.79 (s, 2H), 3.66 (s, 3H), 3.73 (t, J = 6.6 Hz, 2H), 1.65 (t, J = 6.6 Hz, 2H). 13 C-NMR (150 MHz, methanol-d4): δ 204.7, 176.1, 166.5, 166.1, 105.5, 95.9, 52.4, 40.0, 29.5. HR-MS (negative mode): [MH] - Calculated: 239.0561; measured: 239.0563.
[0658]
[0659] (2,4,6-Trihydroxy-1,3-phenylene)bis(benzophenone) (23)
[0660] 270 mg, yield 57%. 1 H-NMR (600 MHz, methanol-d4): δ7.71 (dt, J=7.0, 5.2 Hz, 4H), 7.75 (t, J=7.0 Hz, 2H), 7.47 (t, J=11.1 Hz, 4H), 6.02 (s, 1H). 13 C-NMR (150 MHz, methanol-d4): δ 200.0, 166.2, 142.0, 133.0, 129.7, 129.1, 106.4, 96.0. HR-MS (negative mode): [MH] - Calculated: 333.0768; measured: 333.0766.
[0661] General procedure for AB ring coupling via ZnCl2 (Method A):
[0662] A solution of acyl compound (1 equivalent) and benzyl alcohol (2 equivalents) in dioxane (about 0.1M) was stirred at room temperature under argon atmosphere. ZnCl2 (2 equivalents) was added, and the reaction temperature was increased to 100°C and maintained for 1h. After cooling, the reaction mixture was diluted with ethyl acetate and further washed with saturated NaHCO3 solution. The mixture was washed 3 times with EtOAc. The combined EtOAc extracts were washed with brine and dried with anhydrous Na2SO, evaporated in vacuo, and the remaining residue was purified by silica gel column chromatography using n-hexane-EtOAc as eluent to obtain the compound.
[0663]
[0664] 1,1'-(((5-(cyclohexanecarbonyl)-2,4,6-trihydroxy-1,3-phenylene)bis(methylene))bis(2,4-dihydroxy-6-methoxy-5-methyl-3,1-phenylene))bis(butan-1-one)(24)
[0665] Method A: 57 mg, yield 62%. 1 H-NMR (600MHz, CDCl3): δ10.70(s,1H),9.65(brs,2H),9.28(s,1H),3.81(s,4H),3.71(s,6H),3.08(t,J=7.3Hz, 4H), 2.11 (s, 6H), 1.89 (brs, 2H), 1.81 (brs, 2H), 1.74 (m, 5H), 1.39 (brs, 4H), 1.25 (m, 2H), 0.99 (t, J = 7.3Hz, 6H). 13 C-NMR (150MHz, CDCl3): δ 211.4, 207.0, 161.9, 160.2, 159.2, 157.8, 112.5, 109.6, 107.8, 105.8, 104.9, 61.5, 49.6, 44.2, 29.9, 26.1, 18.1, 16.5, 13.9, 9.1. HR-MS (negative mode): [MH] - Calculated: 707.3073; measured: 707.3070.
[0666]
[0667] 1,1'-(((5-benzoyl-2,4,6-trihydroxy-1,3-phenylene)bis(methylene))bis(2,4-dihydroxy-6-methoxy-5-methyl-3,1-phenylene))bis(butan-1-one)(25)
[0668] Method A: 140 mg, yield 67%. 1H-NMR (600MHz, CDCl3): δ9.27 (s, 1H), 7.56 (d, J = 7.2Hz, 2H), 7.49 (m, 1H), 7.36 (m, 2H), 3.81 (s, 4 H), 3.71 (s, 6H), 3.07 (t, J = 7.2Hz, 4H), 2.11 (s, 6H), 1.72 (q, J = 7.3Hz, 4H), 0.97 (d, J = 7.3Hz, 6H). 13 C-NMR (150MHz, CDCl3): δ 207.0, 200.7, 161.6, 160.3, 159.5, 158.3, 141.0, 131.5, 128.2, 127.6, 112.4, 109.4, 107.8, 105.5, 61.6, 44.2, 18.2, 16.7, 13.9, 9.2. HR-MS (negative mode): [MH] - Calculated: 701.2603; measured: 701.2620.
[0669]
[0670] 4-(3,5-di(3-butyryl-2,6-dihydroxy-4-methoxy-5-methylbenzyl)-2,4,6-trihydroxyphenyl)-4-oxobutanoic acid methyl ester (26)
[0671] Method A: 62 mg, yield 59%. 1 H-NMR (600MHz, CDCl3): δ3.80(s,2H),3.71(s,6H),3.70(s,3H),3.50(t,J=6.6Hz,2H),3.0 9(t,J=7.2Hz,4H),2.67(t,J=6.0Hz,2H),2.10(s,6H),1.73(m,4H),0.99(t,J=7.2Hz,6H). 13 C-NMR (150MHz, CDCl3): δ 207.1, 200.7, 161.6, 160.2, 159.5, 158.3, 141.0, 131.5, 128.3, 127.6, 112.4, 109.4, 107.9, 105.5, 61.6, 44.2, 18.2, 16.7, 13.9, 9.2. HR-MS (negative mode): [MH] - Calculated: 711.2658; measured: 711.2662.
[0672]
[0673] (5-(3-Butyryl-2,6-dihydroxy-4-methoxy-5-methylbenzyl)-2,4,6-trihydroxy-1,3-phenylene)bis(benzophenone) (27)
[0674] Method A: 141 mg, yield 72%. 1 H-NMR (600MHz, CDCl3): δ15.55(s,1H),13.27(s,1H),9.04(s,1H),7.60(d,J=7.1Hz,4H),7.52(t,J=7.4Hz,2H),7.41(t,J=7.8H z, 4H), 3.81 (s, 2H), 3.82 (s, 3H), 3.72 (s, 3H), 3.06 (t, J = 7.2Hz, 2H), 2.13 (s, 3H), 1.71 (q, J = 7.3Hz, 2H), 0.96 (d, J = 7.3Hz, 3H). 13 C-NMR (150MHz, CDCl3): δ 207.0, 200.1, 166.7, 165.2, 161.3, 160.3, 159.4, 140.6, 131.7, 128.1, 127.8, 112.4, 108.8, 107.9, 105.5, 104.1, 61.6, 44.2, 18.1, 16.0, 13.9, 9.2. HR-MS (negative mode): [MH] - Calculated: 569.1817; measured: 569.1810.
[0675]
[0676] 1,1'-(((2,4,6-trihydroxy-5-methyl-1,3-phenylene)bis(methylene))bis(2,4-dihydroxy-6-methoxy-5-methyl-3,1-phenylene))bis(butan-1-one)(28)
[0677] Method A: 105 mg, 86%. 1 H NMR (600MHz, CDCl3) δ15.52(s,2H),9.79(s,1H),9.27(s,2H),3.84(s,4H),3.70(s,6 H), 3.07 (t, J = 7.3Hz, 4H), 2.10 (m, 9H), 1.73 (h, J = 7.4Hz, 4H), 0.99 (t, J = 7.4Hz, 6H). 13CNMR (151MHz,CDCl3)δ207.1,161.5,160.2,159.7,151.4,149.8,112.1,110.1,108.1,106.0,103.4,61.7,44.4,18.4,17.4,14.1,9.2,8.5. HR-MS (negative mode): [MH] - Calculated: 611.2497; measured: 611.2512.
[0678] General procedure for AB ring coupling via p-TsOH (Method B):
[0679] A solution of acyl compound (1 equivalent) and benzyl alcohol (1 equivalent) in dioxane (about 0.1M) was stirred at room temperature under argon atmosphere. p-TsOH (1 equivalent) was added, and the reaction temperature was increased to 100°C and maintained for 6h. After cooling, the reaction mixture was diluted with ethyl acetate and further washed with saturated NaHCO3 solution. The mixture was washed 3 times with EtOAc. The combined EtOAc extracts were washed with brine and dried with anhydrous Na2SO, evaporated in vacuo, and the remaining residue was purified by silica gel column chromatography using n-hexane-EtOAc as eluent to obtain compound.
[0680]
[0681] 2-Methyl-1-(2,4,6-trihydroxy-3-(3,4,5-trimethoxybenzyl)phenyl)butan-1-one(29)
[0682] Method B: 127 mg, yield 34%. 1 H-NMR (600MHz, CDCl3): δ6.54(s,2H),5.86(s,1H),3.88(s,2H),3.79(s,3H),3.50(m,1H ), 2.11 (s, 6H), 1.82 (m, 2H), 1.38 (m, 1H), 1.15 (d, J = 6.72Hz, 3H), 0.89 (t, J = 7.3Hz, 3H). 13 C-NMR (150MHz, CDCl3): δ210.8, 172.2, 164.0, 160.7, 159.4, 152.7, 137.1, 135.5, 106.7, 105.5, 104.5, 95.0, 60.8, 55.9, 45.8, 28.2, 26.9, 16.5, 11.9. HR-MS (negative mode): [MH] - Calculated: 389.1605; measured: 389.1600.
[0683]
[0684] 1-(3-(3-Butyryl-2,6-dihydroxy-4-methoxy-5-methylbenzyl)-2,4,6-trihydroxy-5-(3,4,5-trimethoxybenzyl)phenyl)-2-methylbutan-1-one (30)
[0685] Method A: 37 mg, yield 67%. 1 H-NMR (600MHz, CDCl3): δ6.45(s,2H),3.86(s,2H),3.82(s,3H),3.79(s,6H),3.72(s,3H),3.08(t,J=7.2Hz,2H),2.1 2(s,2H),1.80(m,1H),1.72(m,2H),1.38(m,1H),1.12(d,J=6.7Hz,3H),0.98(d,J=7.3Hz,3H),0.87(d,J=7.3Hz,3H). 13 C-NMR (150MHz,CDCl3):δ211.1,206.9,161.7,160.2,159.5,153.7,136.9,133.9,112.1,109.5,107.8,105.9,104.9,61.5,60.8,56.1,45.8,44.2,29.0,26.8,18.1,16.6,16.4,13.9,11.9,9.1. HR-MS (negative mode): [MH] - Calculated: 625.2654; measured: 625.2660.
[0686]
[0687] Methyl 2,4,6-trihydroxy-3-isobutyrylbenzoate (32)
[0688] 4.23 g, yield 69%. 1 H NMR (600MHz, CDCl3) δ14.46 (s, 1H), 6.01 (s, 1H), 4.08 (s, 3H), 3.89 (m, 1H), 1.17 (d, J = 6.6Hz, 6H). 13 C NMR (150 MHz, CDCl3) δ 211.0, 171.6, 169.6, 104.0, 97.3, 92.4, 53.0, 39.6, 19.0. HR-MS (negative mode): for [MH]+, calculated as 253.0717; found as 253.0711.
[0689] General procedure for AB ring coupling via BF3-Et2O (Method C):
[0690] A solution of acyl compound (1 equivalent) and benzyl alcohol (1 equivalent) in dioxane (about 0.1M) was stirred at room temperature under argon atmosphere. BF3-Et2O (1.1 equivalents) was added, and the reaction temperature was increased to 100°C and maintained for 1h. After cooling, the reaction mixture was diluted with ethyl acetate and further washed with saturated NaHCO3 solution. The mixture was washed 3 times with EtOAc. The combined EtOAc extracts were washed with brine and dried with anhydrous Na2SO, evaporated in vacuo, and the remaining residue was purified by silica gel column chromatography using n-hexane-EtOAc as eluent to obtain the compound.
[0691]
[0692] Methyl 2,4,6-trihydroxy-3-(2-hydroxy-5-methylbenzyl)-5-(2-methylbutyryl)benzoate (33)
[0693] Method C: 78 mg, yield 78%. 1 H-NMR (600MHz, CDCl3): δ7.26(d,J=1.8Hz,1H),6.89(dd,J=6,1.8Hz,1H),6.75(d,J=6Hz,1H),4.10(s,3H),3.82(s,2 H), 3.75 (m, 1H), 3.60 (brs, 2H), 3.24 (s, 3H), 1.82 (m, 1H), 1.40 (m, 1H), 1.15 (d, J = 6.6Hz, 2H), 0.91 (t, J = 7.8Hz, 3H). 13 C-NMR (150MHz, CDCl3): δ 211.5, 170.0, 168.4, 152.1, 132.2, 131.1, 129.0, 128.4, 125.4, 116.3, 107.9, 104.0, 92.5, 53.2, 46.3, 26.7, 22.6, 20.5, 16.4, 11.9. HR-MS (negative mode): [MH] - Calculated: 387.1449; measured: 387.1440.
[0694]
[0695] Methyl 2,4,6-trihydroxy-3-(2-hydroxybenzyl)-5-(2-methylbutyryl)benzoate (34)
[0696] Method C: 24 mg, yield 32%. 1H NMR (600MHz, CDCl3) δ7.48(dd,J=7.6,1.7Hz,1H),7.44(s,1H),7.14–7.05(m,1H),6.86(dd,J=8.1,1.2Hz,1H),6.82(td,J=7.4,1.3Hz,1H),4.10 (s,3H),3.87(s,2H),3.76(h,J=6.6Hz,1H),1.83(dqd,J=13.3,7.5,5.9 Hz,1H),1.48–1.35(m,1H),1.16(d,J=6.7Hz,3H),0.92(t,J=7.4Hz,3H). 13 C NMR (151 MHz, CDCl3) δ 211.7, 170.2, 168.5, 154.7, 132.1, 128.1, 125.8, 120.1, 116.6, 107.9, 104.2, 92.8, 53.5, 46.5, 26.8, 22.9, 16.6, 12.1. HR-MS (positive mode): for [M+H]+, calculated as 375.1439; found as 375.1450.
[0697]
[0698] 3-(3-Butyryl-2,6-dihydroxy-4-methoxy-5-methylbenzyl)-2,4,6-trihydroxy-5-isobutyrylbenzoic acid methyl ester (35)
[0699] Method C: 129 mg, yield 75%. 1 H-NMR (600MHz, CDCl3): δ3.99(s,3H),3.98(m,1H),3.82(s,2H),3.70(s,3H),3.60(brs,1H), 3.06 (t, J = 7.2 Hz, 2H), 2.09 (s, 3H), 1.71 (m, 3H), 1.17 (d, J = 7.2 Hz, 6H), 0.96 (t, J = 7.8 Hz, 3H). 13 C-NMR (150MHz,CDCl3):δ210.9,205.8,171.0,166.2,163.0,160.4,159.1,158.9,110.7,107.9,106.9,104.6,102.6,93.7,60.5,51.8,43.3,38.4,18.1,17.2,14.8,12.9,8.1. HR-MS (negative mode): [MH] - Calculated: 489.1766; measured: 489.1761.
[0700] The spectra of some of the above AGB derivatives are as follows Figures 6A-6M shown.
[0701] Cell culture
[0702] SUNE1 (nasopharyngeal carcinoma), AGS (gastric adenocarcinoma), HeLa (cervical adenocarcinoma), HepG2 (hepatocellular carcinoma), U-87MG (human glioblastoma cells), U2OS (osteosarcoma), MCF-7 (breast cancer), MDA-MB-231 (breast cancer), HCT116 (colorectal cancer), SW480 (colorectal adenocarcinoma), NCI-H460 (large cell lung cancer), NCI-H1650 (adenocarcinoma lung cancer), HCC827 (adenocarcinoma lung cancer), A549 (lung cancer), and CCD- 19 Lu (normal human lung fibroblasts) were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Minimal Essential Medium (MEM, ThermoFisher Scientific), Dulbecco's Modified Eagle Medium (DMEM, ThermoFisher Scientific), and supplemented with 10% fetal bovine serum ( ThermoFisher Scientific) and 100U / mL penicillin-streptomycin (Gibco TM RPMI-1640 medium (ThermoFisherScientific) ThermoFisher Scientific) was used for cell culture. The cells were placed in an incubator containing 5% CO2 and the temperature was set to 37°C. For subcultured cells, 0.05% trypsin-EDTA was used. Split and subculture at a ratio of 1:5.
[0703] Cell viability analysis
[0704] Cell viability analysis was performed using a typical MTT assay. 3Cells were seeded into 96-well flat-bottom plates and allowed to adhere overnight. After 48 h of drug treatment using serial dilutions starting from 100 μM, 10 μL of MTT solution (5 mg / ml, prepared in PBS, filtered) was added to each well and incubated at 37°C for 4 h. The formazan formed was then dissolved with an SDS solution (10% SDS in 10 mM HCl) and the absorbance at 590 nm was determined by a microplate reader. The changes in cell viability for each drug concentration were then calculated and normalized to the control. The dose response curve for each analysis was fit to a Boltzmann S-type function (GraphPad Prism8, version 8.0.0). IC was calculated from the fitted curve 50 The cytotoxicity of AGB and its derivatives was determined by the half-maximal inhibitory concentration (IC 50 Values are drug concentrations that induce 50% cell viability.
[0705] Colony formation assay and wound healing assay
[0706] For colony formation assay, cells were treated with AGB at the indicated concentrations for 8 h, then AGB was removed, 200 cells were trypsinized and seeded into a new 12-well cell culture plate containing 1.5 ml complete cell growth medium. After 14 days of cell growth, cells were fixed with ethanol and then stained with crystal violet (0.05%, w / v, in water) for 15 min. Cell colonies were captured under a microscope and the number of colonies was counted by ImageJ (version 1.50i, NIH, USA, internet site imagej.nih.gov).
[0707] For wound healing assays in this study, cells were grown to approximately 80% confluency in 12-well plates in complete growth medium, and then a straight line was drawn in the center of each well using a 200 μL burette tip. After washing the detached cells with PBS, the cells were cultured in complete growth medium for another 24 h with different concentrations of AGB or DMSO as a vehicle control. The gap created by the burette tip was measured at 0 h and 24 h. Each condition was performed in triplicate.
[0708] Spheroid formation assay
[0709] NCI-H460 cells were seeded at 3,000 cells / ml per well in a 6-well ultra-oligomer plate. The cells were incubated at 37°C for 5 days and the spheres were photographed under an inverted microscope at 40x magnification. Primary tumor spheres were collected and enzymatically isolated using casein to obtain secondary tumor spheres. The isolated cells were replated at a density of 2,000 cells / mL for subsequent passages. Images were captured and four fields of view were randomly selected to measure the relative area occupied by the spheres using ImageJ (National Institutes of Health, Bethesda, MD). Representative images were obtained from 3 independent experiments.
[0710] For the IC of the sphere 50 Briefly, cells were plated in 96-well clear flat-bottom ultra-low-adherence cell culture plates. 5*10 3 The density of cells was plated into each well containing a specific sphere formation medium (DMEM / F12 medium supplemented with 20ng / mL EGF, 20ng / mL bFGF, 2% B27). The cells were then treated with different concentrations of AGB, ranging from 0.3-100μM. After 3 days of treatment, the tumor spheres formed in each well were monitored under a microscope. MTT was then applied to determine cell viability, and the cell viability of the AGB-treated group was calculated by normalization to the control group, and the IC was calculated from the plotted curves fitted to the Boltzmann sigmoid function. 50 value.
[0711] Animal studies
[0712] A human tumor xenograft model was used to evaluate the in vivo anticancer efficacy of AGB, in which human cancer cells were inoculated into immunodeficient mice. Briefly, 12 6-week-old (16-18 g) BALB / c nude mice were randomly divided into two groups, and both groups received NCI-H460 cells (2 x 10 6cells in 0.1 mL PBS) were injected subcutaneously, and tumors became palpable 3 days after injection. Mice received intravenous (iv) injections of AGB or vehicle control (10% DMSO and 0.05% Tween 80 in normal saline) every two days for 2 weeks. The length and width of the tumors were measured by vernier calipers and body weight was monitored every 2 or 3 days. At the end of the experiment, the mice were killed and decapitated. The liver, kidney, and tumors were collected and fixed in 4% formaldehyde for further hematoxylin-eosin (H&E) staining. All animal experiments in this project received human care and the research protocol was in accordance with the guidelines of the Laboratory Animal Services Center of the University of Hong Kong. Tumor size and body weight were recorded before each drug injection and calculated by the formula V=LW. 2 Tumor volume (V) was calculated by RT-PCR using the RT-PCR method, where L is the tumor length and W is the tumor width. The relative tumor volume normalized to day 0 was used to detect tumor growth. The data for each group are expressed as mean ± standard deviation.
[0713] Determination of the maximum tolerated dose (MTD) in mice
[0714] The MTD is the maximum drug dose that exerts the desired efficacy without inducing observable adverse reactions
[14] . The MTD experiments in this study were completed in collaboration with the Tianjin Institute of Pharmaceutical Research (TIPR). Experiments were conducted to determine the MTD of AGB in ICR mice after a single intravenous (iv) injection of 12.8 mg / kg and 16.0 mg / kg, and to evaluate its toxicity during the 14-day recovery period. In this study, a total of 80 mice were randomly divided into four groups (10 male mice and 10 female mice in each group). The four groups included a 16.0 mg / kg AGB group, a 12.8 mg / kg AGB group, a vehicle control group (10% DMSO + 0.8% Tween-80, in saline), and a blank control group (saline).
[0715] After single intravenous administration, the general toxicity of all animals in each group was observed in each group. Then, the body weight of the surviving animals was measured respectively on the 1st, 3rd, 7th and 14th days. At the end of the experiment, hematology, blood biochemistry, anatomy and histopathology were tested in both the vehicle control group and the MTD group (12.8 mg / kg). Data are expressed as mean ± standard deviation.
[0716] Data Statistical Analysis
[0717] Data are expressed as mean ± standard deviation (SD). Statistical analysis among multiple groups was performed using ANOVA followed by Tukey-Kramer test. Differences between two groups were determined by Student's t-test. Statistical significance was accepted at two-tailed p values less than 0.05 (α=0.05).
[0718] result
[0719] Total Synthesis of AGB
[0720] It is important and meaningful to overcome the limitation of insufficient quantity and provide a feasible approach for studying the SAR of AGB. The total synthesis reported for AGB so far has low yields and involves complex reactions (0.6% yield, Li et al., Acta Chimica Sinica, 1978, 36, 43-48; 0.3% yield, Zhu et al., Acta Pharmaceutica Sinica, 1989, 24, 431-437). To improve the total synthesis of AGB and its derivatives, two strategies were developed in this study.
[0721] The first synthetic route (Scheme 1) starts from 2,4,6-trihydroxybenzoic acid (5) to produce the hydroxymethylated compound (6). A methyl group is then introduced on the benzene ring to produce compound (8) via a Vilsmeier-Haack reaction. After acylation of compound (8), decarboxylation is performed to produce intermediate (4). The total yield of AGB using synthetic route 1 is about 7.3% (Scheme 1) calculated from 2,4,6-trihydroxybenzoic acid (5). In this synthetic route, the order of the acylation and methylation steps is changed to obtain the key intermediate, and an Eschenmoser methylation reaction is used in the last step to couple the three subunits.
[0722] The second synthetic route (Scheme 2) starts from phloroglucinol (11) to produce 2,4,6-trihydroxymethylbenzene (13) via a Vilsmeier-Haack reaction, followed by acylation of compound (13) via a Friedel-Crafts reaction. Before methylating one of the multiple hydroxyl groups of compound (13), methyl chloromethyl ether (MOMCl) is used to protect two of its hydroxyl groups. Due to steric hindrance, the introduction of protecting groups on two of the multiple hydroxyl groups of compound (13) allows highly selective methylation. Methylation of the protected compound (13) is carried out using dimethyl sulfate, and then the MOM group is deprotected by heating in 1M HCl methanol solution. The total yield of AGB using synthetic route 2 is about 20.2% calculated from phloroglucinol (11) (Scheme 2).
[0723] All steps in the first and second synthetic routes are easily implemented and have significantly higher overall yields than previously reported syntheses (0.6%, Li et al., Acta Chimica Sinica, 1978, 36, 43-48; 0.3%, Zhu et al., Acta Pharmaceutica Sinica, 1989, 24, 431-437). The structure of AGB was characterized by 1H, 13C-NMR, HRMS and 2D-NMR.
[0724] Several derivatives of AGB were synthesized to further reveal the structure-activity relationship (SAR). The corresponding acyl chlorides were designed and used to synthesize the acyl groups of different lengths on the intermediate subunits. In this work, intermediates 17-19 with 1, 3, and 7 carbons were obtained, respectively. After coupling with intermediate 16, three AGB derivatives were generated, named agrimonol H, agrimonol C, and agrimonol L. The detailed synthetic route is shown in Scheme 3.
[0725] In vitro and in vivo anticancer activity
[0726] MTT assay was used to determine the cytotoxicity of AGB against normal cells (CCD-19Lu) and several human cancer cell lines including breast cancer (MDA-MB-231 and MCF-7), hepatocellular carcinoma (HepG2), cervical cancer (HeLa), gastric adenocarcinoma (AGS), colon cancer (HCT116 and SW480), nasopharyngeal carcinoma (SUNE-1), and lung cancer (H460, HCC827, H1650, and A549) cell lines. Compared with normal human lung fibroblast CCD-19Lu cells, the results of MTT assay showed that AGB exerted a significant selective antiproliferative activity against cancer cells, with IC 50 Values below 10 μM ( Figure 1A For example, after 48-h treatment, AGB showed potent cytotoxicity with an IC of 1.04 for all cancer cell lines tested. 50 The values are in the millimolar range of 1.83 μM to 5.81 μM ( Figure 1A ). For 48-h treatment, the IC 50 The value is 31.14 μM, which is much higher than the average IC 50 value.
[0727] The proliferation inhibition effect of AGB on NCI-H460 cells was further examined by colony analysis. NCI-H460 cells were treated with different concentrations of AGB for 8 h, then treated with casein and re-seeded into fresh normal growth RPMI-1640 medium. After 2 weeks of treatment, cell colonies were stained and counted (image not shown). Figure 1BAs shown, it was found that the number of colonies was significantly reduced when the AGB concentration was higher than 2.5 μM, and the effect was shown in a dose-dependent manner. To study the effect of AGB on cell migration ability, a scratch cell wound healing assay was performed. NCI-H460 cells were seeded into a 24-well cell culture plate at a density of approximately 80% confluence, and scratches were made on the cell monolayer. The cells were then detected in the presence or absence of AGB (1 μM, 4 μM, and 10 μM), and images were captured at 16h and 32h. As shown Figure 1C As shown, cells in the vehicle and 1 μM AGB groups proliferated faster and the width of the scratch was significantly reduced. For cells treated with 4 μM or 10 μM AGB, wound closure was inhibited and larger wound gap sizes were observed ( Figure 1C Using colony assays and wound healing assays, AGB showed significant reduction in cell colony formation and cell migration at approximately 4 μM ( Figure 1B and Figure 1C ).
[0728] Cancer stem cells (CSC) are self-repairing, highly tumorigenic tumor cell subpopulations. They play a key role in the occurrence and development of cancer. To evaluate the effect of AGB on the self-repair ability of tumor spheres, NCI-H460 spheres were grown in ultra-low adhesion plates with cancer stem cell culture medium (DMEM-F12, supplemented with B27, EGF, and FGF) and treated with AGB for two consecutive passages. Treatment with AGB significantly reduced the number of tumor spheres in each passage of tumor sphere culture. When treated with 1.0 μM AGB, the tumor sphere formation efficiency of primary tumor spheres was reduced (40.6% inhibition, p<0.05). Similarly, the use of 0.5 μM or 1.0 μM AGB reduced the tumor sphere formation efficiency of secondary tumor spheres (54.7% inhibition, p<0.01, and 69.7% inhibition, p<0.01) ( Figure 1D In addition, when observed using a 96-well round-bottom cell culture plate, it was found that the size of the tumor spheres formed when treated with AGB for 72 h had an observable decrease compared with the control group and the group treated with 0.5% DMSO (image not shown). Using MTT analysis, the IC of AGB for cancer stem cells after 72-h treatment was determined. 50 The value is 4μM ( Figure 1E ).
[0729] To better mimic the physiological structure and function of in situ tissues, the effects of AGB on patient-derived organoids (PDOs) isolated from metastatic tumors of lung cancer patients were evaluated. Upon treatment with 4-25 μM AGB, significant inhibition of PDO viability in a concentration-dependent manner was observed, accompanied by significant apoptotic properties ( Figure 1F ). AGB showed a maximum viability loss of more than 99% ( Figure 1G ).
[0730] The in vivo anti-tumor potential of AGB was evaluated using a xenograft mouse model. Two different cancer cells (NCI-H460 and A549) were inoculated into nude mice simultaneously. Non-obese diabetic severe combined immunodeficient (NOD / SCID) mice were used for stem cell-like NCI-H460 cells. The mice were then treated with vehicle or AGB (3 mg / kg) by tail vein injection. AGB significantly inhibited tumor growth in all three types of xenograft models (A549, NCI-H460, and stem cell-like NCI-H460), with inhibition rates of 60%, 57%, and 64%, respectively ( Figures 1H-1J In addition, the 3 mg / kg AGB dose did not show any observable toxicity, as no significant changes in mouse body weight were observed (data not shown). To further evaluate the safety of AGB, hematoxylin-eosin (H&E) staining of kidney, liver, and tumor samples was performed ( Figure 1K ). The necrotic area (dashed circle) in the tumor tissue of mice treated with AGB was much larger than that of the vehicle group. Liver and kidney, two most important drug metabolism organs, did not show any significant changes after treatment with AGB.
[0731] Two doses were used for the maximum tolerance test of AGB: 12.8mg / kg and 16.0mg / kg. No toxic reaction symptoms were observed on the day of administration and during the recovery period after the drug except for the 16.0mg / kg treatment group. For the 16.0mg / kg treatment group, most animals (13 / 20) had reduced activity within about 30 minutes after AGB administration, and some mice showed prone position (3 / 20) and ptosis (1 / 20) within about 1 hour after AGB administration. All symptoms were not completely reversed on the first day, and one mouse died on the second day. The remaining mice gradually recovered after one week and did not show any significant toxic symptoms. The weight of mice in the blank control group, vehicle control group, 12.8mg / kg treatment group, and 16.0mg / kg treatment group was monitored (Tables 1 and 2). In the vehicle control group, the average body weight of all mice compared with the blank control group on the day of administration and during the recovery period after drug administration did not show significant abnormalities. In the 12.8 mg / kg treatment group, the average body weight of male mice was lower than that of the blank control at 3 and 7 days after AGB administration, but showed a slow increase; the average body weight of female mice was lower than that of the blank control at 1 and 3 days after AGB administration, but recovered on the 7th and 14th days. No significant body weight abnormalities were observed at each time checkpoint. In the 16.0 mg / kg treatment group, the average body weight of male and female mice was lower than that of the blank control group at 1, 3, and 7 days after AGB administration, but gradually recovered after 14 days after AGB administration.
[0732] Table 1. Body weight of male mice (mean ± standard deviation, g)
[0733]
[0734] Table 2. Body weight of female mice (mean ± standard deviation, g)
[0735]
[0736] Hematological tests (Table 3) and serum bioassays (Table 4) were also performed on the vehicle control group and the 12.8 mg / kg treatment group. As shown in Table 3, on the 14th day after AGB administration, in the 12.8 mg / kg treatment group, E, E%, RBC, HGB, and HCT decreased, while N%, PLT, Ret, and Ret% increased compared to the vehicle control group. Although the difference was not significant, the changes in the above markers may indicate the possible effects of high-dose AGB on the blood system. As shown in Table 4, on the 14th day after AGB administration, there was no significant abnormality in the 12.8 mg / kg treatment group compared to the vehicle control group.
[0737] Table 3. Hematological examination of samples from the vehicle group and the 12.8 mg / kg treatment group.
[0738]
[0739] Note: White blood cells (WBC), neutrophils (N), lymphocytes (L), monocytes (M), eosinophils (E), red blood cells (RBC), hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), and platelet count (PLT), reticulocytes (Ret)
[0740] Table 4. Serum biochemistry tests of samples from the vehicle and 12.8 mg / kg treatment groups.
[0741]
[0742] The results discussed above validate that AGB has potent anticancer activity both in vivo and in vitro. AGB exhibits preferential antiproliferative activity against cancer cells at micromolar concentrations, inhibits colony formation, cell migration, and blocks the self-renewal ability of cancer stem-like cells. At the in vivo level, AGB exhibits low toxicity inhibition of xenograft tumor growth.
[0743] The structure-activity relationship of AGB was also studied. The cytotoxicity of five AGB derivatives was tested using different cancer cell lines. As shown in Table 5, four different cancer cell lines were used to evaluate cytotoxicity (48-h treatment). Compounds AGF, AGS, and agrimonol L (AGL) showed significantly lower cytotoxicity than AGB, while compounds agrimonol H (AGH) and agrimonol C (AGC) both exhibited similar cytotoxicity to AGB. These results indicate that: (i) the acyl length of the intermediate subunit should not exceed 5 carbons; (ii) dimerized acyl pyrogallol is essential for anticancer activity, while the third subunit of trimerized acyl pyrogallol may not contribute to cytotoxicity; (iii) tetramerized acyl pyrogallol has no activity.
[0744]
[0745] Table 5. IC50 values of AGB and its derivatives determined by MTT method (48h, μM)
[0746]
[0747] Table 6 shows the test results (IC50 values) of some other AGB structures determined by the MTT method (48h, μM).
[0748] Table 6. IC50 values of AGB and its derivatives determined by MTT method (48h, μM)
[0749]
[0750]
[0751] ProTargetMiner Analysis
[0752] The above results indicate that AGB has the ability to induce apoptosis, and its potential mechanism was further investigated by ProTargetMiner analysis. General differential expression proteome analysis for studying protein regulation is not a sufficiently specific parameter for elucidating the mechanism of action, because some universal proteins are stimulated by all toxic compounds. ProTargetMiner is a tool for studying the mechanism of action of cancer cells. It is a signature library of proteome responses of human cancer cells to anticancer agents. By comparing a given compound with all other drugs in the library, specific regulatory proteins that respond to a given compound can be screened by orthogonal partial least squares discriminant analysis (OPLS-DA). OPLS-DA analysis filters out those nonspecific regulation, thereby obtaining specific regulation to map the network.
[0753] The differential protein expression between the vehicle group and the AGB-treated group was measured by a quantitative proteomics method labeled with TMT. As a result, the most specifically up-regulated and down-regulated proteins induced by AGB appeared at the outliers ( Figure 2A ). They mainly belonged to vesicular transporters, mitochondrial ribosomal proteins (MRPs), and NADH dehydrogenases, respectively. A protein called OPA1 proved to be the most down-regulated protein.
[0754] To gain a more comprehensive understanding of the changes in related protein complexes, a protein-protein interaction network was mapped using STRING to visualize the top 100 most specifically upregulated or downregulated proteins affected by AGB. Using an unbiased k-means clustering method, six major clusters of interactions (clusters A, B, and C) were obtained, containing 4, 12, and 14 proteins, respectively. Figure 2B As shown, the proportion of proteins affected by AGB in each cluster was grouped and labeled. The six clusters were further subjected to GO analysis. The proteins in cluster A belong to mitochondrial ribosomal proteins and are involved in mitochondrial protein translation. Cluster B mainly contains vesicular transporters that regulate ER to Golgi transport. Cluster C represents biological function proteins of mitochondrial respiratory chain complex I components ( Figure 2C ). The results of ProTargetMiner analysis evaluated by the STRING network analysis method showed that the effects on mitochondrial function and ER-to-Golgi transport may play a role in the anticancer activity of AGB.
[0755] Agrimonia ol B inhibits ER trafficking to the Golgi apparatus and induces ER stress
[0756] Based on the results of ProTargetMiner analysis, mitochondrial function and ER stress were studied. First, the results described in the ProTargetMiner analysis showed that AGB regulated the inhibition of ER-Golgi transport. In cells, proteins are first synthesized in the ER and transported to the Golgi for processing. When the drug blocks the transport of ER to the Golgi, the Golgi will suffer from drastic redistribution and destruction. This blockage causes immature proteins to accumulate in the ER, thereby destroying the structure of the Golgi and inducing ER stress. The Golgi disruptor Brefeldin A (BFA) was used as a positive control drug. BFA is a lactone fungal macrolide antibiotic that specifically inhibits protein transport by targeting the Golgi. The effects of BFA and AGB on the integrity of the Golgi complex were evaluated by immunostaining with anti-GM130 antibodies (one of the Golgi markers). The results showed that NCI-H460 cells incubated with BFA resulted in the redistribution of GM130, indicating Golgi destruction (data not shown). Similar results were obtained when the cells were exposed to AGB treatment. Thus, the effects of BFA and AGB on Golgi integrity and function were shown to have similar mechanisms, leading to Golgi disruption and ER stress in cancer cells.
[0757] The destruction of the Golgi structure leads to impaired glycosylation, resulting in misfolded proteins, which accumulate and induce ER stress. The relationship between AGB and ER stress in cancer cells was examined. Using ER tracer staining, the morphology of ER was destroyed and the content was reduced (image not shown). In order to confirm that NCI-H460 cells produce ER stress response when treated with AGB, the expression of two ER stress markers glucose-regulated protein (GRP) 78 (GRP78) and C / -EBP homologous protein (CHOP) was tested. GAPDH was used as a loading control. Western blot images show that in NCI-H460 cells treated with AGB, GRP78 and CHOP increased significantly in a time-dependent manner (data not shown). In general, there are three sensors that initiate ER stress response, including IRE1, PERK and ATF6. When unfolded proteins accumulate, BiP preferentially binds to unfolded proteins, resulting in the release of PERK, IRE1, and ATF6. Once released from BiP, PERK is activated and dimerized. Activated PERK phosphorylates eIF2α to inhibit global transcription of mRNA. The phosphorylation status of eIF2α in AGB-treated cells was examined, and the results showed that eIF2α was phosphorylated in the NCI-H460 cell line.
[0758] AGB induces mitochondrial fission
[0759] Another cluster highlighted in the ProTargetMiner analysis was related to mitochondrial translation and respiratory function. Using U2OS cells transfected with the mitochondrial-RFP reporter gene, time-lapse microscopy was used to monitor changes in mitochondrial morphology during a 30-hour, 4 μM AGB treatment (data not shown). AGB did trigger dynamic changes in mitochondria. As shown in the images recorded using time-lapse microscopy (data not shown), about 5 hours after the start of imaging, the mitochondria became a linear, very elongated morphology. The lines then slowly broke. At about 10 hours, the mitochondria became small dots, which became brighter. At the end of the imaging (about 30 hours of treatment), some cells underwent mitochondrial outer membrane permeabilization (sudden loss of fluorescence in the mitochondria) and died. These results indicate that after AGB treatment, the cells underwent mitochondrial fission.
[0760] Mitochondria are highly dynamic organelles that frequently fuse and divide, with the ability to change size, shape, and position. The dynamic properties of mitochondria are important for the maintenance of mitochondrial inheritance and mitochondrial function. When the balance between fission and fusion is disrupted, the overall mitochondrial morphology changes significantly due to the relative increase or decrease in either process. Using confocal microscopy analysis stained with MitoTracker Green, mitochondria of NCI-H460 cells in the untreated control group showed normal elongated tubular structures. In contrast, after exposure to 4 μM AGB for different periods of time (0, 2, 5, 8, 10, and 16 h, respectively), the morphology of mitochondria gradually changed to a prominent dot-like structure (staining data not shown), and then the fluorescent signal disappeared after 16 hours ( Figure 3A ).
[0761] Several proteins that control mitochondrial fusion and fission have been identified, including mitochondrial fusion proteins and OPA1 for fusion, and Mff and DRP1 for fission. The effect of AGB on the expression of mitochondrial fusion proteins (Mfn1 and Mfn2) and fission proteins (DRP1 and Mff) was studied. Western blot analysis showed that AGB slightly reduced the expression of Mfn1 and Mfn2 in a dose-dependent manner, indicating that the fusion process was affected (data not shown). Western blot images also showed that phosphor-DRP1 (Ser637) was significantly reduced, while AGB did not change the expression of DRP1 and Mff (data not shown). Protein kinase A phosphorylates DRP1 at residue S637 to inhibit mitochondrial fission, while dephosphorylation at S637 increases the mitochondrial recruitment of DRP1 and promotes mitochondrial fission. The localization of DRP1 was detected by immunofluorescence staining. Immunostaining of Drp1 in mito-RFP-transfected cells showed that AGB significantly promoted the translocation of DRP1 from the cytoplasm to mitochondria (data not shown), indicating that AGB induced DRP1-mediated mitochondrial fission.
[0762] OPA1 is another protein located in the inner membrane of mitochondria and is involved in different functions such as the regulation of mitochondrial morphological dynamics, the maintenance of the respiratory chain, and the control of ATP synthesis. The reduction of L-OPA1 leads to the inhibition of mitochondrial fusion, while the accumulation of S-OPA1 promotes mitochondrial fission. According to the results of ProTargetMiner, OPA1 was found to be the most specifically downregulated protein by OPLS-DA analysis. These results were verified using Western blotting, demonstrating that AGB treatment promoted the cleavage of OPA1 from its long form (L-OPA1) to its short form (S-OPA1) in a dose- and time-dependent manner (data not shown). OPA1 plays a role in maintaining mitochondrial cristae structure. OPA1 fragmentation leads to the disorder of the mitochondrial inner membrane structure. Mitochondrial ultrastructure was observed under transmission electron microscopy (TEM) after treatment with AGB or vehicle for 16 h. Classical long tubular cylinders were observed in the control group, while round vesicles with reduced diameter were dominant in the AGB-treated group, confirming the above-observed mitochondrial fission. Furthermore, the mitochondrial cristae structure in the treated group showed complete lack of structure and adopted an unusual shape consisting of vesicle-like structures with abnormally increased space between the membranes ( Figure 3B ). Collectively, these observations suggest that AGB induces mitochondrial fission.
[0763] Mitochondrial fission and mitochondrial membrane potential depolarization are involved in the induction of apoptosis and play a central role in the apoptotic pathway. Therefore, several apoptosis analyses were performed. First, Hoechst staining revealed chromatin condensation and fragmentation, which is one of the characteristics of apoptosis (image not shown). Flow cytometric analysis by annexin V and PI staining also revealed an increase in early and late apoptotic cell populations after AGB treatment ( Figure 4 ). AGB induced apoptosis in NCI-H460 cells by monitoring PARP, caspase-9 and caspase-3 cleavage and detecting changes in the levels of a group of proteins that are usually involved in apoptotic signaling by Western blot experiments (data not shown). The release of cytochrome c and apoptosis-indu...
Claims
1. Compounds having the following structure: in: (a) L1 and L2 are independently a single bond, a substituted or unsubstituted alkylene group, a substituted or unsubstituted alkenylene group, a carbonyl group, or an alkoxy group; (b) L3 is a single bond, a substituted or unsubstituted alkylene group, or a carbonyl group; (c) A1 and A2 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, carbonyl, or alkoxy, and at least one of A1 and A2 is substituted or unsubstituted aryl; (d) A3 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, carbonyl, or alkoxy; (e) R1-R3 are independently hydrogen, hydroxy, substituted or unsubstituted alkyl, carbonyl, alkoxy, thiol, or amino; and (f) the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, carbonyl, alkoxy, halogen, hydroxy, phenoxy, thiol, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amide, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphanyl, phosphoryl, or phosphonyl.
2. The compound of claim 1, wherein A1 and / or A2 are independently substituted or unsubstituted aryl.
3. The compound of claim 1 or claim 2, wherein the compound has the following structure: in: (a) L1 and L2 are independently a single bond, a substituted or unsubstituted alkylene group, a substituted or unsubstituted alkenylene group, a carbonyl group, or an alkoxy group; (b) L3-L5 are independently a single bond, a substituted or unsubstituted alkylene group, or a carbonyl group; (c) A3-A5 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, carbonyl, or alkoxy; (d) R1-R3 and R9-R 16 are independently hydrogen, hydroxy, substituted or unsubstituted alkyl, carbonyl, alkoxy, thiol, or amino; and (e) the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, carbonyl, alkoxy, halogen, hydroxy, phenoxy, thiol, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amide, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphanyl, phosphoryl, or phosphonyl.
4. The compound of any one of claims 1 to 3, wherein -L1-A1 is identical to -L2-A2, wherein the compound has the following structure: in: (a) L3 and L7 are independently a single bond, a substituted or unsubstituted alkylene group, or a carbonyl group; (b) L6 is a single bond, a substituted or unsubstituted alkylene group, a substituted or unsubstituted alkenylene group, a carbonyl group, or an alkoxy group; (c) A3 and A7 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, carbonyl, or alkoxy; (d) R1-R3 and R 18 -R 21 are independently hydrogen, hydroxy, substituted or unsubstituted alkyl, carbonyl, alkoxy, thiol, or amino; and (e) the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, carbonyl, alkoxy, halogen, hydroxy, phenoxy, thiol, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amide, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphanyl, phosphoryl, or phosphonyl.
5. The compound of any one of claims 1 to 4, wherein R1-R3, R8-R 16 , and / or R 18 -R 21 R4-R7 are independently hydroxy, substituted or unsubstituted alkyl, -OR4, -SR5, or -NR6R7, and R4-R7 are independently hydrogen or substituted or unsubstituted alkyl.
6. The compound of any one of claims 1 to 5, wherein R1 to R3 are hydroxyl groups.
7. The compound of any one of claims 1 to 6, wherein R8-R 16 and / or R 18 -R 21R4 is independently hydroxy, substituted or unsubstituted alkyl, or -OR4, and R4 is substituted or unsubstituted alkyl.
8. The compound of any one of claims 1 to 7, wherein -L3-A3 is a substituted or unsubstituted C1-C6 alkyl, or R 17 is a substituted or unsubstituted C1-C6 alkyl group, a substituted or unsubstituted aryl group, or m can be an integer from 0 to 5, R 26 is a carboxylic acid, an ester, an amino group, or an amide.
9. The compound of claim 8, wherein R 17 It is a substituted or unsubstituted C1-C5 alkyl group, a substituted or unsubstituted C1-C4 alkyl group, a substituted or unsubstituted C1-C3 alkyl group, a substituted or unsubstituted C1-C2 alkyl group, or a substituted or unsubstituted methyl group.
10. The compound of claim 8, wherein R 17 It is a C6 cycloalkyl group.
11. The compound of claim 8, wherein R 17 It is an unsubstituted phenyl group.
12. The compound of claim 8, wherein R 26 For esters.
13. The compound of any one of claims 1 to 12, wherein -L4-A4, -L5-A5, and / or -L7-A7 are independently R 17 is a substituted or unsubstituted C1-C6 alkyl group.
14. The compound of claim 1 or 2, wherein -L1-A1 is different from -L2-A2, wherein the compound has the following structure: in (a) L1 and L2 are independently a single bond, a substituted or unsubstituted alkylene group, a substituted or unsubstituted alkenylene group, -C(O)-, or an alkoxy group; (b) A1 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, carbonyl, or alkoxy; (c) R1-R3, and / or R 13 -R 16 are independently hydrogen, hydroxy, substituted or unsubstituted alkyl, -OR4, -SR5, or -NR6R7, R4-R7 are independently hydrogen or substituted or unsubstituted alkyl; (d)-L3-A3 is R 17 is a substituted or unsubstituted alkyl group, or a substituted or unsubstituted aryl group; and (e) -L5-A5 is hydrogen, substituted or unsubstituted alkyl, or R 17 is a substituted or unsubstituted alkyl group.
15. The compound of claim 1 or 2, wherein -L1-A1 is different from -L2-A2, wherein the compound has the following structure: in (a) L1 and L2 are independently substituted or unsubstituted alkylene or -C(O)-; (b) A1 is a substituted or unsubstituted aryl group, or a C1-C6 alkoxy group; (c) R1-R3 are hydroxyl groups; (d) R 13 -R 16 are independently hydroxy, hydrogen, substituted or unsubstituted alkyl, or -OR4, R4 is substituted or unsubstituted C1-C6 alkyl; (e)-L3-A3 is R 17 is a substituted or unsubstituted C1-C6 alkyl group, or a substituted or unsubstituted aryl group; and (f) -L5-A5 is hydrogen, substituted or unsubstituted C1-C6 alkyl, or R 17 is a substituted or unsubstituted C1-C6 alkyl group.
16. The compound of claim 15, wherein A1 is phenyl substituted with an alkoxy group.
17. The compound of claim 15, wherein A1 is unsubstituted phenyl.
18. The compound of any one of claims 15-17, wherein -L3-A3 is R 17 It is an unsubstituted phenyl group.
19. The compound of claim 1 or 2, wherein -L1-A1 is different from -L2-A2, wherein the compound has the following structure: in (a) L1 and L2 are independently substituted or unsubstituted alkylene or -C(O)-; (b) A1 is C1-C6 alkoxy; (c) R1-R3 are hydroxyl groups; (d) R 13 -R 16 is hydroxy, substituted or unsubstituted C1-C6 alkyl, or -OR4, R4 is substituted or unsubstituted C1-C6 alkyl; (e)-L3-A3 is R 17is a substituted or unsubstituted C1-C6 alkyl group; and (f)-L5-A5 is R 17 is a substituted or unsubstituted C1-C6 alkyl group.
20. The compound of any one of claims 1 to 19, wherein the compound is not and not 21. The compound of any one of claims 1 to 20, wherein the compound is 22. A pharmaceutical formulation comprising: One or more compounds according to any one of claims 1 to 21; and Pharmaceutically acceptable carriers and / or excipients.
23. The pharmaceutical formulation of claim 22, wherein the one or more compounds are in an effective amount to treat cancer, reduce cancer, or treat or ameliorate one or more symptoms associated with cancer in a subject.
24. The pharmaceutical formulation of claim 23, wherein the effective amount of the one or more compounds is effective to induce mitochondrial dysfunction in the subject and / or inhibit ER to Golgi trafficking in cancer cells.
25. The pharmaceutical formulation of claim 23 or 24, wherein the effective amount of the one or more compounds is effective to induce apoptosis of cancer cells in a subject.
26. The pharmaceutical formulation of any one of claims 23-25, wherein the effective amount of one or more compounds in the subject inhibits growth of a tumor in the subject by at least 40%, at least 50%, or at least 55% compared to the same tumor in a control subject.
27. The pharmaceutical formulation of any one of claims 22-26, further comprising a second active agent, optionally more than one second active agent, optionally the second active agent is an anti-cancer agent.
28. The pharmaceutical formulation of any one of claims 22-27, wherein the total concentration of the one or more compounds in the pharmaceutical formulation is at least 0.01 wt%, at least 0.05 wt%, at least 0.1 wt%, 0.01 wt% to 50 wt%, 0.05 wt% to 50 wt%, 0.1 wt% to 50 wt%, 0.01 wt% to 40 wt%, 0.05 wt% to 40 wt%, 0.1 wt% to 40 wt%, 0.01 wt% to 30 wt%, 0.05 wt% to 30 wt%, 0.1 wt% to 30 wt%, 0.01 wt% to 20 wt%, 0.05 wt% to 20 wt%, 0.1 wt% to 20 wt%, 0.01 wt% to 10 wt%, 0.05 wt% to 10 wt%, or 0.1 wt% to 10 wt%.
29. The pharmaceutical formulation of any one of claims 22-28 in unit dosage form, wherein the dose of the compound is from about 0.002 mg to about 1 mg, from about 0.006 mg to about 0.6 mg, from about 0.01 mg to about 0.4 mg, from about 0.02 mg to about 0.3 mg, or from about 0.01 mg to about 0.2 mg.
30. A method for synthesizing a compound according to any one of claims 1 to 21, comprising: (i) heating the reaction mixture at a suitable temperature for a period of time sufficient to form a product comprising the compound, wherein the reaction mixture comprises a solvent, a first reactant having a structure of Formula V The second reactant having the structure of formula VI and a third reactant having the structure of formula VII in (a) L1 and L2 are independently a bond (single, double or triple bond), a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a carbonyl group or an alkoxy group; (b) L3 is a bond (single, double or triple bond), a substituted or unsubstituted alkyl group, or a carbonyl group; (c) A1 and A2 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, carbonyl, or alkoxy, and at least one of A1 and A2 is substituted or unsubstituted aryl; (d) A3 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, carbonyl, or alkoxy; (e) R1-R3 are independently hydrogen, hydroxy, substituted or unsubstituted alkyl, carbonyl, alkoxy, thiol, or amino; (f)R 23 -R 25 are independently hydrogen or substituted or unsubstituted alkyl; and (g) the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, carbonyl, alkoxy, halogen, hydroxy, phenoxy, thiol, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amide, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphanyl, phosphoryl, or phosphonyl, and The second reactant is the same as or different from the third reactant.
31. The method of claim 30, wherein: A1 is and A2 is in: (a) L4 and L5 are independently a bond (single, double or triple bond), a substituted or unsubstituted alkyl group, or a carbonyl group; (b) A4 and A5 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, carbonyl, or alkoxy; (c)R9-R 16 are independently hydrogen, hydroxy, substituted or unsubstituted alkyl, carbonyl, alkoxy, thiol, or amino; and (d) the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, carbonyl, alkoxy, halogen, hydroxy, phenoxy, thiol, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amide, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphinyl, phosphoryl, or phosphonyl.
32. The method of claim 30, wherein the second reactant is the same as the third reactant and has the following structure: in: (a) L6 is a bond (single bond, double bond or triple bond), substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, carbonyl or alkoxy; (b) L7 is a bond (single bond, double bond or triple bond), a substituted or unsubstituted alkyl group, or a carbonyl group; (c) A7 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, carbonyl, or alkoxy; (d) R 18 -R 21 are independently hydrogen, hydroxy, substituted or unsubstituted alkyl, carbonyl, alkoxy, thiol, or amino; (e)R 23 -R 25 are independently hydrogen or substituted or unsubstituted alkyl; and (f) the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, carbonyl, alkoxy, halogen, hydroxy, phenoxy, thiol, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amide, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphinyl, phosphoryl, or phosphonyl.
33. The method of claim 32, further comprising: (ia) converting a pre-reactant having a structure of formula VIII' into a reactant having a structure of formula VIII, in: (a) L7 is a bond (single bond, double bond or triple bond), a substituted or unsubstituted alkyl group, or a carbonyl group; (b) A7 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, carbonyl, or alkoxy; (c)R 18 -R 21 are independently hydrogen, hydroxy, substituted or unsubstituted alkyl, carbonyl, alkoxy, thiol, or amino; and (d) the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, carbonyl, alkoxy, halogen, hydroxy, phenoxy, thiol, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amide, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphinyl, phosphoryl, or phosphonyl.
34. The method of claim 32 or 33, wherein R 19 is methyl; R 18 For-OR 22 , each R 22 is hydrogen or substituted or unsubstituted alkyl.
35. The method of claim 34, further comprising: (ib) converting a first starting material having a structure of Formula X into a pre-reactant having a structure of Formula VIII', or (ib) converting phloroglucinol into a pre-reactant having a structure of Formula VIII': Where (a) R 20 and R 21 (a) and (b) the substituents are independently hydrogen, hydroxy, substituted or unsubstituted alkyl, carbonyl, alkoxy, thiol, or amino; and (b) the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, carbonyl, alkoxy, halogen, hydroxy, phenoxy, thiol, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amide, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphinyl, phosphoryl, or phosphonyl.
36. The method of claim 35, wherein the method comprises: (ib) converting a first starting material having a structure of formula X into a pre-reactant having a structure of formula VIII', wherein step (ib) comprises: (i-b1) converting the first starting material having a structure of formula X into a first intermediate having a structure of formula IX, and (i-b2) converting the first intermediate having a structure of formula IX into a pre-reactant having a structure of formula VIII': Where (a) R 20 and R 21 are independently hydrogen, hydroxy, substituted or unsubstituted alkyl, carbonyl, alkoxy, thiol, or amino; (b) R 22 is hydrogen or substituted or unsubstituted alkyl; and (c) the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, carbonyl, alkoxy, halogen, hydroxy, phenoxy, thiol, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amido, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphinyl, phosphoryl, or phosphonyl.
37. The method of claim 35, wherein the method comprises: (ib) converting phloroglucinol into a pre-reactant having a structure of formula VIII', wherein step (ib) comprises: (i-b1') converting phloroglucinol into a second intermediate having a structure of formula XVII, and (i-b2') converting the second intermediate having a structure of formula XVII into a pre-reactant having a structure of formula VIII': wherein: (a) L7 is a bond (single, double or triple bond), a substituted or unsubstituted alkyl group, or a carbonyl group; (b) A7 is hydrogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, a carbonyl group, or an alkoxy group; (c) R 19 is hydrogen, hydroxyl, substituted or unsubstituted alkyl, carbonyl, alkoxy, thiol, or amino; (d) P1 and P2 are independently protecting groups, such as methoxymethyl ether, tetrahydropyranyl ether, butyl ether, allyl ether, acetone acetal, benzylidene acetal, acetate, pivalate, tert-butyldimethylsilyl ether, tert-butyldibenzylsilyl ether, anisole, benzoic acid ester (benzoic acid ester) and (e) the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, carbonyl, alkoxy, halogen, hydroxy, phenoxy, thiol, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amide, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphanyl, phosphoryl, or phosphonyl.
38. The method of any one of claims 30 to 37, wherein: The first reactant is The second reactant is the same as the third reactant and has the following structure: in: (a) A3 and A7 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, carbonyl, or alkoxy, optionally A3 and A7 are independently substituted or unsubstituted alkyl, such as unsubstituted C1-C 10 Alkyl, unsubstituted C1-C8 alkyl, unsubstituted C1-C7 alkyl, unsubstituted C1-C6 alkyl, unsubstituted C1-C5 alkyl, unsubstituted C1-C4 alkyl, or unsubstituted C1-C3 alkyl; (b) L6 is a bond (single bond, double bond or triple bond), substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, carbonyl or alkoxy; (c)R 22 is hydrogen or substituted or unsubstituted alkyl; (d) R 23 -R 25 (e) the substituents are independently hydrogen or substituted or unsubstituted alkyl; and (e) the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, carbonyl, alkoxy, halogen, hydroxy, phenoxy, thiol, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amide, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphinyl, phosphoryl, or phosphonyl.
39. The method of any one of claims 30-38, wherein the solvent is dichloromethane, dimethyl sulfate, dimethyl sulfoxide, dimethylformamide, butyryl chloride, dichloroethane, nitrobenzene, dioxane, 2-methylbutyryl chloride, ethyl acetate, ethyl lactate, acetone, 1-butanol, 1-propanol, 2-propanol, ethanol, isopropyl acetate, methanol, methyl ethyl ketone, tert-butanol, tetrahydrofuran, 2-methyltetrahydrofuran, acrylonitrile, or toluene, or a combination thereof, or a mixture thereof with water.
40. The process of any one of claims 30-39, wherein the reaction mixture is heated at 1 atm at a temperature of up to 130°C, about 100°C to about 130°C, about 100°C to about 125°C, about 100°C to about 120°C, such as about 110°C, for a period of about 30 minutes to about 4 hours, about 30 minutes to about 3.5 hours, about 30 minutes to about 3 hours, about 30 minutes to about 2.5 hours, about 1 hour to about 4 hours, about 1 hour to about 3 hours, or about 1 hour to about 2 hours, optionally under reflux.
41. The method of any one of claims 30-40, wherein the compound has an overall yield of at least 7%, at least 10%, at least 15%, at least 20%, at least 25%, or at least 30%.
42. The method of any one of claims 30-41, further comprising: The first reactant, the second reactant, the third reactant, and the solvent are mixed to form a reaction mixture before step (i) and / or the product containing the prodrug is purified after step (i).
43. A method for treating cancer, reducing cancer, or treating or ameliorating one or more symptoms associated with cancer in a subject, comprising: (i) administering to the subject the pharmaceutical formulation of any one of claims 22-29, wherein step (i) is performed one or more times.
44. The method of claim 43, wherein the method comprises only a single administration of the pharmaceutical formulation, wherein the pharmaceutical formulation contains an effective amount of the compound to inhibit tumor growth in the subject by at least 40%, at least 50%, or at least 55% compared to the same tumor in a control subject, or wherein the method comprises more than one step of administering a pharmaceutical formulation to the subject, wherein after all the administering steps, an effective amount of a compound has been administered to the subject that inhibits tumor growth in the subject by at least 40%, at least 50%, or at least 55% as compared to the same tumor in a control subject.
45. The method of claim 44, wherein the effective amount of the compound is about 0.1 mg / kg to about 50 mg / kg, about 0.3 mg / kg to about 30 mg / kg, about 0.5 mg / kg to about 20 mg / kg, about 1 mg / kg to about 15 mg / kg, or about 0.5 mg / kg to about 10 mg / kg, such as about 3 mg / kg.
46. The method of any one of claims 43-45, wherein the subject is a mammal.
47. The method of any one of claims 43-46, wherein the pharmaceutical formulation is administered by oral administration, parenteral administration, inhalation, mucosal administration, topically, or a combination thereof.
48. The method of any one of claims 43-47, wherein the cancer is non-small cell lung cancer.
49. The method of any one of claims 43-48, further comprising administering to the subject a second active agent, optionally more than one second active agent, before, during, and / or after step (i).
50. The method of claim 49, wherein the second active agent is an anti-cancer agent.
51. A method for treating cancer cells and / or cancer stem cells in a subject in need thereof, comprising: (i) administering to a subject the pharmaceutical formulation of any one of claims 22 to 29, wherein step (i) is performed one or more times.
52. The method of claim 51, wherein the IC of the compound against the test cancer cells is 50 The values are lower than the IC values of the same compounds against non-cancer cells. 50 value.
53. The method of claim 52, wherein the test cancer cell is MDA-MB-231, MCF-7, HepG2, Hela, AGS, HTC116, SW480, SUNE-1, H460, HCC827, H1650, or A549, or a combination thereof.
54. The method of claim 52 or claim 53, wherein the non-cancer cell is CCD-19Lu.
55. The method of any one of claims 51-54, wherein the method comprises only a single administration of a pharmaceutical formulation, wherein the pharmaceutical formulation contains an effective amount of a compound to induce mitochondrial dysfunction and / or inhibit ER to Golgi transport in cancer cells in a subject compared to the subject prior to administration of the pharmaceutical formulation, or wherein the method comprises more than one step of administering the pharmaceutical formulation to the subject, wherein after all the administering steps, an effective amount of a compound has been administered to the subject that induces mitochondrial dysfunction and / or inhibits ER to Golgi transport in cancer cells in the subject compared to the subject before administration of the pharmaceutical formulation.
56. The method of any one of claims 51-55, wherein the method comprises only a single administration of the pharmaceutical formulation, wherein the pharmaceutical formulation contains an effective amount of a compound to induce apoptosis of cancer cells in a subject compared to the subject prior to administration of the pharmaceutical formulation, or wherein the method comprises more than one step of administering the pharmaceutical formulation to the subject, wherein after all the administering steps, an effective amount of a compound has been administered to the subject to induce apoptosis of cancer cells in the subject compared to the subject before administration of the pharmaceutical formulation.
